

Community Care Plan Florida Healthy Kids

Preferred Drug List






2026

The plan covers the drugs Florida Medicaid covers even if not specified in the PDL (see Section 409.815(2)(n)2, Florida Statutes). If your drug is not on the plan's preferred drug list: First, please call the member's services number located on your Community Care Plan-Florida Healthy Kids ID card.

If the plan does not cover the drug, then:

- Ask your doctor for a similar drug that is covered.
- Your doctor can ask the plan to cover your drug through the prior approval process.

****ATTENTION FHK PROVIDERS AND ENROLLEES**** ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| TYPE | DESCRIPTION |
|--|---|
|  Quantity Limit | There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame. |
|  Step Therapy | In some cases, you may be required to first try certain drugs to treat your medical condition before you move up a "step" to other drug options. |
|  Specialty Drug | These Specialty medications are available at Prime Therapeutics Pharmacy, Memorial Pharmacy, or BHMC Out Patient Pharmacy. |
|  PA Applies | Your provider is required to get prior authorization before you fill your prescription, which ensures appropriate use of the selected drug. Without prior approval, we may not cover this drug. |
|  Quantity Per Day | Quantity Per Day. |

LIST OF COVERED PRESCRIPTION MEDICATIONS

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| ALPHA-ADRENERGIC BLOCKING AGENT (12:16) | |
| NON-SEL.ALPHA-ADRENERGIC BLOCKING AGENTS | |
| <i>dihydroergotamine 1 mg/ml amp</i> | |
| <i>phenoxybenzamine hcl 10 mg cap</i> | |
| SELECTIVE ALPHA-1-ADRENERGIC BLOCK.AGENT | |
| <i>alfuzosin hcl er</i> | |
| <i>silodosin</i> | |
| <i>tamsulosin hcl</i> | |
| ANALGESICS AND ANTIPYRETICS | |
| NON-OPIOID ANALGESICS | |
| <i>butalbital-acetaminophn 50-325</i> | QPD 6.0 per day |
| OPIOID AGONISTS (28:08) | |
| <i>acetaminophen-cod #4 tablet</i> | QPD 6.0 per day |
| <i>acetaminophen-codeine (#2 tablet, #3 tablet)</i> | QPD 12.0 per day |
| <i>asa-butalb-caffeine-codeine</i> | QPD 6.0 per day |
| ASCOMP WITH CODEINE | QPD 6.0 per day |
| <i>butalb-acetamin-caf-cod 50-325</i> | QPD 6.0 per day |
| <i>codeine sulfate 30 mg tablet</i> | QPD 6.0 per day |
| DISKETS | QPD 3.0 per day |
| ENDOCET 10-325 MG TABLET | QPD 6.0 per day |
| ENDOCET 2.5-325 MG TABLET | QPD 12.0 per day |
| ENDOCET 5-325 MG TABLET | QPD 12.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| ENDOCET 7.5-325 MG TABLET | QPD 8.0 per day |
| <i>fentanyl (12 mcg/hr patch, 25 mcg/hr patch, 50 mcg/hr patch, 75 mcg/hr patch, 100 mcg/hr patch)</i> | PA QPD 0.5 per day |
| <i>fentanyl citrate otfc 600 mcg</i> | PA QPD 4.0 per day |
| <i>hydrocodone-acetaminophen (hydrocodone-acetamin 2.5-108/5, hydrocodone-acetamin 5-217/10, hydrocodone-acetamn 7.5-325/15)</i> | QPD 90.0 per day |
| <i>hydrocodone-acetamin 2.5-325</i> | QPD 8.0 per day |
| <i>hydrocodone-acetamin 5-325 mg</i> | QPD 8.0 per day |
| <i>hydrocodone-acetaminophen (7.5-325, 10-325 mg)</i> | QPD 6.0 per day |
| <i>hydrocodone-ibuprofen 7.5-200</i> | QPD 5.0 per day |
| <i>hydromorphone hcl (1 mg/ml solution, 5 mg/5 ml soln)</i> | QPD 48.0 per day |
| <i>hydromorphone 8 mg tablet</i> | QPD 6.0 per day |
| <i>hydromorphone hcl (2 mg tablet, 4 mg tablet)</i> | QPD 6.0 per day |
| <i>methadone 10 mg/5 ml solution</i> | QPD 15.0 per day |
| <i>methadone hcl (5 mg/5 ml soln cup, 5 mg/5 ml solution)</i> | QPD 30.0 per day |
| <i>methadone hcl (10 mg/ml oral conc, hcl 10 mg tablet, 40 mg tablet dispr)</i> | QPD 3.0 per day |
| <i>methadone hcl 5 mg tablet</i> | QPD 3.0 per day |
| METHADONE INTENSOL | QPD 3.0 per day |
| METHADOSE 40 MG TABLET DISPR | QPD 3.0 per day |
| <i>morphine sulf 100 mg/5 ml conc</i> | QPD 9.0 per day |
| <i>morphine sulf 20 mg/5 ml soln</i> | QPD 45.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>morphine sulfate (10 mg/5 ml cup, 10 mg/5 ml soln)</i> | QPD 90.0 per day |
| <i>morphine sulfate ir 15 mg tab</i> | QPD 12.0 per day |
| <i>morphine sulfate ir 30 mg tab</i> | QPD 6.0 per day |
| <i>morphine sulf er 15 mg tablet</i> | PA QPD 3.0 per day |
| <i>morphine sulfate er (er 30 mg tablet, er 60 mg tablet, er 100 mg tablet, er 200 mg tablet)</i> | PA QPD 3.0 per day |
| NUCYNTA ER | PA QPD 2.0 per day |
| <i>oxycodone hcl 100 mg/5 ml conc</i> | QPD 9.0 per day |
| <i>oxycodone hcl (5 mg/5 ml cup, 5 mg/5 ml soln)</i> | QPD 180.0 per day |
| <i>oxycodone hcl (15 mg tab, 20 mg tab, 30 mg tab)</i> | QPD 6.0 per day |
| <i>oxycodone hcl (ir) 10 mg tab</i> | QPD 6.0 per day |
| <i>oxycodone hcl (ir) 5 mg tablet</i> | QPD 12.0 per day |
| <i>oxycodone-acetaminophen 10-325</i> | QPD 6.0 per day |
| <i>oxycodone-acetaminophen 5-325</i> | QPD 12.0 per day |
| <i>oxycodone-acetaminophn 2.5-325</i> | QPD 12.0 per day |
| <i>oxycodone-acetaminophn 7.5-325</i> | QPD 8.0 per day |
| <i>oxymorphone hcl</i> | QPD 6.0 per day |
| <i>tramadol hcl 50 mg tablet</i> | QPD 8.0 per day |
| <i>tramadol hcl er (er 100 mg tablet, er 200 mg tablet, er 300 mg tablet)</i> | PA QPD 1.0 per day |
| <i>tramadol hcl-acetaminophen</i> | QPD 8.0 per day |
| XTAMPZA ER (ER 9 MG CAPSULE, ER 13.5 MG CAPSULE, ER 18 MG CAPSULE, ER 27 MG CAPSULE) | PA QPD 2.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| XTAMPZA ER 36 MG CAPSULE | <div style="background-color: #8B4513; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 8.0 per day |
| OPIOID PARTIAL AGONISTS | |
| BELBUCA | <div style="background-color: #8B4513; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| <i>buprenorphine hcl (2 mg tablet, 8 mg tablet)</i> | <div style="background-color: #800080; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QL</div> max 6 / 90 days |
| <i>buprenorphine-naloxone (4-1mg film, 8-2mg film, 12-3mg flm)</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| <i>buprenorphine-nalox 8-2 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 3.0 per day |
| <i>buprenorphine-naloxone (2-0.5mg fm, 2-0.5mg tb)</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 4.0 per day |
| <i>butorphanol 10 mg/ml spray</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 0.25 per day |
| ANOREXIGENICS; RESPIRATORY, CNS STIMULANTS | |
| AMPHETAMINES | |
| <i>dextroamphetamine 5 mg/5 ml</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 60.0 per day |
| <i>dextroamphetamine 10 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 6.0 per day |
| <i>dextroamphetamine 5 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 12.0 per day |
| <i>dextroamphetamine er 5 mg cap</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 3.0 per day |
| <i>dextroamphetamine sulfate er (er 10 mg cap, er 15 mg cap)</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 4.0 per day |
| <i>dextroamphetamine-amphet er (er 25 mg cap, er 30 mg cap)</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 1.0 per day |
| <i>dextroamphetamine-amphet er (er 5 mg cap, er 10 mg cap, er 15 mg cap, er 20 mg cap)</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| <i>dextroamp-amphetamin 10 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 6.0 per day |
| <i>dextroamp-amphetamin 30 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| <i>dextroamp-amphetamine 5 mg tab</i> | <div style="background-color: #4169E1; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 6.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>dextroamphetamine-amphetamine (dextroamp-amphetam 12.5 mg tab, dextroamp-amphetamin 15 mg tab)</i> | QPD 4.0 per day |
| <i>dextroamphetamine-amphetamine (dextroamp-amphetam 7.5 mg tab, dextroamp-amphetamin 20 mg tab)</i> | QPD 3.0 per day |
| <i>lisdexamphetamine dimesylate (10 mg capsule, 10 mg tb chew, 20 mg capsule, 20 mg tb chew, 30 mg capsule, 30 mg tb chew, 40 mg capsule, 40 mg tb chew, 50 mg capsule, 50 mg tb chew, 60 mg capsule, 60 mg tb chew, 70 mg capsule)</i> | QPD 1.0 per day |
| PROCENTRA | QPD 60.0 per day |
| ZENZEDI 10 MG TABLET | QPD 6.0 per day |
| ZENZEDI 5 MG TABLET | QPD 12.0 per day |
| RESPIRATORY AND CNS STIMULANTS | |
| <i>atomoxetine hcl (10 mg capsule, 40 mg capsule)</i> | QPD 2.0 per day |
| <i>atomoxetine hcl (18 mg capsule, 25 mg capsule)</i> | QPD 4.0 per day |
| <i>atomoxetine hcl (60 mg capsule, 80 mg capsule, 100 mg capsule)</i> | QPD 1.0 per day |
| AZSTARYS | QPD 1.0 per day |
| <i>caffeine cit 60 mg/3 ml oral</i> | |
| <i>dexmethylphenidate 10 mg tab</i> | QPD 2.0 per day |
| <i>dexmethylphenidate 2.5 mg tab</i> | QPD 8.0 per day |
| <i>dexmethylphenidate 5 mg tab</i> | QPD 4.0 per day |
| <i>dexmethylphenidate hcl er (er 25 mg cp, er 30 mg cp, er 35 mg cp, er 40 mg cp)</i> | QPD 1.0 per day |
| <i>dexmethylphenidate hcl er (er 5 mg cap, er 10 mg cp, er 15 mg cp, er 20 mg cp)</i> | QPD 2.0 per day |
| JORNAY PM | QPD 1.0 per day |
| <i>methylphenidate er (er 18 mg tab, er 27 mg tab, er 36 mg tab)</i> | QPD 2.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>methylphenidate er 54 mg tab</i> | QPD 1.0 per day |
| <i>methylphenidate er (er 10 mg tab, er 20 mg tab)</i> | QPD 3.0 per day |
| <i>methylphenidate er (la) (10mg cp, 40mg cp)</i> | QPD 1.0 per day |
| <i>methylphenidate er(la) 20mg cp</i> | QPD 3.0 per day |
| <i>methylphenidate er(la) 30mg cp</i> | QPD 2.0 per day |
| <i>methylphenidate er 27 mg tab (mallinckrodt and kremers/lannett)</i> | QPD 2.0 per day |
| <i>methylphenidate er 36 mg tab (mallinckrodt and kremers/lannett)</i> | QPD 2.0 per day |
| <i>methylphenidate er 54 mg tab (mallinckrodt and kremers/lannett)</i> | QPD 1.0 per day |
| <i>methylphenidate 10 mg/5 ml sol</i> | QPD 30.0 per day |
| <i>methylphenidate 5 mg/5 ml soln</i> | QPD 15.0 per day |
| <i>methylphenidate hcl (2.5 mg chew tb, 5 mg chew tab, 10 mg chew tab)</i> | QPD 6.0 per day |
| <i>methylphenidate 10 mg tablet</i> | QPD 6.0 per day |
| <i>methylphenidate 20 mg tablet</i> | QPD 3.0 per day |
| <i>methylphenidate 5 mg tablet</i> | QPD 12.0 per day |
| <i>methylphenidate hcl cd (10 mg cap, 20 mg cap, 30 mg cap)</i> | QPD 2.0 per day |
| <i>methylphenidate hcl cd (40 mg cap, 50 mg cap, 60 mg cap)</i> | QPD 1.0 per day |
| <i>methylphenidate hcl er (cd) (10mg cp, 20mg cp, 30mg cp)</i> | QPD 2.0 per day |
| <i>methylphenidate hcl er (cd) (40mg cp, 50mg cp, 60mg cp)</i> | QPD 1.0 per day |
| QUILLICHEW ER (ER 20 MG CHEW TAB, ER 40 MG CHEW TAB) | QPD 1.0 per day |
| QUILLICHEW ER 30 MG CHEW TAB | QPD 2.0 per day |
| QUILLIVANT XR | QPD 12.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| WAKEFULNESS-PROMOTING AGENTS | |
| <i>armodafinil (150 mg tablet, 200 mg tablet, 250 mg tablet)</i> | |
| <i>armodafinil 50 mg tablet</i> | |
| <i>modafinil (100 mg tablet, 200 mg tablet)</i> | |
| <i>sodium oxybate</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; border-radius: 5px; padding: 2px 10px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; border-radius: 5px; padding: 2px 10px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; border-radius: 5px; padding: 2px 10px; margin-bottom: 2px;">QPD</div> </div> 18.0 per day |
| SUNOSI | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #804000; color: white; border-radius: 5px; padding: 2px 10px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; border-radius: 5px; padding: 2px 10px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| ANTI-INFECTIVE AGENTS | |
| ANTHELMINTICS | |
| <i>albendazole 200 mg tablet</i> | |
| <i>ivermectin 3 mg tablet</i> | |
| <i>praziquantel 600 mg tablet</i> | |
| URINARY ANTI-INFECTIVES | |
| <i>fosfomycin tromethamine</i> | |
| <i>methenamine hippurate</i> | |
| <i>nitrofurantoin (25 mg cap, 100 mg cap)</i> | |
| <i>nitrofurantoin mcr 50 mg cap</i> | |
| <i>nitrofurantoin 25 mg/5 ml susp</i> | <div style="background-color: #804000; color: white; border-radius: 5px; padding: 2px 10px; display: inline-block;">PA</div> |
| <i>nitrofurantoin mono-macro</i> | |
| <i>trimethoprim 100 mg tablet</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| ANTI-INFECTIVES (EENT) | |
| ANTI-INFECTIVES, MISCELLANEOUS (52:04) | |
| <i>acetic acid 2% ear solution</i> | |
| <i>hydrocortisone-acetic acid</i> | |
| ANTIBACTERIALS (52:04) | |
| AK-POLY-BAC | |
| <i>bacitracin 500 unit/gm ophth</i> | |
| <i>bacitracin-polymyxin</i> | |
| BESIVANCE | |
| <i>ciprofloxacin 0.2% otic soln</i> | |
| <i>ciprofloxacin 0.3% eye drop</i> | |
| <i>ciprofloxacin-dexamethasone</i> | |
| <i>doxycycline hyclate 20 mg tab</i> | |
| <i>erythromycin 0.5% eye ointment</i> | |
| <i>erythromycin 2% solution</i> | |
| <i>gatifloxacin</i> | |
| <i>gentamicin 0.3% eye drop</i> | |
| <i>moxifloxacin 0.5% eye drops</i> | |
| NEO-POLYCIN | |
| NEO-POLYCIN HC | |
| <i>neomycin-bacitracin-poly-hc</i> | |
| <i>neomycin-bacitracin-polymyxin</i> | |
| <i>neomycin-polymyxin-dexameth (neomyc-polym-dexamet ointm, neomyc-polym-dexameth drop)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>neomycin-polymyxin-hc ear susp</i> | |
| <i>neomycin-polymyxin-hydrocort</i> | |
| <i>ofloxacin 0.3% ear drops</i> | |
| <i>ofloxacin 0.3% eye drops</i> | |
| POLYCIN | |
| <i>polymyxin b sul-trimethoprim</i> | |
| <i>tobramycin 0.3% eye drop</i> | |
| <i>tobramycin-dexamethasone</i> | |
| ANTIFUNGALS (EENT) | |
| NATACYN | |
| ANTIVIRALS (EENT) | |
| <i>trifluridine 1% eye drops</i> | |
| ASTRINGENTS (52:04) | |
| <i>chlorhexidine gluconate (15 ml cup, rinse)</i> | |
| PERIOGARD | |
| ANTI-INFECTIVES (SKIN, MUCOUS MEMBRANE) | |
| ANTIBACTERIALS (84:04) | |
| <i>azelaic acid 15% gel</i> | |
| <i>clind ph-benzoyl perox 1.2-5%</i> | |
| <i>gentamicin sulfate (cream, ointment)</i> | |
| <i>metronidazole (0.75% cream, top 1% gel pump, topical 0.75% gl, topical 1% gel)</i> | |
| <i>mupirocin 2% ointment</i> | |
| NEUAC GEL | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| ROSADAN (CREAM, GEL) | |
| <i>tetracycline hcl (250 mg capsule, 500 mg capsule)</i> | |
| ZILXI | |
| ANTIVIRALS (SKIN AND MUCOUS MEMBRANE) | |
| <i>acyclovir 5% ointment</i> | |
| <i>penciclovir 1% cream</i> | |
| ASTRINGENTS, ANTI-INFECTIVE | |
| <i>selenium sulfide 2.5% lotion</i> | |
| <i>silver sulfadiazine 1% cream</i> | |
| SSD | |
| LOCAL ANTI-INFECTIVES, MISCELLANEOUS | |
| <i>sulfacetamide sodium (sod top susp, sodium lotn)</i> | |
| SCABICIDES AND PEDICULICIDES | |
| <i>malathion</i> | |
| <i>permethrin 5% cream</i> | |
| ANTI-INFLAMMATORY AGENTS (EENT) | |
| CORTICOSTEROIDS (EENT) | |
| EYSUVIS | |
| FLAC OTIC OIL | |
| <i>flunisolide 0.025% spray</i> | |
| <i>fluocinolone acetonide oil</i> | |
| <i>fluorometholone</i> | |
| <i>fluticasone prop 50 mcg spray</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| LOTEMAX 0.5% EYE OINTMENT | |
| LOTEMAX SM | |
| <i>loteprednol etabonate (etabonate 0.2% drp, 0.5% ophthalmic gel, etabonate 0.5% drp)</i> | |
| <i>mometasone furoate 50 mcg spray</i> | |
| <i>prednisolone ac 1% eye drop</i> | |
| EENT NONSTEROIDAL ANTI-INFLAM. AGENTS | |
| <i>diclofenac 0.1% eye drops</i> | |
| <i>ketorolac 0.4% ophth solution</i> | |
| <i>ketorolac 0.5% ophth solution</i> | |
| ANTI-INFLAMMATORY AGENTS (RESPIRATORY) | |
| INTERLEUKIN ANTAGONISTS | |
| FASENRA PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin-bottom: 5px;">max 1 / 28 days</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| NUCALA (100 MG/ML AUTO-INJECTOR, 100 MG/ML SYRINGE) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-bottom: 5px;">0.108 per day</div> </div> |
| NUCALA 40 MG/0.4 ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-bottom: 5px;">0.015 per day</div> </div> |
| TEZSPIRE 210 MG/1.91 ML PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-bottom: 5px;">0.069 per day</div> </div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| LEUKOTRIENE MODIFIERS | |
| <i>montelukast sodium (4 mg tab chew, 5 mg tab chew, 10 mg tablet)</i> | |
| <i>zafirlukast</i> | |
| MAST-CELL STABILIZERS | |
| <i>cromolyn 20 mg/2 ml neb soln</i> | |
| <i>cromolyn 100 mg/5 ml oral conc</i> | |
| ANTI-INFLAMMATORY AGENTS (SKIN, MUCOUS) | |
| ADRENERGIC AGONISTS | |
| <i>brimonidine 0.33% gel pump</i> | |
| CORTICOSTEROIDS (SKIN, MUCOUS MEMBRANE) | |
| ALA-CORT | QPD 15.134 per day |
| <i>alclometasone dipro 0.05% crm</i> | QPD 4.0 per day |
| ANUCORT-HC | |
| ANUSOL-HC 25 MG SUPPOSITORY | |
| <i>betamethasone dp aug 0.05% crm</i> | QPD 7.143 per day |
| <i>betamethasone dp aug 0.05% lot</i> | QPD 7.0 per day |
| <i>betamethasone dp aug 0.05% oin</i> | QPD 7.143 per day |
| <i>betamethasone dipropionate (dp crm, dp oint)</i> | QPD 4.5 per day |
| <i>betamethasone dp 0.05% lot</i> | QPD 4.0 per day |
| <i>betamethasone valerate (va cream, valer ointm)</i> | QPD 4.5 per day |
| <i>clobetasol emollient 0.05% crm</i> | QPD 7.5 per day |
| <i>clobetasol propionate (cream, gel, ointment)</i> | QPD 7.5 per day |
| <i>clobetasol propionate (prop foam, solution)</i> | QPD 7.143 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| CORTIFOAM | |
| <i>desonide (cream, ointment)</i> | QPD 4.0 per day |
| <i>desoximetasone (cream, ointment)</i> | QPD 4.0 per day |
| <i>fluocinolone acetonide (body oil, scalp oil)</i> | QPD 3.943 per day |
| <i>fluocinolone acetonide (0.01% cream, 0.01% solution, 0.025% ointment)</i> | QPD 4.0 per day |
| <i>fluocinonide (cream, gel, ointment, solution)</i> | QPD 4.0 per day |
| <i>fluocinonide 0.1% cream</i> | QPD 8.572 per day |
| <i>fluocinonide-e</i> | QPD 4.0 per day |
| <i>fluticasone propionate (0.005% oint, 0.05% cream)</i> | QPD 4.0 per day |
| <i>halobetasol prop 0.05% cream</i> | QPD 7.143 per day |
| HEMMOREX-HC 25 MG SUPPOSITORY | |
| <i>hydrocortisone 1% cream</i> | QPD 15.134 per day |
| <i>hydrocortisone 100 mg/60 ml</i> | |
| <i>hydrocortisone (cream, ointment)</i> | QPD 15.134 per day |
| <i>hydrocortisone 1% ointment</i> | QPD 15.12 per day |
| <i>hydrocortisone ac 25 mg supp</i> | |
| <i>hydrocortisone val 0.2% cream</i> | QPD 4.0 per day |
| KOURZEQ | |
| <i>mometasone furoate 0.1% cream</i> | QPD 4.5 per day |
| <i>mometasone furoate 0.1% oint</i> | QPD 4.5 per day |
| <i>mometasone furoate 0.1% soln</i> | QPD 4.0 per day |
| ORALONE | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---------------------------------|
| PROCTO-MED HC | |
| PROCTOSOL-HC | |
| PROCTOZONE-HC | |
| <i>triamcinolone acetonide (0.025% lotion, 0.1% lotion)</i> | QPD 4.0 per day |
| <i>triamcinolone 0.5% ointment</i> | QPD 4.0 per day |
| <i>triamcinolone acetonide (0.025% cream, 0.025% oint, 0.1% cream, 0.1% ointment, 0.5% cream)</i> | QPD 15.134 per day |
| <i>triamcinolone 0.1% paste</i> | |
| TRIDERM | QPD 15.134 per day |
| IMMUNOMODULATORY AGENTS (84:06) | |
| ADBRY | S |
| | PA |
| | QPD 0.143 per day |
| ADBRY AUTOINJECTOR | S |
| | PA |
| | QPD 0.143 per day |
| EBGLYSS PEN | S |
| | PA |
| | QPD 0.072 per day |
| EBGLYSS SYRINGE | S |
| | PA |
| | QPD 0.072 per day |
| NEMLUVIO | S |
| | PA |
| | QPD 0.036 per day |
| RHAPSIDO | S |
| | PA |
| | QPD 2.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| SKYRIZI 150 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 84 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| SKYRIZI 180 MG/1.2 ML ON-BODY | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1.2 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| SKYRIZI 360 MG/2.4 ML ON-BODY | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 2.4 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| SKYRIZI PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 84 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| <i>tacrolimus (0.03% ointment, 0.1% ointment)</i> | |
| TREMIFYA 100 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| TREMIFYA 200 MG/2 ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #3498db; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">0.072 per day</div> </div> |
| TREMIFYA ONE-PRESS | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| TREMIFYA 100 MG/ML PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| TREMIFYA 200 MG/2 ML PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b6914; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #3498db; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">0.072 per day</div> </div> |



****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| TREMFYA PEN INDUCTION (2 PEN) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-bottom: 2px;">QL</div> <div style="margin-bottom: 2px;">max 12 / 180 days</div> <div style="background-color: #c00000; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8b4513; color: white; padding: 5px;">PA</div> </div> |
| JANUS KINASE INHIBITORS (84:06) | |
| CIBINQO | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8b4513; color: white; padding: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 5px;">QPD 1.0 per day</div> </div> |
| SOTYKTU | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8b4513; color: white; padding: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 5px;">QPD 1.0 per day</div> </div> |
| NONSTEROIDAL ANTI-INFLAMMAT.AGENTS(SKIN) | |
| <i>diclofenac sodium 3% gel</i> | |
| PHOSPHODIESTERASE-4 INHIBITORS (84:06) | |
| EUCRISA | |
| ANTIANEMIA DRUGS | |
| IRON PREPARATIONS | |
| FER-IN-SOL | |
| <i>ferrous sulf 300 mg/5 ml cup</i> | |
| <i>ferrous sulfate (15 mg iron/ml drp, 44 mg iron/5ml lq, 220 mg/5 ml elix, 220 mg/5 ml liq)</i> | |
| ICAR | |
| <i>infant-toddler iron</i> | |
| IRONUP | |
| NOVAFERRUM YUMMY PEDIATRIC | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| PEDIA IRON | |
| PEDIATRIC FE-VITE | |
| <i>pediatric iron</i> | |
| WEE CARE | |
| ANTIARRHYTHMIC AGENTS | |
| CLASS IA ANTIARRHYTHMICS | |
| <i>disopyramide phosphate</i> | |
| <i>quinidine gluconate</i> | |
| CLASS IB ANTIARRHYTHMICS | |
| <i>mexiletine hcl (150 mg capsule, 200 mg capsule, 250 mg capsule)</i> | |
| CLASS IC ANTIARRHYTHMICS | |
| <i>flecainide acetate (100 mg tab, 150 mg tab)</i> | |
| <i>flecainide acetate 50 mg tab</i> | |
| <i>propafenone hcl (225 mg tab, 300 mg tab)</i> | |
| <i>propafenone hcl 150 mg tablet</i> | |
| <i>propafenone hcl er</i> | |
| CLASS III ANTIARRHYTHMICS | |
| <i>amiodarone hcl 100 mg tablet</i> | |
| <i>amiodarone hcl 200 mg tablet</i> | |
| <i>dofetilide</i> | |
| MULTAQ | |
| PACERONE 100 MG TABLET | |
| PACERONE 200 MG TABLET | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| CLASS IV ANTIARRHYTHMICS | |
| CARTIA XT (120 MG CAPSULE, 180 MG CAPSULE, 240 MG CAPSULE) | |
| CARTIA XT 300 MG CAPSULE | |
| DILT XR 120 MG CAPSULE | |
| DILT-XR (180 MG CAPSULE, 240 MG CAPSULE) | |
| <i>diltiazem 12hr er</i> | |
| <i>diltiazem 24hr er (24hr er 120 mg cap, 24hr er 180 mg cap)</i> | |
| <i>diltiazem 24hr er (24hr er 240 mg cap, 24hr er 300 mg cap, 24hr er 360 mg cap, 24hr er 420 mg cap)</i> | |
| <i>diltiazem 24h er(cd) 300 mg cp</i> | |
| <i>diltiazem 24hr er (cd) (24h 120 mg cp, 24h 180 mg cp, 24h 240 mg cp)</i> | |
| <i>diltiazem 24h er(la) 120 mg tb</i> | |
| <i>diltiazem 24h er(xr) 120 mg cp</i> | |
| <i>diltiazem 24hr er (xr) (24h 180 mg cp, 24h 240 mg cp)</i> | |
| <i>diltiazem 90 mg tablet</i> | |
| <i>diltiazem hcl (30 mg tablet, 60 mg tablet, 120 mg tablet)</i> | |
| TAZTIA XT (120 MG CAPSULE, 180 MG CAPSULE) | |
| TAZTIA XT (240 MG CAPSULE, 300 MG CAPSULE, 360 MG CAPSULE) | |
| TIADYLT ER (ER 120 MG CAPSULE, ER 180 MG CAPSULE) | |
| TIADYLT ER (ER 240 MG CAPSULE, ER 300 MG CAPSULE, ER 360 MG CAPSULE, ER 420 MG CAPSULE) | |
| <i>verapamil er (er 120 mg capsule, er 180 mg capsule, er 240 mg capsule)</i> | |
| <i>verapamil er (er 120 mg tablet, er 180 mg tablet, er 240 mg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>verapamil hcl (40 mg tablet, 80 mg tablet, 120 mg tablet)</i> | |
| <i>verapamil sr (sr 120 mg capsule, sr 180 mg capsule, sr 240 mg capsule)</i> | |
| ANTIBACTERIALS (08:12) | |
| AMINOGLYCOSIDE ANTIBIOTICS | |
| <i>neomycin 500 mg tablet</i> | |
| <i>tobramycin (300 mg/4 ml, 300 mg/5 ml)</i> |  max 56 days / fill  |
| QUINOLONE ANTIBIOTICS | |
| <i>ciprofloxacin</i> | |
| <i>ciprofloxacin hcl (250 mg tab, 500 mg tab, 750 mg tab)</i> | |
| <i>levofloxacin 25 mg/ml solution</i> | |
| <i>levofloxacin (250 mg tablet, 500 mg tablet, 750 mg tablet)</i> | |
| <i>moxifloxacin hcl 400 mg tablet</i> | |
| <i>ofloxacin 300 mg tablet</i> | |
| SULFONAMIDE ANTIBIOTICS (SYSTEMIC) | |
| <i>sulfadiazine 500 mg tablet</i> | |
| <i>sulfamethoxazole-trimethoprim (20 ml cup, susp)</i> | |
| <i>sulfamethoxazole-trimethoprim (ds tablet, ss tablet)</i> | |
| <i>sulfasalazine 500 mg tablet</i> | |
| <i>sulfasalazine dr</i> | |
| SULFATRIM | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| TETRACYCLINE ANTIBIOTICS | |
| AVIDOXY | |
| <i>demeclocycline hcl</i> | |
| <i>doxycycline hyclate (50 mg cap, 100 mg cap, 100 mg tab)</i> | |
| <i>doxycycline monohydrate (50 mg cap, 50 mg tablet, 100 mg cap, 100 mg tablet)</i> | |
| <i>doxycycline monohydrate (25 mg/5 ml susp, mono 75 mg tablet, mono 150 mg tablet)</i> | |
| <i>minocycline 50 mg capsule</i> | |
| <i>minocycline hcl (75 mg capsule, 100 mg capsule)</i> | |
| MONDOXYNE NL 100 MG CAPSULE | |
| ANTIBACTERIALS, MISCELLANEOUS | |
| GLYCOPEPTIDE ANTIBIOTICS | |
| <i>vancomycin hcl (25 mg/ml oral soln, 50 mg/ml oral soln, hcl 125 mg capsule, 250 mg/5ml oral sol, hcl 250 mg capsule)</i> | |
| LINCOMYCIN ANTIBIOTICS | |
| CLINDACIN ETZ 1% PLEDGET | |
| CLINDACIN P | |
| <i>clindamycin (pediatric)</i> | |
| <i>clindamycin hcl (75 mg capsule, 150 mg capsule, 300 mg capsule)</i> | |
| <i>clindamycin phosphate (ph 1% gel, ph 1% solution, phos 1% pledget, phosp 1% lotion, 2% vaginal cream)</i> | |
| OXAZOLIDINONE ANTIBIOTICS | |
| <i>linezolid 100 mg/5 ml susp</i> | PA |
| <i>linezolid 600 mg tablet</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|------------------------|
| RIFAMYCIN ANTIBIOTICS | |
| XIFAXAN 550 MG TABLET | |
| ANTICHOLINERGIC AGENTS | |
| ANTIMUSCARINICS/ANTISPASMODICS | |
| ANORO ELLIPTA | QPD 2.0 per day |
| COMBIVENT RESPIMAT | QPD 0.267 per day |
| <i>dicyclomine 10 mg/5 ml soln</i> | |
| <i>dicyclomine hcl (10 mg capsule, 20 mg tablet)</i> | |
| <i>glycopyrrolate 1 mg/5 ml soln</i> | PA QPD 45.0 per day |
| <i>glycopyrrolate (1 mg tablet, 2 mg tablet)</i> | |
| INCRUSE ELLIPTA | QPD 1.0 per day |
| <i>ipratropium br 17 mcg hfa inh</i> | QPD 0.86 per day |
| <i>ipratropium br 0.02% soln</i> | |
| <i>ipratropium-albuterol</i> | |
| <i>methscopolamine bromide (2.5 mg tb, 5 mg tab)</i> | |
| <i>scopolamine</i> | |
| SPIRIVA RESPIMAT | QPD 0.134 per day |
| STIOLTO RESPIMAT INHALER (60) | QPD 0.134 per day |
| TRELEGY ELLIPTA | QPD 2.0 per day |
| ANTICOAGULANTS | |
| COUMARIN DERIVATIVES | |
| JANTOVEN | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---------------------------------------|
| <i>warfarin sodium (1 mg tablet, 2 mg tablet, 2.5 mg tablet, 3 mg tablet, 4 mg tablet, 5 mg tablet, 6 mg tablet, 7.5 mg tablet, 10 mg tablet)</i> | |
| DIRECT FACTOR XA INHIBITORS | |
| ELIQUIS DVT-PE TREAT START 5MG | QL max 74 / 180 days |
| ELIQUIS 2.5 MG TABLET | QPD 2.0 per day |
| ELIQUIS 5 MG TABLET | QPD 2.467 per day |
| ELIQUIS 0.5 MG PKT(1X0.5MG TB) | QPD 5.0 per day |
| ELIQUIS 1.5 MG PKT(3X0.5MG TB) | QPD 15.0 per day |
| ELIQUIS 2 MG PKT(4X 0.5 MG TB) | QPD 20.0 per day |
| ELIQUIS SPRINKLE | QPD 2.467 per day |
| <i>rivaroxaban 1 mg/ml suspension</i> | QPD 20.667 per day |
| <i>rivaroxaban 2.5 mg tablet</i> | QPD 2.0 per day |
| XARELTO 1 MG/ML SUSPENSION | QPD 20.667 per day |
| XARELTO DVT-PE TREAT START 30D | QPD 1.7 per day |
| XARELTO (2.5 MG TABLET, 15 MG TABLET) | QPD 2.0 per day |
| XARELTO 10 MG TABLET | QPD 1.0 per day |
| XARELTO 20 MG TABLET | QPD 1.0 per day |
| DIRECT THROMBIN INHIBITORS | |
| <i>dabigatran etexilate (75 mg cap, 150 mg cp)</i> | QPD 2.0 per day |
| <i>dabigatran etexilate 110 mg cp</i> | QPD 4.0 per day |
| HEPARINS | |
| <i>enoxaparin 30 mg/0.3 ml syr</i> | QL max 9 / 90 days S |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| <i>enoxaparin 40 mg/0.4 ml syr</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-right: 10px;">QL</div> <div style="margin-right: 10px;">max 12 / 90 days</div> </div> <div style="background-color: #d62728; color: white; padding: 5px; margin-left: 10px;">S</div> |
| <i>enoxaparin 60 mg/0.6 ml syr</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-right: 10px;">QL</div> <div style="margin-right: 10px;">max 18 / 90 days</div> </div> <div style="background-color: #d62728; color: white; padding: 5px; margin-left: 10px;">S</div> |
| <i>enoxaparin sodium (80 mg/0.8 ml syr, 120 mg/0.8 ml syr)</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-right: 10px;">QL</div> <div style="margin-right: 10px;">max 24 / 90 days</div> </div> <div style="background-color: #d62728; color: white; padding: 5px; margin-left: 10px;">S</div> |
| <i>enoxaparin sodium (100 mg/ml syringe, 150 mg/ml syringe, 300 mg/3 ml vial)</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-right: 10px;">QL</div> <div style="margin-right: 10px;">max 30 / 90 days</div> </div> <div style="background-color: #d62728; color: white; padding: 5px; margin-left: 10px;">S</div> |
| <i>heparin sodium (sod 1,000 unit/ml vial, 2,000 unit/2 ml vial, 5,000 unit/ml carpupct, sod 5,000 unit/0.5 ml, sod 5,000 unit/ml syrg, sod 5,000 unit/ml vial, 10,000 unit/10 ml vial, sod 10,000 unit/ml vl, sod 20,000 unit/ml vl, 30,000 unit/30 ml vial, 40,000 unit/4 ml vial, 50,000 unit/10 ml vial, 50,000 unit/5 ml vial)</i> | |
| INDIRECT FACTOR XA INHIBITORS | |
| <i>fondaparinux 10 mg/0.8 ml syr</i> | <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 5px;">S</div> <div style="display: flex; align-items: center;"> <div style="background-color: #1f77b4; color: white; padding: 5px; margin-right: 10px;">QPD</div> <div>0.8 per day</div> </div> |
| <i>fondaparinux 2.5 mg/0.5 ml syr</i> | <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 5px;">S</div> <div style="display: flex; align-items: center;"> <div style="background-color: #1f77b4; color: white; padding: 5px; margin-right: 10px;">QPD</div> <div>0.5 per day</div> </div> |
| <i>fondaparinux 5 mg/0.4 ml syr</i> | <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 5px;">S</div> <div style="display: flex; align-items: center;"> <div style="background-color: #1f77b4; color: white; padding: 5px; margin-right: 10px;">QPD</div> <div>0.4 per day</div> </div> |
| <i>fondaparinux 7.5 mg/0.6 ml syr</i> | <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 5px;">S</div> <div style="display: flex; align-items: center;"> <div style="background-color: #1f77b4; color: white; padding: 5px; margin-right: 10px;">QPD</div> <div>0.6 per day</div> </div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| ANTICONVULSANTS | |
| ANTICONVULSANTS, MISCELLANEOUS | |
| <i>brivaracetam (10 mg tablet, 10 mg/ml oral sol, 25 mg tablet, 50 mg tablet, 75 mg tablet, 100 mg tablet)</i> | |
| <i>carbamazepine (100 mg tab chew, 100 mg/5 ml susp, 200 mg tablet)</i> | |
| <i>carbamazepine er (er 100 mg cap, er 100 mg tablet, er 200 mg cap, er 200 mg tablet, er 300 mg cap, er 400 mg tablet)</i> | |
| EPIDIOLEX | <div style="text-align: center;"> S PA </div> |
| EPITOL | |
| <i>felbamate (400 mg tablet, 600 mg tablet, 600 mg/5 ml susp, 600 mg/5 ml susp cup)</i> | |
| <i>lamotrigine (25 mg tablet, 100 mg tablet, 150 mg tablet, 200 mg tablet)</i> | |
| <i>lamotrigine (5 mg disper tablet, 25 mg disper tab)</i> | |
| <i>lamotrigine (blue)</i> | |
| <i>lamotrigine (green)</i> | |
| <i>lamotrigine (orange)</i> | |
| <i>lamotrigine er</i> | |
| <i>levetiracetam (100 mg/ml soln, 500 mg/5 ml cup, 750 mg tablet, 1,000 mg tablet, 1,000mg/10ml cup)</i> | |
| <i>levetiracetam (250 mg tablet, 500 mg tablet)</i> | |
| <i>levetiracetam er</i> | |
| <i>perampanel (0.5 mg/ml oral susp, 2 mg tablet, 4 mg tablet, 6 mg tablet, 8 mg tablet, 10 mg tablet, 12 mg tablet)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| ROWEEPRA | |
| SUBVENITE (25 MG TABLET, 100 MG TABLET, 150 MG TABLET, 200 MG TABLET) | |
| SUBVENITE (BLUE) | |
| SUBVENITE (GREEN) | |
| SUBVENITE (ORANGE) | |
| <i>topiramate (15 mg cap, 25 mg cap, 50 mg cap)</i> | |
| <i>topiramate (25 mg tablet, 50 mg tablet, 100 mg tablet, 200 mg tablet)</i> | |
| <i>topiramate er 200mg sprink cap</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |
| <i>topiramate er sprinkle (er 25mg sprinkl cap, er 50mg sprinkl cap, er 100mg sprink cap, er 150mg sprink cap)</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| BARBITURATES (ANTICONVULSANTS) | |
| <i>primidone 250 mg tablet</i> | |
| <i>primidone 50 mg tablet</i> | |
| BENZODIAZEPINES (ANTICONVULSANTS) | |
| <i>clobazam 2.5 mg/ml suspension</i> | <div style="background-color: #DC143C; color: white; padding: 2px 5px; border-radius: 3px; width: 20px; margin: 0 auto;">S</div> |
| <i>clobazam (10 mg tablet, 20 mg tablet)</i> | |
| <i>clonazepam (0.5 mg tablet, 1 mg tablet, 2 mg tablet)</i> | |
| <i>clonazepam (0.125 mg dis tab, 0.125 mg odt, 0.25 mg odt, 0.5 mg dis tablet, 0.5 mg odt, 1 mg dis tablet, 1 mg odt, 2 mg odt)</i> | |
| GABA-MEDIATED ANTICONVULSANTS | |
| <i>divalproex dr 125 mg cap sprnk</i> | |
| <i>divalproex sodium (dr 125 mg tab, dr 250 mg tab, dr 500 mg tab)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>divalproex sodium er</i> | |
| <i>gabapentin (100 mg capsule, 300 mg capsule, 400 mg capsule, 600 mg tablet, 800 mg tablet)</i> | |
| <i>gabapentin (250 mg/5 ml soln, 250 mg/5ml soln cup, 300 mg/6ml soln cup)</i> | |
| <i>gabapentin er (er 300 mg tablet, er 450 mg tablet, er 750 mg tablet)</i> | ST QPD 1.0 per day |
| <i>gabapentin er 600 mg tablet</i> | ST QPD 3.0 per day |
| <i>gabapentin er 900 mg tablet</i> | ST QPD 2.0 per day |
| <i>pregabalin (150 mg capsule, 200 mg capsule)</i> | QPD 3.0 per day |
| <i>pregabalin (225 mg capsule, 300 mg capsule)</i> | QPD 2.0 per day |
| <i>pregabalin (75 mg capsule, 100 mg capsule)</i> | QPD 6.0 per day |
| <i>pregabalin 25 mg capsule</i> | QPD 12.0 per day |
| <i>pregabalin 50 mg capsule</i> | QPD 9.0 per day |
| <i>pregabalin 20 mg/ml solution</i> | QPD 30.0 per day |
| RELGAABI (300 MG CAPSULE, 400 MG CAPSULE) | |
| <i>tiagabine hcl</i> | |
| <i>valproic acid (250 mg capsule, 250 mg/5 ml cup, 250 mg/5 ml soln, 500 mg/10 ml cup)</i> | |
| <i>vigabatrin (500 mg powder packt, 500 mg tablet)</i> | S |
| VIGADRONE (500 MG POWDER PACKET, 500 MG TABLET) | S |
| VIGPODER | S |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| HYDANTOINS | |
| DILANTIN 30 MG CAPSULE | |
| PHENYTEK | |
| <i>phenytoin (50 mg infatab chew, 50 mg tablet chew, 125 mg/5 ml susp)</i> | |
| <i>phenytoin sodium extended</i> | |
| ION CHANNEL INHIBITION AGENTS | |
| <i>eslicarbazepine acetate</i> | |
| <i>lacosamide (10 mg/ml solution, 50 mg tablet, 50 mg/5 ml cup, 100 mg tablet, 100 mg/10 ml cup, 150 mg tablet, 150 mg/15 ml cup, 200 mg tablet, 200 mg/20 ml cup)</i> | |
| <i>oxcarbazepine (300 mg tablet, 300 mg/5 ml cup, 300 mg/5 ml susp, 600 mg tablet)</i> | |
| <i>oxcarbazepine 150 mg tablet</i> | |
| <i>oxcarbazepine er</i> | |
| <i>rufinamide (40 mg/ml suspension, 200 mg tablet, 400 mg tablet)</i> | |
| <i>zonisamide (25 mg capsule, 50 mg capsule)</i> | |
| <i>zonisamide 100 mg capsule</i> | |
| SUCCINIMIDES | |
| <i>ethosuximide (250 mg capsule, 250 mg/5 ml soln)</i> | |
| <i>methsuximide</i> | |
| ANTIDEPRESSANTS | |
| ANTIDEPRESSANTS, MISCELLANEOUS | |
| <i>bupropion hcl 100 mg tablet</i> | QPD 4.0 per day |
| <i>bupropion hcl 75 mg tablet</i> | QPD 6.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---------------------------|
| <i>bupropion hcl sr 150 mg tablet</i> | QPD 2.0 per day |
| <i>bupropion hcl sr 100 mg tablet</i> | QPD 4.0 per day |
| <i>bupropion hcl sr 200 mg tablet</i> | QPD 2.0 per day |
| <i>bupropion hcl xl 150 mg tablet</i> | QPD 3.0 per day |
| <i>bupropion hcl xl 300 mg tablet</i> | QPD 1.0 per day |
| ZURZUVAE (20 MG CAPSULE, 25 MG CAPSULE) | QL max 28 / 365 days S |
| ZURZUVAE 30 MG CAPSULE | QL max 14 / 365 days S |

MONOAMINE OXIDASE INHIBITORS

tranylcypromine sulfate

SEL.SEROTONIN,NOREPI REUPTAKE INHIBITOR

| | |
|---|------------------|
| <i>desvenlafaxine succinate er (er 25 mg, er 50 mg)</i> | QPD 1.0 per day |
| <i>desvenlafaxine succnt er 100mg</i> | QPD 4.0 per day |
| <i>duloxetine hcl dr 20 mg cap</i> | QPD 6.0 per day |
| <i>duloxetine hcl dr 30 mg cap</i> | QPD 4.0 per day |
| <i>duloxetine hcl dr 60 mg cap</i> | QPD 2.0 per day |
| <i>venlafaxine hcl (75 mg tablet, 100 mg tablet)</i> | QPD 3.0 per day |
| <i>venlafaxine hcl 25 mg tablet</i> | QPD 15.0 per day |
| <i>venlafaxine hcl 37.5 mg tablet</i> | QPD 10.0 per day |
| <i>venlafaxine hcl 50 mg tablet</i> | QPD 7.0 per day |
| <i>venlafaxine hcl er 150 mg cap</i> | QPD 2.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>venlafaxine hcl er 37.5 mg cap</i> | QPD 6.0 per day |
| <i>venlafaxine hcl er 75 mg cap</i> | QPD 3.0 per day |
| SELECTIVE-SEROTONIN REUPTAKE INHIBITORS | |
| <i>citalopram hbr 10 mg/5 ml soln</i> | QPD 20.0 per day |
| <i>citalopram hbr 10 mg tablet</i> | QPD 4.0 per day |
| <i>citalopram hbr 20 mg tablet</i> | QPD 2.0 per day |
| <i>citalopram hbr 40 mg tablet</i> | QPD 1.0 per day |
| <i>escitalopram oxalate (oxalate 5 mg/5 ml, 10 mg/10 ml cup)</i> | QPD 20.0 per day |
| <i>escitalopram 10 mg tablet</i> | QPD 2.0 per day |
| <i>escitalopram 20 mg tablet</i> | QPD 1.0 per day |
| <i>escitalopram 5 mg tablet</i> | QPD 4.0 per day |
| <i>fluoxetine hcl (10 mg capsule, 10 mg tablet)</i> | QPD 8.0 per day |
| <i>fluoxetine hcl 20 mg capsule</i> | QPD 4.0 per day |
| <i>fluoxetine hcl 40 mg capsule</i> | QPD 2.0 per day |
| <i>fluoxetine hcl (20 mg/5 ml soln cup, 20 mg/5 ml solution)</i> | QPD 20.0 per day |
| <i>fluoxetine hcl 20 mg tablet</i> | QPD 4.0 per day |
| <i>fluvoxamine maleate (25 mg tab, 50 mg tab)</i> | QPD 1.0 per day |
| <i>fluvoxamine maleate 100 mg tab</i> | QPD 3.0 per day |
| <i>paroxetine hcl 10 mg tablet</i> | QPD 6.0 per day |
| <i>paroxetine hcl 20 mg tablet</i> | QPD 3.0 per day |
| <i>paroxetine hcl 30 mg tablet</i> | QPD 2.0 per day |
| <i>paroxetine hcl 40 mg tablet</i> | QPD 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>sertraline 20 mg/ml oral conc</i> | QPD 10.0 per day |
| <i>sertraline hcl 100 mg tablet</i> | QPD 2.0 per day |
| <i>sertraline hcl 25 mg tablet</i> | QPD 8.0 per day |
| <i>sertraline hcl 50 mg tablet</i> | QPD 4.0 per day |
| SEROTONIN MODULATORS | |
| <i>mirtazapine (30 mg tablet, 45 mg tablet)</i> | QPD 1.0 per day |
| <i>mirtazapine (15 mg odt, 15 mg tablet)</i> | QPD 3.0 per day |
| <i>mirtazapine (7.5 mg tablet, 30 mg odt, 45 mg odt)</i> | QPD 1.0 per day |
| <i>trazodone hcl (50 mg tablet, 100 mg tablet, 150 mg tablet)</i> | |
| <i>vilazodone hcl</i> | QPD 1.0 per day |
| TRICYCLICS, OTHER NOREPI-RU INHIBITORS | |
| <i>amitriptyline hcl (10 mg tab, 25 mg tab, 50 mg tab, 75 mg tab, 100 mg tab)</i> | |
| <i>amitriptyline hcl 150 mg tab</i> | |
| <i>clomipramine hcl (25 mg capsule, 50 mg capsule, 75 mg capsule)</i> | |
| <i>desipramine 10 mg tablet</i> | |
| <i>desipramine hcl (25 mg tablet, 50 mg tablet, 75 mg tablet, 100 mg tablet, 150 mg tablet)</i> | |
| <i>doxepin hcl (10 mg capsule, 10 mg/ml oral conc, 25 mg capsule, 50 mg capsule)</i> | |
| <i>doxepin hcl (75 mg capsule, 100 mg capsule, 150 mg capsule)</i> | |
| <i>imipramine hcl (10 mg tablet, 25 mg tablet, 50 mg tablet)</i> | |
| <i>nortriptyline hcl (10 mg cap, 25 mg cap, 50 mg cap, 75 mg cap)</i> | |
| <i>nortriptyline 10 mg/5 ml soln</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>protriptyline hcl</i> | |
| <i>trimipramine maleate</i> | |
| ANTIDIABETIC AGENTS | |
| ALPHA-GLUCOSIDASE INHIBITORS | |
| <i>acarbose (25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | |
| ANTIDIABETIC AGENTS, MISCELLANEOUS | |
| <i>mifepristone 300 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 4.0 per day |
| BIGUANIDES | |
| <i>metformin hcl (500 mg tablet, 850 mg tablet, 1,000 mg tablet)</i> | |
| <i>metformin hcl er</i> | |
| DIPEPTIDYL PEPTIDASE-4(DPP-4) INHIBITORS | |
| JANUMET | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day |
| JANUMET XR (50-500 MG TABLET, 100-1,000 MG TABLET) | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day |
| JANUMET XR 50-1,000 MG TABLET | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day |
| JANUVIA | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day |
| INCRETIN MIMETICS | |
| MOUNJARO (5 MG/0.5 ML PEN, 7.5 MG/0.5 ML PEN, 10 MG/0.5 ML PEN, 12.5 MG/0.5 ML PEN, 15 MG/0.5 ML PEN) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.072 per day |
| MOUNJARO 2.5 MG/0.5 ML PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> max 2 / 180 days |
| OZEMPIC (0.25-0.5 MG/DOSE PEN, 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.108 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| OZEMPIC (4 MG TABLET, 9 MG TABLET) | <div style="display: flex; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; margin-right: 5px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| OZEMPIC 1.5 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; margin-right: 5px;">PA</div> <div style="background-color: #800080; color: white; padding: 2px 5px; margin-right: 5px;">QL</div> <div>max 30 / 180 days</div> </div> |
| RYBELSUS (7 MG TABLET, 14 MG TABLET) | <div style="display: flex; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; margin-right: 5px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| RYBELSUS 3 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; margin-right: 5px;">PA</div> <div style="background-color: #800080; color: white; padding: 2px 5px; margin-right: 5px;">QL</div> <div>max 30 / 180 days</div> </div> |
| TRULICITY | <div style="display: flex; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; margin-right: 5px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>0.072 per day</div> </div> |
| MEGLITINIDES | |
| <i>nateglinide</i> | |
| <i>repaglinide (0.5 mg tablet, 1 mg tablet)</i> | |
| <i>repaglinide 2 mg tablet</i> | |
| SODIUM-GLUC COTRANSPORT 2 (SGLT2) INHIB | |
| <i>dapagliflozin</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| FARXIGA | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| GLYXAMBI | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| JARDIANCE | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| SYNJARDY | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>2.0 per day</div> </div> |
| SYNJARDY XR (5-1,000 MG TABLET, 10-1,000 MG TABLET, 12.5-1,000 MG TAB) | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>2.0 per day</div> </div> |
| SYNJARDY XR 25-1,000 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: #4169E1; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-------------------------------------|
| TRIJARDY XR (10-5-1,000 MG TAB, 25-5-1,000 MG TAB) | QPD 1.0 per day |
| TRIJARDY XR (5-2.5-1,000 MG TAB, 12.5-2.5-1,000 MG) | QPD 2.0 per day |
| XIGDUO XR (2.5 MG TAB, 5 MG TABLET) | QPD 2.0 per day |
| XIGDUO XR (5 MG-500 MG TABLET, 10 MG-1,000 MG TAB, 10 MG-500 MG TABLET) | QPD 1.0 per day |
| SULFONYLUREAS | |
| <i>glimepiride (1 mg tablet, 2 mg tablet, 4 mg tablet)</i> | |
| <i>glipizide (5 mg tablet, 10 mg tablet)</i> | |
| <i>glipizide er</i> | |
| <i>glipizide xl</i> | |
| <i>glipizide-metformin</i> | |
| <i>glyburide (1.25 mg tablet, 2.5 mg tablet, 5 mg tablet)</i> | |
| <i>glyburide-metformin hcl</i> | |
| THIAZOLIDINEDIONES | |
| <i>pioglitazone hcl</i> | |
| <i>pioglitazone-metformin</i> | |
| ANTIDOTES (91:04) | |
| ACETAMINOPHEN ANTIDOTE | |
| <i>acetylcysteine (10% vial, 20% vial)</i> | |
| CHEMOTHERAPY ANTIDOTES/PROTECTANTS | |
| <i>leucovorin calcium (15 mg tab, 25 mg tab)</i> | PA QPD 1.0 per day |
| <i>leucovorin calcium 5 mg tab</i> | PA QPD 4.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>mesna 400 mg tablet</i> | S |
| ANTIEMETICS | |
| 5-HT3 RECEPTOR ANTAGONISTS | |
| <i>granisetron hcl 1 mg tablet</i> | |
| <i>ondansetron hcl (4 mg/5 ml soln cup, 4 mg/5 ml solution)</i> | |
| <i>ondansetron hcl (4 mg tablet, 8 mg tablet)</i> | |
| <i>ondansetron odt (odt 4 mg tablet, odt 8 mg tablet)</i> | |
| ANTIHISTAMINES (GI DRUGS) | |
| COMPRO | |
| <i>doxylamine succ-pyridoxine hcl</i> | |
| <i>meclizine hcl (12.5 mg tablet, 25 mg tablet, 50 mg tablet)</i> | |
| <i>prochlorperazine</i> | |
| <i>prochlorperazine maleate (5 mg tablet, 10 mg tab)</i> | |
| <i>trimethobenzamide 300 mg cap</i> | |
| NEUROKININ-1 RECEPTOR ANTAGONISTS | |
| <i>aprepitant (40 mg capsule, 125 mg capsule, 125-80-80 mg pack)</i> | |
| <i>aprepitant 80 mg capsule</i> | |
| EMEND 125 MG POWDER PACKET | |
| VARUBI | S |
| ANTIFUNGAL (SYSTEMIC) | |
| ALLYLAMINE ANTIFUNGALS | |
| <i>terbinafine hcl 250 mg tablet</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| ANTIFUNGALS, MISCELLANEOUS | |
| <i>griseofulvin (125 mg/5 ml susp, micro 500 mg tab)</i> | |
| <i>griseofulvin ultramicrosize (125 mg tab, 250 mg tab)</i> | |
| AZOLE ANTIFUNGALS | |
| <i>fluconazole (10 mg/ml susp, 40 mg/ml susp)</i> | |
| <i>fluconazole (50 mg tablet, 100 mg tablet, 150 mg tablet, 200 mg tablet)</i> | |
| <i>itraconazole (10 mg/ml solution, 100 mg capsule, 100 mg/10 ml cup)</i> | |
| NOXAFIL 300 MG POWDERMIX SUSP | PA |
| <i>posaconazole (dr 100 mg tablet, 200 mg/5 ml susp)</i> | PA |
| <i>voriconazole 40 mg/ml susp</i> | S PA |
| <i>voriconazole (50 mg tablet, 200 mg tablet)</i> | PA |
| PYRIMIDINE ANTIFUNGALS | |
| <i>flucytosine (250 mg capsule, 500 mg capsule)</i> | |
| ANTIFUNGALS (SKIN AND MUCOUS MEMBRANE) | |
| AZOLES (SKIN AND MUCOUS MEMBRANE) | |
| <i>clotrimazole (solution, solution spray, topical cream)</i> | |
| <i>clotrimazole (10 mg lozenge, 10 mg troche)</i> | |
| <i>clotrimazole-betamethasone crm</i> | |
| <i>econazole nitrate 1% cream</i> | |
| JUBLIA | |
| <i>ketoconazole 2% shampoo</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>ketoconazole (2% cream, 200 mg tablet)</i> | |
| <i>terconazole (0.4% cream, 0.8% cream, 80 mg suppository)</i> | |
| HYDROXYPYRIDONES (SKIN, MUCOUS MEMBRANE) | |
| CICLODAN 8% SOLUTION | |
| <i>ciclopirox 0.77% cream</i> | |
| <i>ciclopirox (0.77% gel, 0.77% topical susp, 1% shampoo, 8% solution)</i> | |
| POLYENES (SKIN AND MUCOUS MEMBRANE) | |
| KLAYESTA | |
| NYAMYC | |
| <i>nystatin (100,000 unit/gm cream, 100,000 unit/gm oint, 100,000 unit/ml susp, 500,000 unit/5 ml cup)</i> | |
| <i>nystatin (100,000 unit/gm powd, 500,000 unit oral tab)</i> | |
| NYSTOP | |
| ANTIGLAUCOMA AGENTS | |
| ALPHA-ADRENERGIC AGONISTS (52:40) | |
| <i>brimonidine 0.2% eye drop</i> | |
| BETA-ADRENERGIC BLOCKING AGENTS (52:40) | |
| <i>dorzolamide-timolol eye drops</i> | |
| <i>timolol maleate (0.25% drop, 0.5% drops)</i> | |
| CARBONIC ANHYDRASE INHIBITORS (52:40) | |
| <i>acetazolamide 125 mg tablet</i> | |
| <i>acetazolamide 250 mg tablet</i> | |
| <i>acetazolamide er</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|------------------------|
| <i>dorzolamide hcl</i> | |
| <i>methazolamide (25 mg tablet, 50 mg tablet)</i> | |
| SIMBRINZA | |
| MIOTICS | |
| <i>pilocarpine hcl (1% drops, 2% drops, 4% drops)</i> | |
| <i>pilocarpine hcl 1.25% eye drop</i> | QPD 0.167 per day |
| PROSTAGLANDIN ANALOGS | |
| <i>bimatoprost 0.01% eye drops</i> | QL max 2.5 per 30 days |
| <i>latanoprost 0.005% eye drops</i> | QL max 2.5 per 30 days |
| LUMIGAN | QL max 2.5 per 30 days |
| ANTIHEMORRHAGIC AGENTS | |
| HEMOSTATICS | |
| AFSTYLA | S PA |
| ALPHANATE | S PA |
| ALPHANINE SD | S PA |
| <i>aminocaproic acid (0.25 gram/ml, 500 mg tab, 1,000 mg tab)</i> | |
| COAGADDEX | S |
| CORIFACT | S |
| ELOCTATE | S PA |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------|-----------------------|
| ESPEROCT | S PA |
| FEIBA | S |
| FIBRYGA | S |
| HUMATE-P | S PA |
| IDELVION | S PA |
| IXINITY | S PA |
| KOATE | S PA |
| KOGENATE FS | S PA |
| KOVALTRY | S PA |
| NOVOEIGHT | S PA |
| NOVOSEVEN RT | S PA |
| NUWIQ | S PA |
| PROFILNINE | S PA |
| REBINYN | S PA |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| RECOMBINATE | S PA |
| RIASTAP | S |
| RIXUBIS | S PA |
| <i>tranexamic acid 650 mg tablet</i> | |
| TRETTEN | S |
| WILATE | S PA |
| ANTIHISTAMINE DRUGS | |
| FIRST GENERATION ANTIHISTAMINES | |
| <i>carbinoxamine maleate 4 mg tab</i> | |
| SECOND GENERATION ANTIHISTAMINES | |
| <i>cetirizine hcl (1 mg/ml soln, 1 mg/ml syrup)</i> | |
| <i>desloratadine 5 mg tablet</i> | |
| <i>levocetirizine dihydrochloride (2.5 mg/5 ml sol, 5 mg tablet)</i> | |
| ANTIHYPOGLYCEMIC AGENTS | |
| ANTIHYPOGLYCEMIC AGENTS, MISCELLANEOUS | |
| <i>diazoxide 50 mg/ml oral susp</i> | |
| GLYCOGENOLYTIC AGENTS | |
| BAQSIMI | |
| GLUCAGON 1 MG EMERGENCY KIT | |
| GVOKE | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| GVOKE HYPOPEN 1-PACK | |
| GVOKE HYPOPEN 2-PACK | |
| GVOKE PFS 1-PACK SYRINGE | |
| GVOKE PFS 2-PACK SYRINGE | |
| ZEGALOGUE AUTOINJECTOR | |
| ZEGALOGUE SYRINGE | |
| ANTILIPEMIC AGENTS | |
| ACL INHIBITORS | |
| NEXLETOL | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| NEXLIZET | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| ANTILIPEMIC AGENTS, MISCELLANEOUS | |
| <i>niacin er</i> | |
| BILE ACID SEQUESTRANTS | |
| <i>cholestyramine powder</i> | |
| <i>cholestyramine light powder</i> | |
| <i>colesevelam 625 mg tablet</i> | |
| <i>colestipol hcl (1 gm tablet, granules, granules packet)</i> | |
| PREVALITE POWDER | |
| CHOLESTEROL ABSORPTION INHIBITORS | |
| <i>ezetimibe</i> | |
| <i>ezetimibe-simvastatin</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| FIBRIC ACID DERIVATIVES | |
| <i>fenofibrate (48 mg tablet, 54 mg tablet, 67 mg capsule, 134 mg capsule, 145 mg tablet, 160 mg tablet, 200 mg capsule)</i> | |
| <i>gemfibrozil 600 mg tablet</i> | |
| HMG-COA REDUCTASE INHIBITORS | |
| <i>atorvastatin calcium (10 mg tablet, 20 mg tablet)</i> | |
| <i>atorvastatin calcium (40 mg tablet, 80 mg tablet)</i> | |
| <i>lovastatin (10 mg tablet, 20 mg tablet, 40 mg tablet)</i> | |
| <i>pravastatin sodium</i> | |
| <i>rosuvastatin calcium</i> | |
| <i>simvastatin (5 mg tablet, 10 mg tablet, 20 mg tablet, 40 mg tablet)</i> | |
| <i>simvastatin 80 mg tablet</i> | |
| OMEGA-3-MEDIATED ANTILIPEMICS | |
| VASCEPA | |
| PCSK9 INHIBITORS | |
| REPATHA PUSHTRONEX | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806040; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.25 per day</div> |
| REPATHA SURECLICK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806040; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.215 per day</div> |
| REPATHA SYRINGE | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806040; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.215 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|----------------------------|
| ANTIMETABOLITES, IMMUNOSUPPRESS THERAPY | |
| ANTIMETABOLITES, IMMUNOSUPP THERAPY MISC | |
| AZASAN | |
| <i>azathioprine (50 mg tablet, 75 mg tablet, 100 mg tablet)</i> | |
| <i>mycophenolate mofetil (200 mg/ml susp, 250 mg capsule, 500 mg tablet)</i> | S |
| <i>mycophenolic acid</i> | S |
| MYHIBBIN | S |
| ANTIMIGRAINE AGENTS | |
| CALCITONIN GENE-RELATED PEPTIDE ANTAG. | |
| AIMOVIG AUTOINJECTOR | PA QPD 0.036 per day |
| AJOVY AUTOINJECTOR | QL max 4.5 / 84 days PA |
| AJOVY AUTOINJECTOR (3 PACK) | QL max 4.5 / 84 days PA |
| AJOVY SYRINGE | QL max 4.5 / 84 days PA |
| EMGALITY PEN | PA QPD 0.036 per day |
| EMGALITY 120 MG/ML SYRINGE | PA QPD 0.036 per day |
| EMGALITY SYRINGE (100 MG/ML SYR(1 OF 3), 300 MG (100 MG X3SYR)) | QL max 9 / 180 days PA |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-------------------------|
| NURTEC ODT | PA QPD 0.534 per day |
| QULIPTA | PA QPD 1.0 per day |
| UBRELVY | PA QPD 0.534 per day |
| SELECTIVE SEROTONIN AGONISTS | |
| <i>eletriptan hbr</i> | QPD 0.4 per day |
| <i>naratriptan hcl</i> | QPD 0.6 per day |
| <i>rizatriptan (5 mg odt, 5 mg tablet, 10 mg odt, 10 mg tablet)</i> | QPD 0.6 per day |
| <i>sumatriptan (5 mg nasal spray, 20 mg nasal spray)</i> | QPD 0.4 per day |
| <i>sumatriptan succinate (4 mg/0.5 ml inject, 6 mg/0.5ml autoinj)</i> | QPD 0.2 per day |
| <i>sumatriptan succinate (25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | QPD 0.6 per day |
| <i>sumatriptan 6 mg/0.5 ml vial</i> | QPD 0.167 per day |
| <i>zolmitriptan (2.5 mg tablet, 5 mg tablet)</i> | QPD 0.4 per day |
| ZOMIG (2.5 MG TABLET, 5 MG TABLET) | QPD 0.4 per day |
| ANTIMYCOBACTERIALS | |
| ANTILEPROSY AGENTS | |
| <i>dapsone (25 mg tablet, 100 mg tablet)</i> | |
| ANTITUBERCULOSIS AGENTS | |
| <i>ethambutol hcl</i> | |
| <i>isoniazid 50 mg/5 ml solution</i> | |
| <i>isoniazid (100 mg tablet, 300 mg tablet)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---------------------------------|
| <i>pretomanid</i> | |
| PRIFTIN | |
| <i>pyrazinamide 500 mg tablet</i> | |
| <i>rifabutin</i> | |
| <i>rifampin (150 mg capsule, 300 mg capsule)</i> | |
| SIRTURO | S |
| ANTINEOPLASTIC AGENTS | |
| <i>abiraterone acetate 250 mg tab</i> | S PA QPD 4.0 per day |
| <i>abiraterone acetate 500 mg tab</i> | S PA QPD 2.0 per day |
| ABIRTEGA | S PA QPD 4.0 per day |
| ALECENSA | S PA QPD 8.0 per day |
| ALUNBRIG 90 MG-180 MG TAB PACK | QL max 30 / 180 days S PA |
| ALUNBRIG (90 MG TABLET, 180 MG TABLET) | S PA QPD 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| ALUNBRIG 30 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 4.0 per day </div> |
| <i>anastrozole 1 mg tablet</i> | |
| BESREMI | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 0.072 per day </div> |
| <i>bexarotene 75 mg capsule</i> | |
| <i>bicalutamide</i> | |
| BOSULIF (50 MG CAPSULE, 400 MG TABLET, 500 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 1.0 per day </div> |
| BOSULIF 100 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 5.0 per day </div> |
| BOSULIF 100 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 3.0 per day </div> |
| BRUKINSA 80 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 4.0 per day </div> |
| BRUKINSA 160 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 2.0 per day </div> |
| CABOMETYX | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> 1.0 per day </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| CALQUENCE | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| <i>capecitabine</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> |
| CAPRELSA 100 MG TABLET | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| CAPRELSA 300 MG TABLET | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| COMETRIQ 100 MG DAILY-DOSE PK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| COMETRIQ 140 MG DAILY-DOSE PK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 4.0 per day</div> |
| COMETRIQ 60 MG DAILY-DOSE PACK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |
| COTELLIC | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.25 per day</div> |
| <i>cyclophosphamide (25 mg capsule, 50 mg capsule)</i> | |
| <i>cyclophosphamide (25 mg tablet, 50 mg tablet)</i> | |
| <i>dasatinib (50 mg tablet, 70 mg tablet, 80 mg tablet, 100 mg tablet, 140 mg tablet)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| <i>dasatinib 20 mg tablet</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |
| EMCYT | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| <i>ERIVEDGE</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| <i>ERLEADA 240 MG TABLET</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| <i>ERLEADA 60 MG TABLET</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 4.0 per day</div> |
| <i>erlotinib hcl (100 mg tablet, 150 mg tablet)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| <i>erlotinib hcl 25 mg tablet</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| <i>etoposide 50 mg capsule</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| <i>everolimus (0.25 mg tablet, 0.5 mg tablet, 0.75 mg tablet, 1 mg tablet)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| <i>everolimus (2.5 mg tablet, 5 mg tablet, 7.5 mg tablet, 10 mg tablet)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| <i>everolimus (2 mg tab susp, 5 mg tab susp)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #806432; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>everolimus 3 mg tab for susp</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |
| <i>exemestane</i> | |
| <i>gefitinib</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| GILOTRIF | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| GLEOSTINE | <div style="background-color: #660099; color: white; padding: 2px; text-align: center;">QL max 42 days / fill</div> <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| HYCAMTIN | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> |
| <i>hydroxyurea 500 mg capsule</i> | |
| IBRANCE (75 MG CAPSULE, 75 MG TABLET, 100 MG CAPSULE, 100 MG TABLET, 125 MG CAPSULE, 125 MG TABLET) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.75 per day</div> |
| <i>imatinib mesylate 100 mg tab</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |
| <i>imatinib mesylate 400 mg tab</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| IMBRUVICA 140 MG CAPSULE | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| IMBRUVICA 70 MG/ML SUSPENSION | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 7.2 per day</div> |
| IMBRUVICA (70 MG CAPSULE, 140 MG TABLET, 280 MG TABLET, 420 MG TABLET) | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| INLYTA 1 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 6.0 per day</div> |
| INLYTA 5 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 4.0 per day</div> |
| ITOVEBI 3 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| ITOVEBI 9 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| JAKAFI | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| KISQALI 200 MG DAILY DOSE | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.75 per day</div> |
| KISQALI 400 MG DAILY DOSE | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #8b5732; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.5 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| KISQALI 600 MG DAILY DOSE | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 2.25 per day</div> |
| KISQALI FEMARA 200 MG CO-PACK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 1.75 per day</div> |
| KISQALI FEMARA 400 MG CO-PACK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 2.5 per day</div> |
| KISQALI FEMARA 600 MG CO-PACK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 3.25 per day</div> |
| <i>lapatinib</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 6.0 per day</div> |
| <i>lenalidomide (15 mg capsule, 20 mg capsule, 25 mg capsule)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.75 per day</div> |
| <i>lenalidomide (2.5 mg capsule, 5 mg capsule, 10 mg capsule)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| LENVIMA (12 MG DAILY, 18 MG DAILY, 24 MG DAILY) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 3.0 per day</div> |
| LENVIMA (4 MG CAPSULE, 10 MG DAILY DOSE) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|------------------------------|
| LENVIMA (8 MG DAILY, 14 MG DAILY, 20 MG DAILY) | S PA QPD 2.0 per day |
| <i>letrozole 2.5 mg tablet</i> | |
| LEUKERAN | S |
| <i>lomustine</i> | QL max 42 days / fill S |
| LONSURF 15 MG-6.14 MG TABLET | S PA QPD 2.143 per day |
| LONSURF 20 MG-8.19 MG TABLET | S PA QPD 2.858 per day |
| LYNPARZA | S PA QPD 4.0 per day |
| LYSODREN | S PA |
| MATULANE | S PA |
| MEKINIST 0.05 MG/ML SOLUTION | S PA QPD 41.8 per day |
| MEKINIST 0.5 MG TABLET | S PA QPD 3.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| MEKINIST 2 MG TABLET | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| <i>mercaptopurine (20 mg/ml suspen, 50 mg tablet)</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| <i>methotrexate 2.5 mg tablet</i> | |
| <i>methotrexate 1 gm vial</i> | |
| <i>methotrexate 1 gram/40 ml vial</i> | |
| MYLERAN | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| <i>nilotinib hcl</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 4.0 per day</div> |
| <i>nilutamide</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> |
| NINLARO | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 0.108 per day</div> |
| NUBEQA | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 4.0 per day</div> |
| ODOMZO | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 1.0 per day</div> |
| OGSIVEO (100 MG TABLET, 150 MG TABLET) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 2.0 per day</div> |
| OGSIVEO 50 MG TABLET | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD 6.0 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|------------------------------------|---|
| OTREXUP | |
| <i>pazopanib hcl 200 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>4.0 per day</div> </div> |
| <i>pazopanib hcl 400 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>2.0 per day</div> </div> |
| <i>pomalidomide</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>0.75 per day</div> </div> |
| PURIXAN | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| RASUVO | |
| ROMVIMZA | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>0.286 per day</div> </div> |
| ROZLYTREK 100 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>1.0 per day</div> </div> |
| ROZLYTREK 200 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>3.0 per day</div> </div> |
| ROZLYTREK 50 MG PELLETT PACKET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>12.0 per day</div> </div> |
| RUBRACA | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> <div>4.0 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| RYDAPT | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 8.0 per day |
| SCEMBLIX 100 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 4.0 per day |
| SCEMBLIX 20 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| SCEMBLIX 40 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 8.0 per day |
| <i>sorafenib</i> | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 4.0 per day |
| STIVARGA | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 3.0 per day |
| <i>sunitinib malate (25 mg capsule, 37.5 mg cap, 50 mg capsule)</i> | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>sunitinib malate 12.5 mg cap</i> | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 3.0 per day |
| TABLOID | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> |
| TAFINLAR (50 MG CAPSULE, 75 MG CAPSULE) | <div style="background-color: #e91e63; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #795548; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; text-align: center;">QPD</div> 4.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| TAFINLAR 10 MG TABLET FOR SUSP | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 30.0 per day |
| TALZENNA (0.1 MG CAPSULE, 0.1 MG SOFTGEL, 0.35 MG CAPSULE, 0.35 MG SOFTGEL, 0.5 MG CAPSULE, 0.5 MG SOFTGEL, 0.75 MG CAPSULE, 0.75 MG SOFTGEL, 1 MG CAPSULE, 1 MG SOFTGEL) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| TALZENNA (0.25 MG CAPSULE, 0.25 MG SOFTGEL) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 3.0 per day |
| TAZVERIK | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 8.0 per day |
| <i>temozolomide</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> </div> |
| TORPENZ | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| <i>tretinoin 10 mg capsule</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> </div> |
| VENCLEXTA (10 MG TAB (10MG X 2), 10 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 2.0 per day |
| VENCLEXTA 100 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 6.0 per day |
| VENCLEXTA 50 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| VENCLEXTA STARTING PACK | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin-bottom: 5px;">max 42 / 180 days</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| VERZENIO | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">2.0 per day</div> </div> |
| VITRAKVI 100 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">2.0 per day</div> </div> |
| VITRAKVI 25 MG CAPSULE | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">6.0 per day</div> </div> |
| VITRAKVI 20 MG/ML SOLUTION | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">10.0 per day</div> </div> |
| XALKORI (20 MG PELLETT, 50 MG PELLETT, 200 MG CAPSULE, 250 MG CAPSULE) | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">4.0 per day</div> </div> |
| XALKORI 150 MG PELLETT | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">6.0 per day</div> </div> |
| XTANDI (40 MG CAPSULE, 40 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">4.0 per day</div> </div> |
| XTANDI 80 MG TABLET | <div style="display: flex; flex-direction: column; align-items: flex-start;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-left: 5px;">2.0 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| YONSA | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 4.0 per day |
| ZEJULA | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 1.0 per day |
| ZELBORAF | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 8.0 per day |
| ZOLINZA | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 4.0 per day |
| ZYDELIG | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| ZYKADIA | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #795548; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 3.0 per day |
| ANTIPARKINSONIAN AGENTS (CNS) | |
| ADAMANTANES (CNS) | |
| <i>amantadine (50 mg/5 ml solution, 100 mg capsule, 100 mg/10 ml cup)</i> | |
| ANTICHOLINERGIC AGENTS (CNS) | |
| <i>benztropine mesylate (0.5 mg tab, 1 mg tablet, 2 mg tablet)</i> | |
| <i>trihexyphenidyl hcl (2 mg tablet, 5 mg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| CATECHOL-O-METHYLTRANSFERASE(COMT)INHIB. | |
| <i>entacapone</i> | |
| <i>tolcapone</i> | |
| DOPAMINE PRECURSORS | |
| <i>carbidopa-levodopa 10-100 tab</i> | |
| <i>carbidopa-levodopa (carbidopa-levo 10-100 mg odt, carbidopa-levo 25-100 mg odt, carbidopa-levo 25-250 mg odt, carbidopa-levodopa 25-100 tab, carbidopa-levodopa 25-250 tab)</i> | |
| <i>carbidopa-levodopa er (er 25-100 tab, er 50-200 tab)</i> | |
| <i>carbidopa-levodopa-entacapone</i> | |
| INBRIJA | S |
| MONOAMINE OXIDASE B INHIBITORS | |
| <i>rasagiline mesylate (0.5 mg tab, 1 mg tab)</i> | |
| <i>selegiline hcl (5 mg capsule, 5 mg tablet)</i> | |
| ANTIPROTOZOALS | |
| AMEBICIDES | |
| HUMATIN | |
| ANTIMALARIALS | |
| <i>atovaquone-proguanil hcl</i> | |
| <i>chloroquine phosphate (250 mg tablet, 500 mg tablet)</i> | |
| <i>hydroxychloroquine sulfate (100 mg tab, 300 mg tab)</i> | |
| <i>hydroxychloroquine sulfate (200 mg tab, 400 mg tab)</i> | |
| <i>mefloquine hcl</i> | |
| <i>primaquine</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>pyrimethamine 25 mg tablet</i> | S |
| <i>quinine sulfate 324 mg capsule</i> | |
| ANTIPROTOZOALS, CRYPTOSPORIDIOSIS | |
| ALINIA 100 MG/5 ML SUSPENSION | QL max 300 / 90 days |
| <i>nitazoxanide 500 mg tablet</i> | QL max 12 / 90 days |
| ANTIPROTOZOALS, P JIROVECII PNEUMONIA | |
| <i>atovaquone</i> | |
| <i>pentamidine 300 mg inhal powdr</i> | |
| ANTIPROTOZOALS,NITROIMIDAZOLE-DERIVATIVE | |
| SOLOSEC | |
| <i>tinidazole (250 mg tablet, 500 mg tablet)</i> | |
| ANTIPROTOZOALS,NITROIMIDAZOLE-DERIVATIVE | |
| NITROIMIDAZOLE DERIVATIVE, ANTI-LEISHMAL | |
| IMPAVIDO | S |
| NITROIMIDAZOLE DERIVATIVE, TRYPANOCIDAL | |
| <i>benznidazole</i> | |
| NITROIMIDAZOLE DERIVATIVES, MISC | |
| <i>metronidazole vaginal 0.75% gl</i> | |
| <i>metronidazole (250 mg tablet, 500 mg tablet)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| ANTIPSYCHOTIC AGENTS | |
| ATYPICAL ANTIPSYCHOTICS | |
| <i>aripiprazole 1 mg/ml solution</i> | QPD 30.0 per day |
| <i>aripiprazole (2 mg tablet, 5 mg tablet, 10 mg tablet, 15 mg tablet, 20 mg tablet)</i> | QPD 1.0 per day |
| <i>aripiprazole 30 mg tablet</i> | QPD 1.0 per day |
| <i>aripiprazole odt</i> | QPD 2.0 per day |
| <i>asenapine maleate</i> | QPD 2.0 per day |
| <i>clozapine 100 mg tablet</i> | QPD 9.0 per day |
| <i>clozapine 200 mg tablet</i> | QPD 4.0 per day |
| <i>clozapine 25 mg tablet</i> | QPD 3.0 per day |
| <i>clozapine 50 mg tablet</i> | QPD 3.0 per day |
| <i>clozapine odt (odt 12.5 mg tablet, odt 100 mg tablet)</i> | QPD 3.0 per day |
| <i>clozapine odt 150 mg tablet</i> | QPD 6.0 per day |
| <i>clozapine odt 200 mg tablet</i> | QPD 4.0 per day |
| <i>clozapine odt 25 mg tablet</i> | QPD 9.0 per day |
| <i>lurasidone hcl (20 mg tablet, 40 mg tablet, 60 mg tablet, 120 mg tablet)</i> | QPD 1.0 per day |
| <i>lurasidone hcl 80 mg tablet</i> | QPD 2.0 per day |
| <i>olanzapine (2.5 mg tablet, 5 mg tablet, 7.5 mg tablet, 10 mg tablet, 15 mg tablet)</i> | QPD 1.0 per day |
| <i>olanzapine 20 mg tablet</i> | QPD 1.0 per day |
| <i>olanzapine odt</i> | QPD 1.0 per day |
| <i>paliperidone er (er 1.5 mg tablet, er 3 mg tablet, er 9 mg tablet)</i> | QPD 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>paliperidone er 6 mg tablet</i> | QPD 2.0 per day |
| <i>quetiapine fumarate (25 mg tab, 50 mg tab, 100 mg tab, 200 mg tab)</i> | QPD 3.0 per day |
| <i>quetiapine fumarate (300 mg tab, 400 mg tab)</i> | QPD 2.0 per day |
| <i>quetiapine er 50 mg tablet</i> | QPD 2.0 per day |
| <i>quetiapine fumarate er (er 150 mg tablet, er 200 mg tablet)</i> | QPD 1.0 per day |
| <i>quetiapine fumarate er (er 300 mg tablet, er 400 mg tablet)</i> | QPD 2.0 per day |
| REXULTI (0.25 MG TABLET, 0.5 MG TABLET, 1 MG TABLET, 2 MG TABLET, 3 MG TABLET, 4 MG TABLET) | QPD 1.0 per day |
| <i>risperidone 1 mg/ml solution</i> | QPD 16.0 per day |
| <i>risperidone (0.25 mg tablet, 0.5 mg tablet, 1 mg tablet, 2 mg tablet, 3 mg tablet)</i> | QPD 2.0 per day |
| <i>risperidone 4 mg tablet</i> | QPD 4.0 per day |
| <i>risperidone 4 mg odt</i> | QPD 4.0 per day |
| <i>risperidone odt (0.5 mg odt, 1 mg odt, 2 mg odt, 3 mg odt)</i> | QPD 2.0 per day |
| VRAYLAR | QPD 1.0 per day |
| <i>ziprasidone hcl</i> | QPD 2.0 per day |
| BUTYROPHENONES | |
| <i>haloperidol (0.5 mg tablet, 1 mg tablet)</i> | |
| <i>haloperidol (2 mg tablet, 5 mg tablet, 10 mg tablet, 20 mg tablet)</i> | |
| <i>haloperidol lactate (2 mg/ml conc, 10 mg/5 ml cup)</i> | |
| DIBENZOXAPINES | |
| <i>loxapine</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| PHENOTHIAZINES | |
| <i>chlorpromazine hcl (10 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablet, 200 mg tablet)</i> | |
| <i>fluphenazine hcl (1 mg tablet, 2.5 mg tablet, 5 mg tablet, 10 mg tablet)</i> | |
| <i>perphenazine (2 mg tablet, 4 mg tablet, 8 mg tablet, 16 mg tablet)</i> | |
| <i>trifluoperazine hcl</i> | |
| THIOXANTHENES | |
| <i>thiothixene</i> | |
| ANTIRETROVIRALS | |
| HIV CAPSID INHIBITORS | |
| YEZTUGO 300 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: #4a4a9a; color: white; padding: 2px 5px; margin-right: 5px;">QL</div> <div style="margin-right: 5px;">max 4 / 365 days</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; margin-right: 5px;">S</div> </div> |
| YEZTUGO 463.5 MG/1.5 ML VIAL | <div style="display: flex; align-items: center;"> <div style="background-color: #4a4a9a; color: white; padding: 2px 5px; margin-right: 5px;">QL</div> <div style="margin-right: 5px;">max 182 days / fill</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; margin-right: 5px;">S</div> </div> |
| HIV ENTRY AND FUSION INHIBITORS | |
| <i>maraviroc 150 mg tablet</i> | <div style="display: flex; align-items: center; margin-bottom: 2px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; margin-right: 5px;">S</div> </div> <div style="display: flex; align-items: center;"> <div style="background-color: #0070c0; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div style="margin-right: 5px;">2.0 per day</div> </div> |
| <i>maraviroc 300 mg tablet</i> | <div style="display: flex; align-items: center; margin-bottom: 2px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; margin-right: 5px;">S</div> </div> <div style="display: flex; align-items: center;"> <div style="background-color: #0070c0; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> <div style="margin-right: 5px;">4.0 per day</div> </div> |
| HIV INTEGRASE INHIBITOR ANTIRETROVIRALS | |
| APRETUDE | <div style="display: flex; align-items: center;"> <div style="background-color: #4a4a9a; color: white; padding: 2px 5px; margin-right: 5px;">QL</div> <div style="margin-right: 5px;">max 60 days / fill</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; margin-right: 5px;">S</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| BIKTARVY | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| DOVATO | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| ISENTRESS (100 MG POWDER PACKET, 400 MG TABLET) | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |
| ISENTRESS (25 MG TABLET CHEW, 100 MG TABLET CHEW) | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 6.0 per day </div> |
| ISENTRESS HD | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |
| JULUCA | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| TIVICAY | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |
| TIVICAY PD | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 12.0 per day </div> |
| HIV NONNUCLEOSIDE REV. TRANSCRIP. INHIB. | |
| DELSTRIGO | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| <i>efavirenz 600 mg tablet</i> | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| <i>efavir-lamiv-tenof 600-300-300</i> | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| <i>etravirine</i> | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| INTELENCE 25 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 4.0 per day </div> |
| <i>nevirapine 200 mg tablet</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 2.0 per day </div> |
| <i>nevirapine er 400 mg tablet</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| <i>rilpivirine</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| HIV NUCLEOSIDE, NUCLEOTIDE RT INHIBITORS | |
| <i>abacavir 20 mg/ml solution</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 32.0 per day </div> |
| <i>abacavir 300 mg tablet</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 2.0 per day </div> |
| <i>abacavir-lamivudine</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| CIMDUO | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| DESCOVY 120-15 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| DESCOVY 200-25 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| <i>efavirenz-emtricitabine-tenofovir disoproxil fumarate</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |
| <i>emtricitabine</i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; margin-right: 5px;">QPD</div> 1.0 per day </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| <i>emtricitabine-riopivirine-tenof</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>emtricitabine-tenofovir disop (100-150mg, 133-200mg, 167-250mg)</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>emtricitabine-tenofv 200-300mg</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| GENVOYA | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>lamivudine (10 mg/ml oral soln, 300 mg/30ml sol cup)</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 32.0 per day |
| <i>lamivudine 150 mg tablet</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| <i>lamivudine 300 mg tablet</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>lamivudine hbv</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> |
| <i>lamivudine-zidovudine</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| ODEFSEY | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| <i>stavudine</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| <i>tenofovir disoproxil fumarate</i> | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| TRIUMEQ | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 1.0 per day |
| TRIUMEQ PD | <div style="background-color: red; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: blue; color: white; padding: 2px; text-align: center;">QPD</div> 6.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| VIREAD POWDER | S QPD 8.0 per day |
| VIREAD (150 MG TABLET, 200 MG TABLET, 250 MG TABLET) | S QPD 1.0 per day |
| <i>zidovudine 100 mg capsule</i> | S QPD 6.0 per day |
| <i>zidovudine 50 mg/5 ml syrup</i> | S QPD 64.0 per day |
| <i>zidovudine 300 mg tablet</i> | S QPD 2.0 per day |
| HIV PROTEASE INHIBITOR ANTIRETROVIRALS | |
| <i>atazanavir sulfate (150 mg cap, 300 mg cap)</i> | S QPD 1.0 per day |
| <i>atazanavir sulfate 200 mg cap</i> | S QPD 2.0 per day |
| <i>darunavir 600 mg tablet</i> | S QPD 2.0 per day |
| <i>darunavir 800 mg tablet</i> | S QPD 1.0 per day |
| EVOTAZ | S QPD 1.0 per day |
| <i>fosamprenavir calcium</i> | S QPD 4.0 per day |
| KALETRA 80 MG-20 MG/ML SOLN | S QPD 16.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-------------------------|
| <i>lopinavir-ritonavir 100-25mg tb</i> | S QPD 6.0 per day |
| <i>lopinavir-ritonavir 200-50mg tb</i> | S QPD 4.0 per day |
| PREZCOBIX | S QPD 1.0 per day |
| PREZISTA 100 MG/ML SUSPENSION | S QPD 13.334 per day |
| PREZISTA 150 MG TABLET | S QPD 6.0 per day |
| PREZISTA 75 MG TABLET | S QPD 10.0 per day |
| <i>ritonavir</i> | S QPD 12.0 per day |
| SYMTUZA | S QPD 1.0 per day |
| ANTITHROMBOTIC AGENTS | |
| PLATELET-AGGREGATION INHIBITORS | |
| <i>cilostazol</i> | |
| <i>clopidogrel 75 mg tablet</i> | |
| <i>dipyridamole (25 mg tablet, 50 mg tablet, 75 mg tablet)</i> | |
| <i>prasugrel hcl</i> | |
| <i>ticagrelor</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| PLATELET-REDUCING AGENTS | |
| <i>anagrelide hcl</i> | |
| ANTITOXINS, IMMUNE GLOB, TOXOIDS, VACCINES | |
| TOXOIDS | |
| ADACEL TDAP (SYRINGE, VIAL) | |
| BOOSTRIX TDAP (SYRINGE, VIAL) | |
| DAPTACEL DTAP | |
| INFANRIX DTAP | |
| <i>tdvax</i> | |
| TENIVAC (SYRINGE, VIAL) | |
| VAXELIS (SYRINGE, VIAL) | |
| VACCINES | |
| ABRYOVO | |
| ACTHIB | |
| AFLURIA 2025-2026 | |
| AFLURIA 2025-2026 (3YR UP) | |
| AFLURIA QUAD 2023-2024 | |
| AFLURIA QUAD 2023-24 (3YR UP) | |
| AFLURIA TRIV 2024-25 (3YR UP) | |
| AFLURIA TRIVALENT 2024-25 | |
| AREXVY | |
| AREXVY ADJUVANT COMPONENT | |
| AREXVY ANTIGEN COMPONENT | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| BEXSERO | |
| CAPVAXIVE | |
| COMIRNATY 2023-2024 (2023-24(12Y SYRG, 2023-24(12Y VIAL) | |
| COMIRNATY 2024-2025 | |
| COMIRNATY 2025-2026 (12Y UP) | |
| COMIRNATY 2025-2026(5-11Y) | |
| ENGERIX-B ADULT (20 MCG/ML SYRN, 20 MCG/ML VIAL) | |
| ENGERIX-B PEDIATRIC-ADOLESCENT | |
| FLUAD 2025-2026 | |
| FLUAD QUAD 2023-2024 | |
| FLUAD TRIVALENT 2024-2025 | |
| FLUARIX 2025-2026 | |
| FLUARIX QUAD 2023-2024 | |
| FLUARIX TRIVALENT 2024-2025 | |
| FLUBLOK 2025-2026 | |
| FLUBLOK QUAD 2023-2024 | |
| FLUBLOK TRIVALENT 2024-2025 | |
| FLUCELVAX 2025-2026 SYRINGE | |
| FLUCELVAX 2025-2026 VIAL | |
| FLUCELVAX QUAD 2023-2024 SYR | |
| FLUCELVAX QUAD 2023-2024 VIAL | |
| FLUCELVAX TRIVAL 2024-2025 SYR | |
| FLUCELVAX TRIVAL 2024-2025 VL | |
| FLULAVAL 2025-2026 | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--------------------------------|-----------------------|
| FLULAVAL QUAD 2023-2024 | |
| FLULAVAL TRIVALENT 2024-2025 | |
| FLUMIST 2025-2026 | |
| FLUMIST HOME 2025-2026 | |
| FLUMIST QUAD 2023-2024 | |
| FLUMIST TRIVALENT 2024-2025 | |
| FLUZONE 2025-2026 SYRINGE | |
| FLUZONE 2025-2026 VIAL | |
| FLUZONE HIGH-DOSE 2025-2026 | |
| FLUZONE HIGH-DOSE QUAD 2023-24 | |
| FLUZONE HIGH-DOSE TRIV 2024-25 | |
| FLUZONE QUAD 2023-2024 SYRINGE | |
| FLUZONE QUAD 2023-2024 VIAL | |
| FLUZONE QUAD SOUTH HEM2024 SYR | |
| FLUZONE TRIVALENT 2024-25 SYRG | |
| FLUZONE TRIVALENT 2024-25 VIAL | |
| GARDASIL 9 (9 SYRINGE, 9 VIAL) | |
| HAVRIX | |
| HEPLISAV-B | |
| HIBERIX | |
| IMOVAX RABIES VACCINE | |
| IPOL VIAL | |
| JYNNEOS | |
| JYNNEOS (NATIONAL STOCKPILE) | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| KINRIX | |
| M-M-R II VACCINE | |
| MENQUADFI | |
| MENVEO A-C-Y-W-135-DIP (1 VIAL-A-C-Y-W-135-DIP, A-C-Y-W KIT (2 VIALS)) | |
| MNEXSPIKE 2025-2026 (12Y UP) | |
| MODERNA COVID 23-24(6M-11Y)EUA | |
| MODERNA COVID 24-25(6M-11Y)EUA | |
| MRESVIA | |
| NOVAVAX COVID 2023-2024 (EUA) | |
| NOVAVAX COVID 2024-2025 (EUA) | |
| NUVAXOVID 2025-2026 | |
| PEDIARIX | |
| PEDVAXHIB | |
| PENBRAYA | |
| PENMENVY MEN A-B-C-W-Y | |
| PENMENVY MENACWY COMPONENT | |
| PENMENVY MENB COMPONENT | |
| PENTACEL | |
| PFIZER COVID 2023-24(5-11Y)EUA | |
| PFIZER COVID 2024-25(5-11Y)EUA | |
| PFIZER COVID 2024-25(6M-4Y)EUA | |
| PNEUMOVAX 23 (23 SYRINGE, 23 VIAL) | |
| PREHEVBRIO | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| PREVNAR 20 | |
| PRIORIX | |
| PROQUAD | |
| QUADRACEL DTAP-IPV (SYRINGE, VIAL) | |
| RABAVERT | |
| RECOMBIVAX HB (5 MCG/0.5 ML SYR, 5 MCG/0.5 ML VL, 10 MCG/ML SYR, 10 MCG/ML VIAL, 40 MCG/ML VIAL) | |
| ROTARIX | |
| ROTATEQ | |
| SHINGRIX (50 MCG/0.5 ML SYRINGE, VIAL KIT) | |
| SPIKEVAX 2023-2024 (2023-24 SYRG, 2023-24 VIAL) | |
| SPIKEVAX 2024-2025 | |
| SPIKEVAX 2025-2026 (12Y UP) | |
| SPIKEVAX 2025-2026 (6M-11Y) | |
| TRUMENBA | |
| TWINRIX | |
| VAQTA (25 UNITS/0.5 ML SYRINGE, 25 UNITS/0.5 ML VIAL, 50 UNITS/ML SYRINGE, 50 UNITS/ML VIAL) | |
| VARIVAX VACCINE | |
| VAXNEUVANCE | |
| ANTIULCER AGENTS AND ACID SUPPRESSANTS | |
| ANTIULCER AGENTS AND ACID SUPPRESS.,MISC | |
| TALICIA | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|------------------------|
| HISTAMINE H2-ANTAGONISTS | |
| <i>cimetidine 300 mg/5 ml soln</i> | PA QPD 40.0 per day |
| <i>cimetidine (300 mg tablet, 400 mg tablet, 800 mg tablet)</i> | |
| <i>cimetidine 200 mg tablet</i> | |
| <i>famotidine 40 mg/5 ml susp</i> | PA QPD 80.0 per day |
| <i>famotidine 20 mg tablet</i> | |
| <i>famotidine 40 mg tablet</i> | |
| <i>nizatidine 150 mg capsule</i> | |
| PROSTAGLANDINS | |
| <i>misoprostol (100 mcg tablet, 200 mcg tablet)</i> | |
| PROTECTANTS | |
| <i>sucralfate 1 gm tablet</i> | |
| PROTON-PUMP INHIBITORS | |
| <i>dexlansoprazole dr 30 mg cap</i> | QPD 2.0 per day |
| <i>dexlansoprazole dr 60 mg cap</i> | QPD 1.0 per day |
| <i>esomeprazole magnesium (dr 20 mg cap, dr 40 mg cap)</i> | QPD 2.0 per day |
| <i>esomeprazole magnesium (dr 2.5 mg packet, dr 5 mg packet, dr 10 mg packet, dr 20 mg packet, dr 40 mg packet)</i> | QPD 2.0 per day |
| <i>lansoprazole (dr 15 mg capsule, dr 15 mg odt, dr 30 mg capsule, dr 30 mg odt)</i> | QPD 2.0 per day |
| <i>omeprazole (dr 10 mg capsule, dr 20 mg capsule, dr 40 mg capsule)</i> | QPD 2.0 per day |
| <i>omeprazole-sodium bicarbonate (20-1, 100 cap, 20-1,680 pkt, 40-1, 100 cap, 40-1,680 pkt)</i> | QPD 2.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>pantoprazole dr 40 mg susp pkt</i> | QPD 2.0 per day |
| <i>pantoprazole sodium (dr 20 mg tab, dr 40 mg tab)</i> | QPD 2.0 per day |
| <i>rabeprazole sod dr 20 mg tab</i> | QPD 2.0 per day |
| ANTIVIRALS (SYSTEMIC) | |
| CORONAVIRUS (COVID-19) | |
| PAXLOVID 150-100 MG (MODERATE) | QL max 20 / 30 days |
| PAXLOVID 300-100 MG DOSE PACK | QL max 30 / 30 days |
| PAXLOVID 300/150-100MG(SEVERE) | QL max 11 / 30 days |
| INTERFERON ANTIVIRALS | |
| PEGASYS (180 MCG/0.5 ML SYRINGE, 180 MCG/ML VIAL) | S PA |
| NEURAMINIDASE INHIBITOR ANTIVIRALS | |
| <i>oseltamivir phos 30 mg capsule</i> | QL max 40 / 120 days |
| <i>oseltamivir phosphate (45 mg capsule, 75 mg capsule)</i> | QL max 20 / 120 days |
| <i>oseltamivir 6 mg/ml suspension</i> | QL max 300 / 120 days |
| NUCLEOSIDE AND NUCLEOTIDE ANTIVIRALS | |
| <i>acyclovir (200 mg/5 ml susp, 200 mg/5 ml susp cup, 800 mg/20ml susp cup)</i> | |
| <i>acyclovir (200 mg capsule, 400 mg tablet, 800 mg tablet)</i> | |
| <i>adefovir dipivoxil</i> | S |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| BARACLUDE 0.05 MG/ML SOLUTION | S |
| <i>entecavir</i> | S |
| <i>famciclovir (125 mg tablet, 250 mg tablet, 500 mg tablet)</i> | |
| LAGEVRIO (EUA) | QL max 40 / 30 days |
| <i>ribavirin (200 mg capsule, 200 mg tablet)</i> | S |
| <i>valacyclovir hcl 1 gram tablet</i> | |
| <i>valacyclovir hcl 500 mg tablet</i> | |
| <i>valganciclovir hcl (hcl 50 mg/ml, 450 mg tablet)</i> | |
| VEMLIDY | S |
| ANXIOLYTICS, SEDATIVES AND HYPNOTICS | |
| ANXIOLYTICS, SEDATIVES, AND HYPNOTICS, MISC | |
| <i>hydroxyzine hcl (10 mg/5 ml soln, 10 mg/5 ml syrup)</i> | |
| <i>hydroxyzine hcl (10 mg tablet, 25 mg tablet, 50 mg tablet)</i> | |
| <i>hydroxyzine pamoate (25 mg cap, 50 mg cap)</i> | |
| BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) | |
| <i>butalb-acetamin-caff 50-325-40</i> | QPD 6.0 per day |
| <i>phenobarbital (20 mg/5 ml cup, 20 mg/5 ml elix, 20 mg/5 ml soln, 30 mg/7.5 ml cup, 32.4 mg tablet, 60 mg/15 ml cup, 64.8 mg tablet, 97.2 mg tablet)</i> | |
| <i>phenobarbital (15 mg tablet, 16.2 mg tablet, 30 mg tablet, 60 mg tablet, 100 mg tablet)</i> | |
| BENZODIAZEPINES (ANXIOLYTIC, SEDATIVE/HYP) | |
| <i>alprazolam (0.25 mg tablet, 0.5 mg tablet, 1 mg tablet, 2 mg tablet)</i> | |
| <i>alprazolam er (er 0.5 mg tablet, er 1 mg tablet, er 3 mg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| <i>alprazolam er 2 mg tablet</i> | |
| <i>alprazolam xr (0.5 mg tablet, 1 mg tablet, 3 mg tablet)</i> | |
| <i>alprazolam xr 2 mg tablet</i> | |
| <i>chlordiazepoxide hcl</i> | |
| <i>clorazepate dipotassium</i> | |
| <i>diazepam (2.5mg rectal gel(2pk), 5 mg/ml oral conc, 10 mg rectal gel syrg, 10mg rectal gel (2pk), 20 mg rectal gel syrg, 20mg rectal gel (2pk), 25 mg/5 ml oral conc)</i> | |
| <i>diazepam (2 mg tablet, 5 mg tablet, 5 mg/5 ml solution, 10 mg tablet)</i> | |
| <i>estazolam</i> | |
| <i>lorazepam 2 mg/ml oral concent</i> | |
| <i>lorazepam (0.5 mg tablet, 1 mg tablet, 2 mg tablet)</i> | |
| LORAZEPAM INTENSOL | |
| <i>oxazepam</i> | |
| <i>temazepam (15 mg capsule, 30 mg capsule)</i> | |
| MELATONIN RECEPTOR AGONISTS | |
| <i>tasimelteon</i> | <div style="display: flex; align-items: center; gap: 5px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| NON-BENZODIAZEPINE ANXIOLYTICS | |
| <i>buspirone hcl (5 mg tablet, 10 mg tablet, 15 mg tablet, 30 mg tablet)</i> | |
| NON-BENZODIAZEPINE HYPNOTICS | |
| <i>eszopiclone (2 mg tablet, 3 mg tablet)</i> | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day |
| <i>eszopiclone 1 mg tablet</i> | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-------------------------------------|
| <i>zaleplon 10 mg capsule</i> | QPD 1.0 per day |
| <i>zaleplon 5 mg capsule</i> | QPD 2.0 per day |
| <i>zolpidem tartrate 10 mg tablet</i> | QPD 1.0 per day |
| <i>zolpidem tartrate 5 mg tablet</i> | QPD 2.0 per day |
| <i>zolpidem tartrate 12.5 mg tab</i> | QPD 1.0 per day |
| <i>zolpidem tartrate 6.25 mg tab</i> | QPD 2.0 per day |
| OREXIN RECEPTOR ANTAGONISTS | |
| BELSOMRA | ST QPD 1.0 per day |
| AUTONOMIC DRUGS | |
| PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) | |
| <i>bethanechol chloride (5 mg tablet, 10 mg tablet, 25 mg tablet, 50 mg tablet)</i> | |
| <i>cevimeline hcl</i> | |
| <i>donepezil hcl (5 mg tablet, 10 mg tablet)</i> | |
| <i>donepezil hcl 23 mg tablet</i> | |
| <i>donepezil hcl odt</i> | |
| <i>galantamine er</i> | |
| <i>galantamine hbr</i> | |
| <i>pilocarpine hcl (5 mg tablet, 7.5 mg tablet)</i> | |
| <i>pyridostigmine bromide (60 mg/5 ml soln, br 60 mg tablet)</i> | |
| <i>pyridostigmine er 180 mg tab</i> | |
| <i>rivastigmine (1.5 mg capsule, 3 mg capsule, 4.5 mg capsule, 4.6 mg/24hr patch, 6 mg capsule, 9.5 mg/24hr patch, 13.3 mg/24hr ptch)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| SMOKING CESSATION AGENTS | |
| CHANTIX STARTING MONTH BOX | |
| NICODERM CQ | |
| NICORETTE (2 MG CHEWING GUM, 2 MG LOZENGE, 2 MG MINI LOZENGE, 4 MG CHEWING GUM, 4 MG LOZENGE, 4 MG MINI LOZENGE) | |
| <i>nicotine gum</i> | |
| <i>nicotine lozenge (2 mg lozenge, 2 mg mini lozenge, cvs 2 mg lozenge, cvs 2 mg mini lozenge, eq 2 mg lozenge, ft 2 mg lozenge, ft 2 mg mini lozenge, gnp 2 mg lozenge, gnp 2 mg mini lozenge, 4 mg lozenge, 4 mg mini lozenge, cvs 4 mg lozenge, cvs 4 mg mini lozenge, eq 2 mg mini lozenge, eq 4 mg lozenge, eq 4 mg mini lozenge, ft 4 mg lozenge, ft 4 mg mini lozenge, gnp 4 mg lozenge, gnp 4 mg mini lozenge, gs 2 mg lozenge, gs 2 mg mini lozenge, gs 4 mg lozenge, gs 4 mg mini lozenge, hm 2 mg lozenge, hm 4 mg mini lozenge, kro 2 mg lozenge, kro 4 mg lozenge, kro 4 mg mini lozenge, ra 2 mg lozenge, ra 2 mg mini lozenge, ra 4 mg lozenge, ra 4 mg mini lozenge, sm 2 mg lozenge, sm 4 mg lozenge, sw 2 mg lozenge, sw 4 mg lozenge)</i> | |
| <i>nicotine transdermal system</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>nicotine patch (7 mg/24hr patch, cvs 7 mg/24hr patch, eq 7 mg/24hr patch, gnp 7 mg/24hr patch, hm 7 mg/24hr patch, kro 7 mg/24hr patch, sm 7 mg/24hr patch, 14 mg/24hr patch, cvs 14 mg/24hr patch, ft 7 mg/24hr patch, gnp 14 mg/24hr patch, kro 14 mg/24hr patch, ra 7 mg/24hr patch, sm 14 mg/24hr patch, 21 mg/24hr patch, cvs 21 mg/24hr patch, eq 14 mg/24hr patch, eq 21 mg/24hr patch, ft 14 mg/24hr patch, ft 21 mg/24hr patch, gnp 21 mg/24hr patch, hm 14 mg/24hr patch, hm 21 mg/24hr patch, kro 21 mg/24hr patch, ra 14 mg/24hr patch, ra 21 mg/24hr patch, sm 21 mg/24hr patch)</i> | |
| NICOTROL NS | |
| QUIT 2 (2 MG CHEWING GUM, 2 MG LOZENGE) | |
| QUIT 4 (4 MG CHEWING GUM, 4 MG LOZENGE) | |
| STOP SMOKING AID | |
| <i>varenicline tartrate (0.5 mg tablet, 1 mg cont month bx, 1 mg tablet, starting month box)</i> | |
| BETA-3-ADRENERGIC AGONISTS | |
| SELECTIVE BETA-3-ADRENERGIC AGONISTS | |
| <i>mirabegron er</i> | QPD 1.0 per day |
| MYRBETRIQ ER 8 MG/ML SUSP | QPD 10.715 per day |
| MYRBETRIQ (ER 25 MG TABLET, ER 50 MG TABLET) | QPD 1.0 per day |
| BETA-ADRENERGIC AGONISTS | |
| SELECTIVE BETA-2-ADRENERGIC AGONISTS | |
| ADVAIR HFA | QPD 0.4 per day |
| AIRSUPRA | QPD 1.07 per day |
| <i>albuterol sulfate (2 mg/5 ml syrup cup, sul 2.5 mg/3 ml soln, sulf 2 mg/5 ml syrup, 8 mg/20 ml syrup cup)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---------------------------------|
| <i>albuterol sulfate (sul 0.63 mg/3 ml sol, sul 1.25 mg/3 ml sol, sulfate 2 mg tab, 2.5 mg/0.5 ml sol, sulfate 4 mg tab)</i> | |
| <i>albuterol sulfate hfa</i> | QPD 1.2 per day |
| <i>arformoterol tartrate</i> | |
| BREO ELLIPTA | QPD 2.0 per day |
| BREYNA | QPD 1.03 per day |
| <i>budesonide-formoterol fumarate</i> | QPD 1.03 per day |
| DULERA | QPD 1.3 per day |
| <i>fluticasone-salmeterol (55-14, 113-14, 232-14)</i> | QPD 0.034 per day |
| <i>fluticasone-salmeterol (100-50, 250-50, 500-50)</i> | QPD 2.0 per day |
| <i>levalbuterol concentrate</i> | |
| <i>levalbuterol hcl</i> | |
| SEREVENT DISKUS | QPD 2.0 per day |
| STRIVERDI RESPIMAT | QPD 0.134 per day |
| <i>terbutaline sulfate (2.5 mg tab, 5 mg tab)</i> | |
| VENTOLIN HFA | QPD 1.2 per day |
| WIXELA INHUB | QPD 2.0 per day |
| BLOOD FORMATION, COAGULATION, THROMBOSIS | |
| BLOOD FORM.,COAG,THROMBOSIS AGENTS MISC. | |
| PYRUKYND (20-5 MG PACK, 50-20 MG PACK) | QL max 14 / 365 days S PA |
| PYRUKYND (5 MG TABLET, 20 MG TABLET, 20 MG TAPER PACK, 50 MG TABLET, 50 MG TAPER PACK) | S PA QPD 2.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| PYRUKYND 5 MG TAPER PACK | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin-bottom: 5px;">max 7 / 365 days</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| HEMATOPOIETIC AGENTS | |
| ARANESP (10 MCG/0.4 ML SYRINGE, 25 MCG/0.42 ML SYRINGE, 25 MCG/ML VIAL, 40 MCG/0.4 ML SYRINGE, 40 MCG/ML VIAL, 60 MCG/0.3 ML SYRINGE, 60 MCG/ML VIAL, 100 MCG/0.5 ML SYRINGE, 100 MCG/ML VIAL, 150 MCG/0.3 ML SYRINGE, 200 MCG/0.4 ML SYRINGE, 200 MCG/ML VIAL, 300 MCG/0.6 ML SYRINGE, 500 MCG/1 ML SYRINGE) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| DOPTELET | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-top: 5px;">2.0 per day</div> </div> |
| DOPTELET SPRINKLE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-top: 5px;">2.0 per day</div> </div> |
| <i>eltrombopag olamine (12.5 mg susp pkt, 12.5 mg tablet, 25 mg susp packet, 25 mg tablet)</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-top: 5px;">1.0 per day</div> </div> |
| <i>eltrombopag olamine (50 mg tablet, 75 mg tablet)</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-top: 5px;">2.0 per day</div> </div> |
| EPOGEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| FULPHILA | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> </div> |
| FYLNETRA | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> </div> |
| MULPLETA | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin-top: 5px;">1.0 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| NIVESTYM (300 MCG/0.5 ML SYRING, 300 MCG/ML VIAL, 480 MCG/0.8 ML SYRING, 480 MCG/1.6 ML VIAL) | S |
| PROCRIT | S PA |
| RETACRIT | S PA |
| ZARXIO | S |
| HEMORRHEOLOGIC AGENTS | |
| <i>pentoxifylline er 400 mg tab</i> | |
| BRONCHODILATORS | |
| ANTICHOLINERGIC AGENTS (RESPIR. TRACT) | |
| BREZTRI AEROSPHERE | QPD 0.357 per day |
| CALCINEURIN INHIBITORS (90:28) | |
| CALCINEURIN INHIBITORS, MISC (90:28) | |
| <i>cyclosporine (25 mg capsule, 100 mg capsule)</i> | S |
| <i>cyclosporine modified (25 mg, 50 mg, 100 mg, 100mg/ml)</i> | S |
| GENGRAF (25 MG CAPSULE, 100 MG CAPSULE, 100 MG/ML SOLUTION) | S |
| <i>tacrolimus (0.5 mg capsule, 1 mg capsule, 5 mg capsule)</i> | S |
| CALCIUM-CHANNEL BLOCKING AGENTS | |
| DIHYDROPYRIDINES | |
| <i>amlodipine besylate (2.5 mg tab, 5 mg tab, 10 mg tab)</i> | |
| <i>amlodipine besylate-benazepril</i> | |
| <i>amlodipine-olmesartan</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| <i>amlodipine-valsartan</i> | |
| <i>amlodipine-valsartan-hctz</i> | |
| <i>felodipine er</i> | |
| <i>nifedipine (10 mg capsule, 20 mg capsule)</i> | |
| <i>nifedipine er (er 30 mg tablet, er 60 mg tablet)</i> | |
| <i>nifedipine er 90 mg tablet</i> | |
| <i>nimodipine 30 mg capsule</i> | |
| CARDIAC DRUGS | |
| CARDIAC DRUGS, MISCELLANEOUS | |
| ATTRUBY | <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <div style="background-color: #e91e63; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #795548; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> </div> <div style="text-align: right;">4.0 per day</div> </div> |
| <i>ranolazine er</i> | |
| VYNDAMAX | <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <div style="background-color: #e91e63; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #795548; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> </div> <div style="text-align: right;">1.0 per day</div> </div> |
| VYNDAQEL | <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <div style="background-color: #e91e63; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #795548; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> </div> <div style="text-align: right;">4.0 per day</div> </div> |
| CARDIOTONIC AGENTS | |
| CORLANOR 5 MG/5 ML ORAL SOLN | <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <div style="background-color: #795548; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> </div> <div style="text-align: right;">20.0 per day</div> </div> |
| DIGITEK | |
| <i>digoxin 0.05 mg/ml solution</i> | <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> <div style="background-color: #795548; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> </div> </div> |
| <i>digoxin (0.125 mg tablet, 0.25 mg tablet, 125 mcg tablet, 250 mcg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| <i>digoxin 62.5 mcg tablet</i> | |
| <i>ivabradine hcl</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 2.0 per day </div> |
| CARDIOVASCULAR DRUGS | |
| ALPHA-ADRENERGIC BLOCKING AGENTS (24:16) | |
| <i>doxazosin mesylate (1 mg tab, 2 mg tab, 4 mg tab, 8 mg tab)</i> | |
| <i>prazosin 5 mg capsule</i> | |
| <i>prazosin hcl (1 mg capsule, 2 mg capsule)</i> | |
| <i>terazosin hcl</i> | |
| BETA-ADRENERGIC BLOCKING AGENTS (24:20) | |
| <i>acebutolol hcl (200 mg capsule, 400 mg capsule)</i> | |
| <i>atenolol (25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | |
| <i>atenolol-chlorthalidone</i> | |
| <i>betaxolol hcl (10 mg tablet, 20 mg tablet)</i> | |
| <i>bisoprolol fumarate 10 mg tab</i> | |
| <i>bisoprolol fumarate 5 mg tab</i> | |
| <i>bisoprolol-hydrochlorothiazide</i> | |
| <i>carvedilol</i> | |
| HEMANGEOL | <div style="background-color: #DC143C; color: white; padding: 2px 5px; border-radius: 3px; display: inline-block;">S</div> |
| <i>labetalol hcl (200 mg tablet, 300 mg tablet)</i> | |
| <i>labetalol hcl 100 mg tablet</i> | |
| <i>metoprolol succinate</i> | |
| <i>metoprolol tartrate (25 mg tab, 37.5 mg tb, 50 mg tab, 75 mg tab, 100 mg tab)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| <i>metoprolol-hydrochlorothiazide</i> | |
| <i>nadolol (20 mg tablet, 40 mg tablet, 80 mg tablet)</i> | |
| <i>nebivolol hcl</i> | |
| <i>pindolol</i> | |
| <i>propranolol 40 mg/5 ml soln</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 80.0 per day </div> |
| <i>propranolol 60 mg tablet</i> | |
| <i>propranolol hcl (10 mg tablet, 20 mg tablet, 40 mg tablet, 80 mg tablet)</i> | |
| <i>propranolol hcl er (er 120 mg capsule, er 160 mg capsule)</i> | |
| <i>propranolol hcl er (er 60 mg capsule, er 80 mg capsule)</i> | |
| <i>sotalol (160 mg tablet, 240 mg tablet)</i> | |
| <i>sotalol (80 mg tablet, 120 mg tablet)</i> | |
| SOTALOL AF (80 MG TABLET, 120 MG TABLET) | |
| SOTALOL AF 160 MG TABLET | |
| CARDIOVASCULAR DRUGS, NSAID ANTI-INFL | |
| <i>colchicine 0.6 mg tablet</i> | |
| CENTRAL ALPHA-AGONISTS | |
| <i>clonidine</i> | |
| <i>clonidine hcl (0.1 mg tablet, 0.2 mg tablet, 0.3 mg tablet)</i> | |
| <i>clonidine hcl er 0.1 mg tablet</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 4.0 per day </div> |
| <i>guanfacine hcl</i> | |
| <i>guanfacine hcl er (er 1 mg tablet, er 4 mg tablet)</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 1.0 per day </div> |
| <i>guanfacine hcl er 2 mg tablet</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.0 per day </div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|------------------------|
| <i>guanfacine hcl er 3 mg tablet</i> | QPD 2.0 per day |
| <i>methyl dopa 250 mg tablet</i> | |
| <i>methyl dopa 500 mg tablet</i> | |
| CENTRAL NERVOUS SYSTEM AGENTS | |
| AMYOTROPHIC LATERAL SCLEROSIS(ALS) AGENT | |
| <i>riluzole</i> | |
| ANTIMANIC AGENTS | |
| <i>lithium carbonate (150 mg cap, 300 mg cap, 300 mg tab, 600 mg cap)</i> | |
| <i>lithium carbonate er</i> | |
| <i>lithium citrate</i> | |
| CENTRAL NERVOUS SYSTEM AGENTS, MISC. | |
| <i>carbidopa 25 mg tablet</i> | |
| <i>memantine hcl (2 mg/ml solution, 10 mg/5 ml cup)</i> | PA QPD 10.0 per day |
| <i>memantine 5-10 mg titration pk</i> | |
| <i>memantine hcl (5 mg tablet, 10 mg tablet)</i> | |
| NUDEXTA | |
| OPIOID ANTAGONISTS (28:10) | |
| KLOXXADO | |
| <i>naloxone 0.4 mg/ml vial</i> | |
| <i>naloxone hcl (0.4 mg/ml syringe, 2 mg/2 ml syringe, 4 mg/10 ml vial, hcl 4 mg nasal spray)</i> | |
| <i>naltrexone 50 mg tablet</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| OPVEE | |
| REXTOVY | |
| ZURNAI | |
| VESICULAR MONOAMINE TRANSPORT2 INHIBITOR | |
| <i>tetrabenazine 12.5 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; border-radius: 5px; padding: 2px 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; border-radius: 5px; padding: 2px 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; border-radius: 5px; padding: 2px 5px;">QPD 8.0 per day</div> </div> |
| <i>tetrabenazine 25 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; border-radius: 5px; padding: 2px 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; border-radius: 5px; padding: 2px 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0070c0; color: white; border-radius: 5px; padding: 2px 5px;">QPD 4.0 per day</div> </div> |
| CEPHALOSPORIN ANTIBIOTICS | |
| 1ST GENERATION CEPHALOSPORIN ANTIBIOTICS | |
| <i>cefadroxil 500 mg capsule</i> | |
| <i>cefadroxil (250 mg/5 ml susp, 500 mg/5 ml susp)</i> | |
| <i>cephalexin (250 mg capsule, 500 mg capsule)</i> | |
| <i>cephalexin (125 mg/5 ml susp, 250 mg/5 ml susp, 750 mg capsule)</i> | |
| 2ND GENERATION CEPHALOSPORIN ANTIBIOTICS | |
| <i>cefprozil (125 mg/5 ml susp, 250 mg tablet, 250 mg/5 ml susp, 500 mg tablet)</i> | |
| <i>cefuroxime axetil 250 mg tab</i> | |
| <i>cefuroxime axetil 500 mg tab</i> | |
| 3RD GENERATION CEPHALOSPORIN ANTIBIOTICS | |
| <i>cefdinir 300 mg capsule</i> | |
| <i>cefdinir (125 mg/5 ml susp, 250 mg/5 ml susp)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| <i>cefixime (100 mg/5 ml susp, 200 mg/5 ml susp, 400 mg capsule)</i> | |
| <i>cefpodoxime proxetil (100 mg tablet, 200 mg tablet)</i> | |
| COMPLEMENT INHIBITORS (92:32) | |
| BRADYKININ RECEPTOR ANTAGONISTS | |
| <i>icatibant</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.6 per day |
| CONSTIPATION THERAPY | |
| GUANYLATE CYCLASE C (GCC) RECEPT AGONIST | |
| TRULANCE | |
| OPIOID ANTAGONISTS (56:18) | |
| MOVANTIK | |
| SYMPROIC | |
| CYSTIC FIBROSIS (CFTR) MODULATORS | |
| CYSTIC FIBROSIS (CFTR) CORRECTORS | |
| ALYFTREK 10-50-125 MG TABLET | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 2.0 per day |
| ALYFTREK 4-20-50 MG TABLET | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 3.0 per day |
| SYMDEKO | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 2.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| TRIKAFTA (80-40-60MG/59.5MG PKT, 100-50-75 MG/75MG PKT) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| TRIKAFTA (50-25-37.5 MG/75 MG, 100-50-75 MG/150 MG) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD</div> 3.0 per day |
| CYSTIC FIBROSIS (CFTR) POTENTIATORS | |
| KALYDECO (5.8 MG GRANULES PKT, 13.4 MG GRANULES PKT, 25 MG GRANULES PACKET, 50 MG GRANULES PACKET, 75 MG GRANULES PACKET, 150 MG TABLET) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD</div> 2.0 per day |
| DENTAL AGENTS | |
| NUTRITIONAL SUPPLEMENTS | |
| CLINPRO 5000 | |
| DENTA 5000 PLUS | |
| DENTA 5000 PLUS SENSITIVE | |
| DENTAGEL | |
| <i>fluoride</i> | |
| FLUORIDEX | |
| FLUORIDEX SENSITIVITY RELIEF | |
| FLUORIMAX 5000 | |
| FLUORIMAX 5000 SENSITIVE | |
| FRAICHE 5000 | |
| GEL-KAM | |
| JUST RIGHT 5000 | |
| PERIOMED | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| PREVIDENT 5000 ENAMEL PROTECT | |
| PREVIDENT 5000 SENSITIVE | |
| SF | |
| SF 5000 PLUS | |
| <i>sodium fluoride (0.2% rinse, 0.25 (0.55) mg, 0.5 mg(1.1 mg), 0.5 mg/ml drop, 1 mg (2.2 mg), 1.1% cream, 1.1% gel, 5000 ppm cream, 5000 ppm paste)</i> | |
| SODIUM FLUORIDE 5000 DRY MOUTH | |
| SODIUM FLUORIDE 5000 PLUS | |
| <i>sodium fluoride enamel protect</i> | |
| <i>sodium fluoride sensitive</i> | |
| <i>sodium fluoride-potassium nitr</i> | |
| DEVICES | |
| <i>contour solution</i> | |
| <i>contour next control solution (1 sol, 2 sol)</i> | |
| <i>dexcom g6 receiver</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QL</div> <div>max 1 / 365 days</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">ST</div> </div> |
| <i>dexcom g6 sensor</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">ST</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>0.1 per day</div> </div> |
| <i>dexcom g6 transmitter</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QL</div> <div>max 1 / 90 days</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">ST</div> </div> |
| <i>dexcom g7 15 day sensor</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">ST</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>0.067 per day</div> </div> |
| <i>dexcom g7 receiver</i> | <div style="display: flex; align-items: center;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QL</div> <div>max 1 / 365 days</div> </div> <div style="display: flex; align-items: center; margin-top: 2px;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">ST</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>dexcom g7 sensor</i> | <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">ST</div> <div style="background-color: #0070C0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 0.1 per day |
| <i>freestyle control solution</i> | |
| <i>ilet infusion kit-flex</i> | <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 2.5 per day |
| <i>ilet infusion kit-inset</i> | <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 2.5 per day |
| <i>ilet inf-contact detach 23"6mm</i> | <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 3.334 per day |
| <i>ilet starter kit contact23"6mm</i> | <div style="background-color: #800080; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>ilet insulin pump</i> | <div style="background-color: #800080; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>ilet starter kit-inset</i> | <div style="background-color: #800080; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>inhaler assistance devices and accessories</i> | |
| <i>lancets</i> | |
| <i>lancing device/lancets</i> | |
| <i>medisense (h-l solution, h-m-l soln)</i> | |
| <i>medisense glucose ketone</i> | |
| <i>medisense glucose ketone contr</i> | |
| <i>needles (including pen needles)</i> | |
| <i>novopen echo</i> | |
| <i>omnipod 5 (g6/libre 2 plus)</i> | <div style="background-color: #808000; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.




| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| <i>omnipod 5 dexg7g6 intro(gen 5)</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>omnipod 5 dexg7g6 pods (gen 5)</i> | <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 1.0 per day |
| <i>omnipod 5 g6-g7 intro kt(gen5)</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>omnipod 5 g6-g7 pods (gen 5)</i> | <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 1.0 per day |
| <i>omnipod 5 intro(g6/libre2plus)</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>omnipod dash intro kit (gen 4)</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |
| <i>omnipod dash pods (gen 4)</i> | <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 1.0 per day |
| <i>syringes (including insulin syringes)</i> | |
| <i>twiist refill kt(csst-ndl-syr)</i> | <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 0.034 per day |
| <i>twiist rfl(infus-csst-ndl-syr)</i> | <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QPD</div> 0.034 per day |
| <i>twiist starter kit</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; display: inline-block; border-radius: 5px;">QL</div> max 1 / 720 days <div style="background-color: #8b572d; color: white; padding: 2px; display: inline-block; border-radius: 5px;">PA</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| DIAGNOSTIC AGENTS | |
| DIABETES MELLITUS | |
| <i>contour next test strip</i> | QPD 6.8 per day |
| <i>contour plus test strip</i> | QPD 6.8 per day |
| <i>contour test strip</i> | QPD 6.8 per day |
| <i>freestyle insulinx test strip</i> | QPD 6.8 per day |
| <i>freestyle insulinx test strips</i> | QPD 6.8 per day |
| <i>freestyle lite test strip</i> | QPD 6.8 per day |
| <i>freestyle precision neo</i> | QPD 6.8 per day |
| <i>freestyle test strips</i> | QPD 6.8 per day |
| <i>optium ez</i> | QPD 6.8 per day |
| <i>precision xtra test strips</i> | QPD 6.8 per day |
| DISEASE-MODIFYING ANTIRHEUMATIC DRUGS | |
| DISEASE-MODIFYING ANTIRHEUMAT DRUGS MISC | |
| ENTYVIO PEN | S |
| | PA |
| | QPD 0.049 per day |
| MONOCARBOXYLIC ACID AMIDE AGENTS | |
| <i>leflunomide (10 mg tablet, 20 mg tablet)</i> | |
| DIURETICS (40:28) | |
| LOOP DIURETICS (40:28) | |
| <i>bumetanide (0.5 mg tablet, 1 mg tablet)</i> | |
| <i>bumetanide 2 mg tablet</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>furosemide (10 mg/ml solution, 20 mg tablet, 40 mg tablet, 80 mg tablet)</i> | |
| <i>toremide</i> | |
| POTASSIUM-SPARING DIURETICS (40:28) | |
| <i>amiloride hcl</i> | |
| <i>amiloride-hydrochlorothiazide</i> | |
| <i>triamterene (50 mg capsule, 100 mg capsule)</i> | |
| <i>triamterene-hydrochlorothiazid (37.5-25 mg cp, 37.5-25 mg tb, 75-50 mg tab)</i> | |
| THIAZIDE DIURETICS (40:28) | |
| <i>hydrochlorothiazide (12.5 mg cp, 12.5 mg tb, 25 mg tab, 50 mg tab)</i> | |
| THIAZIDE-LIKE DIURETICS (40:28) | |
| <i>chlorthalidone</i> | |
| <i>indapamide</i> | |
| <i>metolazone (5 mg tablet, 10 mg tablet)</i> | |
| <i>metolazone 2.5 mg tablet</i> | |
| VASOPRESSIN ANTAGONISTS | |
| JYNARQUE 30 MG TABLET | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 1.0 per day |
| JYNARQUE (15 MG TABLET, 15 MG-15 MG TABLET, 30 MG-15 MG TABLET, 45 MG-15 MG TABLET, 60 MG-30 MG TABLET, 90 MG-30 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 2.0 per day |
| <i>tolvaptan 15 mg tablet</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #660099; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> </div> max 30 / 365 days |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| <i>tolvaptan 30 mg tablet</i> |  max 60 / 365 days  |
| DOPAMINE RECEPTOR AGONISTS ERGOT-DERIV. DOPAMINE RECEPTOR AGONISTS | |
| <i>bromocriptine mesylate (2.5 mg tablet, 5 mg capsule)</i> | |
| <i>cabergoline</i> | |
| NONERGOT-DERIV. DOPAMINE RECEPTOR AGONIST | |
| <i>apomorphine 30 mg/3 ml cartrdg</i> |  |
| <i>pramipexole dihydrochloride</i> | |
| <i>ropinirole hcl</i> | |
| ELECTROLYTIC, CALORIC, AND WATER BALANCE ACIDIFYING AGENTS | |
| K-PHOS NO.2 | |
| PHOSPHA 250 NEUTRAL | |
| PHOSPHO-TRIN 250 NEUTRAL | |
| PHOSPHO-TRIN K500 | |
| PHOSPHOROUS 250 MG TABLET | |
| WES-PHOS 250 NEUTRAL | |
| ALKALINIZING AGENTS | |
| CYTRA-2 | |
| <i>potassium citrate er</i> | |
| <i>sodium citrate-citric acid</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| AMMONIA DETOXICANTS | |
| <i>carglumic acid</i> | S PA |
| CONSTULOSE | |
| ENULOSE | |
| GENERLAC | |
| <i>glycerol phenylbutyrate</i> | S PA |
| <i>lactulose (10 gm/15 ml soln cup, 10 gm/15 ml solution, 20 gm/30 ml soln cup)</i> | |
| <i>sodium phenylbutyrate (500mg tb, powder)</i> | S PA |
| IRRIGATING SOLUTIONS | |
| NEBUSAL 3% VIAL | |
| PULMOSAL | |
| <i>sodium chloride 3% vial</i> | |
| <i>sodium chloride 7% vial</i> | |
| REPLACEMENT PREPARATIONS | |
| KLOR-CON | |
| KLOR-CON 10 | |
| KLOR-CON 8 | |
| KLOR-CON M10 | |
| KLOR-CON M15 | |
| KLOR-CON M20 | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>potassium chloride (cl10%(20meq/15ml)cup, cl10%(40meq/30ml)cup, cl20%(40meq/15ml)cup, cl 10% (20 meq/15ml), cl 20 meq packet, cl 20% (40 meq/15ml), cl er 15 meq tablet)</i> | |
| <i>potassium chloride (er 8 capsule, er 8 tablet, er 10 capsule, er 10 tablet, er 20 tablet)</i> | |
| URICOSURIC AGENTS | |
| <i>probenecid</i> | |
| <i>probenecid-colchicine</i> | |
| EMOLLIENTS, DEMULCENTS, AND PROTECTANTS | |
| BASIC LOTIONS AND LINIMENTS | |
| <i>ammonium lactate 12% lotion</i> | |
| BASIC OINTMENTS AND PROTECTANTS | |
| <i>ammonium lactate 12% cream</i> | |
| <i>calcipotriene 0.005% cream</i> | |
| ENSTILAR | |
| <i>nitroglycerin 0.4% ointment</i> | |
| ENZYMES | |
| ENZYME COFACTORS/CHAPERONES | |
| <i>nitisinone</i> | S |
| NITYR | S |
| ORFADIN 4 MG/ML SUSPENSION | S |
| <i>sapropterin dihydrochloride (100 mg powder pkt, 100 mg tablet, 500 mg powder pkt)</i> | S PA |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| ENZYME INHIBITORS | |
| <i>miglustat</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 3.0 per day |
| YARGESA | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 3.0 per day |
| ZOKINVY | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #806442; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 4.0 per day |
| REVCOVI | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> </div> |
| ESTROGENS AND ANTIESTROGENS | |
| ESTROGEN AGONIST-ANTAGONISTS | |
| <i>raloxifene hcl</i> | |
| SOLTAMOX | |
| <i>tamoxifen citrate (10 mg tablet, 20 mg tablet)</i> | |
| <i>toremifene citrate</i> | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> </div> |
| ESTROGENS | |
| ABIGALE | |
| ABIGALE LO | |
| AMABELZ | |
| CLIMARA PRO | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.143 per day |
| <i>conjugated estrogens</i> | |
| DIVIGEL (0.25 MG GEL PACKET, 0.5 MG GEL PACKET, 0.75 MG GEL PACKET, 1 MG GEL PACKET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| DOTTI | QPD 0.286 per day |
| DUAVEE | |
| <i>estradiol 0.01% cream</i> | QL max 255 / 365 days |
| <i>estradiol (0.06% 1.25g gel pump, 0.1% (1.25mg) gel pk)</i> | QPD 1.25 per day |
| <i>estradiol ((0.25mg) gel pk, (0.5mg) gel pkt, (0.75mg) gel pk, (1 mg) gel pkt)</i> | QPD 1.0 per day |
| <i>estradiol (0.5 mg tablet, 1 mg tablet, 2 mg tablet)</i> | |
| <i>estradiol 10 mcg vaginal insrt</i> | |
| <i>estradiol (once weekly)</i> | QPD 0.143 per day |
| <i>estradiol (twice weekly)</i> | QPD 0.286 per day |
| <i>estradiol valerate (50 mg/5 ml, 100 mg/5 ml, 200 mg/5 ml)</i> | |
| <i>estradiol-norethindrone acetat</i> | |
| ESTRING | QL max 1 / 90 days |
| FYAVOLV | |
| JINTELI | |
| LYLLANA | QPD 0.286 per day |
| MIMVEY | |
| <i>norethindron-ethinyl estradiol (norethin-eth 1 mg-5 mcg, norethind-eth 0.5-2.5)</i> | |
| PREMARIN (0.3 MG TABLET, 0.45 MG TABLET, 0.625 MG TABLET, 0.9 MG TABLET, 1.25 MG TABLET, VAGINAL CREAM-APPL) | |
| PREMPHASE | |
| PREMPRO | |
| YUVAFEM | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| EYE, EAR, NOSE AND THROAT (EENT) PREPS. | |
| ANTI-INFLAMMATORY AGENTS (EENT) | |
| RESTASIS | |
| ANTIALLERGIC AGENTS | |
| <i>azelastine hcl (hcl 0.05% drops, 0.1% (137 mcg) spry)</i> | |
| <i>bepotastine besilate</i> | |
| <i>epinastine hcl</i> | |
| <i>olopatadine hcl (0.1% drops, 0.2% drop)</i> | |
| EENT DRUGS, MISCELLANEOUS | |
| <i>ipratropium bromide (0.03% spray, 0.06% spray)</i> | |
| LOCAL ANESTHETICS (EENT) | |
| <i>lidocaine 2% viscous soln</i> | |
| <i>lidocaine hcl 4% solution</i> | <div style="display: flex; align-items: center; justify-content: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>5.0 per day</div> </div> |
| <i>lidocaine hcl viscous</i> | |
| MYDRIATICS | |
| <i>atropine sulfate (drop, drops)</i> | |
| <i>cyclopentolate hcl (drop, drops)</i> | |
| FIRST GENERATION ANTIHISTAMINES | |
| ETHANOLAMINE DERIVATIVES | |
| DIPHEN (12.5 MG/5 ML ELIXIR, 12.5 MG/5 ML SOLUTION) | |
| FIRST GEN. ANTIHIST. DERIVATIVES, MISC. | |
| <i>cyproheptadine hcl (2 mg/5 ml soln, 2 mg/5 ml syrup, 4 mg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| PHENOTHIAZINE DERIVATIVES | |
| <i>promethazine hcl (12.5 mg suppos, 25 mg suppository)</i> | |
| <i>promethazine hcl (6.25 mg/5 ml soln, 6.25 mg/5 ml syrps, 12.5 mg tablet, 25 mg tablet, 50 mg tablet)</i> | |
| PROMETHEGAN (12.5 MG SUPPOS, 25 MG SUPPOSITORY) | |
| GASTROINTESTINAL DRUGS | |
| ANTI-INFLAMMATORY AGENTS (GI DRUGS) | |
| <i>alosetron hcl</i> | |
| <i>balsalazide disodium</i> | |
| <i>mesalamine (4 gm/60 ml enema, 800 mg dr tablet, 1,000 mg supp)</i> | |
| <i>mesalamine dr 1.2 gm tablet</i> | |
| <i>mesalamine dr</i> | |
| <i>mesalamine er 0.375 gram cap</i> | |
| ANTIDIARRHEA AGENTS | |
| <i>diphenoxylate-atrop 2.5-0.025</i> | |
| <i>loperamide 2 mg capsule</i> | |
| VIBERZI | |
| CATHARTICS AND LAXATIVES | |
| GAVILYTE-G | |
| GAVILYTE-N | |
| <i>peg 3350-electrolyte</i> | |
| <i>peg-3350 and electrolytes</i> | |
| <i>sod sulf-potass sulf-mag sulf</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|------------------------------|
| CHOLELITHOLYTIC AGENTS | |
| CHENODAL | S |
| CTEXTLI | S PA QPD 3.0 per day |
| <i>ursodiol (250 mg tablet, 300 mg capsule, 500 mg tablet)</i> | |
| DIGESTANTS | |
| CREON (DR 3,000 UNIT CAPSULE, DR 6,000 UNIT CAPSULE, DR 12,000 UNIT CAPSULE, DR 24,000 UNIT CAPSULE, DR 36,000 UNIT CAPSULE) | |
| ZENPEP | |
| GI DRUGS, MISCELLANEOUS | |
| <i>dronabinol</i> | |
| IMMUNOMODULATORY AGENTS (56:44) | |
| OMVOH (100 MG/ML SYRINGE, 200 MG DOSE - 2 SYRINGES, 200 MG/2 ML SYRINGE) | S PA QPD 0.072 per day |
| OMVOH 300 MG DOSE - 2 SYRINGES | S PA QPD 0.108 per day |
| OMVOH 300 MG DOSE - 2 PENS | S PA QPD 0.108 per day |
| OMVOH PEN (100 MG/ML PEN, 200 MG DOSE - 2 PENS, 200 MG/2 ML PEN) | S PA QPD 0.072 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-------------------------------------|
| PROKINETIC AGENTS | |
| <i>metoclopramide 5 mg/5 ml soln</i> | |
| <i>metoclopramide hcl (5 mg tablet, 10 mg tablet)</i> | |
| GENITOURINARY SMOOTH MUSCLE RELAXANTS | |
| ANTIMUSCARINICS | |
| <i>oxybutynin chloride (5 mg/5 ml soln cup, 5 mg/5 ml solution, 5 mg/5 ml syrup)</i> | QPD 20.0 per day |
| <i>oxybutynin 5 mg tablet</i> | QPD 4.0 per day |
| <i>oxybutynin chloride er (er 10 mg tablet, er 15 mg tablet)</i> | QPD 2.0 per day |
| <i>oxybutynin cl er 5 mg tablet</i> | QPD 1.0 per day |
| <i>solifenacin succinate</i> | QPD 1.0 per day |
| <i>tolterodine tartrate</i> | QPD 2.0 per day |
| <i>tolterodine tartrate er</i> | QPD 1.0 per day |
| <i>tropium chloride</i> | QPD 2.0 per day |
| <i>tropium chloride er</i> | QPD 1.0 per day |
| GONADOTROPINS AND ANTIGONADOTROPINS | |
| ANTIGONADTROPINS | |
| MYFEMBREE | PA QPD 1.0 per day |
| ORIAHNN | PA QPD 2.0 per day |
| ORLISSA 150 MG TABLET | PA QPD 1.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| ORILISSA 200 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #8B4513; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QPD</div> <div>2.0 per day</div> </div> |
| GONADOTROPINS | |
| <i>leuprolide 2wk 14 mg/2.8 ml kt</i> | <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px;">S</div> |
| <i>leuprolide 2wk 14 mg/2.8 ml vl</i> | <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px;">S</div> |
| LUPRON DEPOT (11.25 MG 3MO KIT, 22.5 MG 3MO KIT) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #6A329F; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QL</div> <div>max 90 days / fill</div> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-top: 5px;">S</div> </div> |
| LUPRON DEPOT (3.75 MG KIT, 7.5 MG KIT) | <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px;">S</div> |
| LUPRON DEPOT 45 MG 6MO KIT | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #6A329F; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QL</div> <div>max 180 days / fill</div> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-top: 5px;">S</div> </div> |
| LUPRON DEPOT-4 MONTH KIT | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #6A329F; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QL</div> <div>max 120 days / fill</div> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-top: 5px;">S</div> </div> |
| LUPRON DEPOT-PED (7.5 MG KIT, 11.25 MG KIT, 15 MG KIT) | <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px;">S</div> |
| LUPRON DEPOT-PED (11.25 MG 3MO, 30 MG 3MO KIT) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #6A329F; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QL</div> <div>max 90 days / fill</div> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-top: 5px;">S</div> </div> |
| LUPRON DEPOT-PED 45 MG 6MO KIT | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #6A329F; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QL</div> <div>max 180 days / fill</div> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-top: 5px;">S</div> </div> |
| HCV ANTIVIRALS | |
| HCV POLYMERASE INHIBITOR ANTIVIRALS | |
| EPCLUSA (150-37.5 MG PELLETT PKT, 200 MG-50 MG TABLET, 200-50 MG PELLETT PACK, 400 MG-100 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #DC143C; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">S</div> <div style="background-color: #8B4513; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">PA</div> <div style="background-color: #4169E1; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 5px;">QPD</div> <div>1.0 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| HARVONI (33.75-150 MG PELLETT PK, 45-200 MG PELLETT PACKET, 45-200 MG TABLET, 90-400 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| SOVALDI (150 MG PELLETT PACKET, 200 MG PELLETT PACKET, 200 MG TABLET, 400 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| VOSEVI | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 1.0 per day |
| HCV PROTEASE INHIBITOR ANTIVIRALS | |
| MAVYRET 50-20 MG PELLETT PACKET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 5.0 per day |
| MAVYRET 100-40 MG TABLET | <div style="display: flex; flex-direction: column; align-items: center;"> <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">QPD</div> </div> 3.0 per day |
| HEAVY METAL ANTAGONISTS | |
| CHEMET | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| <i>deferasirox (90 mg granule pkt, 90 mg tablet, 125 mg tb for susp, 180 mg granule pkt, 180 mg tablet, 250 mg tb for susp, 360 mg granule pkt, 360 mg tablet, 500 mg tb for susp)</i> | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| <i>deferiprone</i> | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| <i>deferiprone (3 times a day)</i> | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| <i>penicillamine 250 mg tablet</i> | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |
| <i>trientine hcl 250 mg capsule</i> | <div style="background-color: #c00000; color: white; padding: 2px 10px; border-radius: 5px; margin-bottom: 2px;">S</div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--------------------------|
| HORMONES AND SYNTHETIC SUBSTITUTES | |
| ADRENALS | |
| ARNUIITY ELLIPTA | QPD 1.0 per day |
| ASMANEX (TWISTHALER 110 MCG #30, TWISTHALER 220 MCG #30, TWISTHALER 220 MCG #60, TWISTHALR 220 MCG #120) | QPD 0.034 per day |
| ASMANEX HFA | QPD 0.434 per day |
| <i>budesonide (0.25 mg/2 ml susp, 0.5 mg/2 ml susp, 1 mg/2 ml inh susp)</i> | |
| <i>budesonide 2 mg rectal foam</i> | |
| <i>budesonide dr</i> | |
| <i>budesonide ec</i> | |
| <i>dexamethasone 0.5 mg/5 ml elx</i> | |
| <i>dexamethasone (0.5 mg tablet, 0.75 mg tablet, 1 mg tablet, 1.5 mg tablet, 2 mg tablet, 4 mg tablet, 6 mg tablet)</i> | |
| <i>dexamethasone 0.1% eye drop</i> | |
| <i>fludrocortisone 0.1 mg tablet</i> | |
| <i>hydrocortisone (5 mg tablet, 10 mg tablet, 20 mg tablet)</i> | |
| <i>methylprednisolone (4 mg dosepk, 4 mg tablet, 16 mg tab, 32 mg tab)</i> | |
| <i>methylprednisolone 8 mg tablet</i> | |
| <i>prednisolone (15 mg/5 ml soln, 15 mg/5 ml syrup)</i> | |
| <i>prednisolone 15mg/5ml soln cup</i> | |
| <i>prednisolone sodium phosphate (5 mg/5 ml soln, sod ph 25 mg/5 ml)</i> | |
| <i>prednisone 5 mg/5 ml solution</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-------------------------|
| <i>prednisone (1 mg tablet, 2.5 mg tablet, 5 mg tab dose pack, 5 mg tablet, 10 mg tab dose pack, 10 mg tablet, 20 mg tablet, 50 mg tablet)</i> | |
| QVAR REDIHALER 40 MCG | QPD 0.354 per day |
| QVAR REDIHALER 80 MCG | QPD 0.707 per day |
| ANDROGENS | |
| <i>danazol (50 mg capsule, 100 mg capsule, 200 mg capsule)</i> | PA |
| DEPO-TESTOSTERONE | PA QPD 0.358 per day |
| <i>methyltestosterone 10 mg cap</i> | PA QPD 20.0 per day |
| <i>testosterone (1% (25mg/2.5g) pk, 1.62% gel pump)</i> | PA QPD 5.0 per day |
| <i>testosterone (1% (50 mg/5 g) pk, 12.5 mg/1.25 gram, 50 mg/5 gram gel)</i> | PA QPD 10.0 per day |
| <i>testosterone 30 mg/1.5 ml pump</i> | PA QPD 6.0 per day |
| <i>testosterone cypionate (200 mg/ml, 1,000 mg/10ml, 2,000 mg/10ml)</i> | PA QPD 0.358 per day |
| CONTRACEPTIVES | |
| AFIRMELLE | |
| AFTERA | |
| ALTAVERA | |
| ALYACEN | |
| AMETHIA | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------|-----------------------|
| AMETHYST | |
| APRI | |
| ARANELLE | |
| ASHLYNA | |
| AUBRA | |
| AUBRA EQ | |
| AUROVELA | |
| AUROVELA 24 FE | |
| AUROVELA FE | |
| AVIANE | |
| AYUNA | |
| AZURETTE | |
| BALZIVA | |
| BLISOVI 24 FE | |
| BLISOVI FE | |
| BRIELLYN | |
| CAMILA | |
| CAMRESE | |
| CAMRESE LO | |
| CAZANT | |
| CHARLOTTE 24 FE | |
| CHATEAL EQ | |
| CRYSSELLE | |
| CURAE | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------------------------|-----------------------|
| CYRED | |
| CYRED EQ | |
| DASETTA | |
| DAYSEE | |
| DEBLITANE | |
| <i>desogestr-eth estrad eth estra</i> | |
| DOLISHALE | |
| <i>drospirenone-eth estra-levomef</i> | |
| <i>drospirenone-ethinyl estradiol</i> | |
| ECONTRA EZ | |
| ECONTRA ONE-STEP | |
| ELINEST | |
| ELLA | |
| EMZAHH | |
| ENPRESSE | |
| ENSKYCE | |
| ERRIN | |
| ESTARYLLA | |
| <i>ethynodiol-eth estra 1mg-35mcg</i> | |
| <i>ethynodiol-eth estra 1mg-50mcg</i> | |
| FALMINA | |
| FEIRZA | |
| FINZALA | |
| GALBRIELA | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------|-----------------------|
| HAILEY | |
| HAILEY 24 FE | |
| HAILEY FE | |
| HEATHER | |
| HER STYLE | |
| ICLEVIA | |
| INCASSIA | |
| INTROVALE | |
| ISIBLOOM | |
| JAIMIESS | |
| JASMIEL | |
| JENCYCLA | |
| JOLESSA | |
| JULEBER | |
| JUNEL | |
| JUNEL FE | |
| JUNEL FE 24 | |
| KAITLIB FE | |
| KALLIGA | |
| KARIVA | |
| KELNOR 1-35 | |
| KELNOR 1-50 | |
| KURVELO | |
| LARIN | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| LARIN 24 FE | |
| LARIN FE | |
| LAYOLIS FE | |
| LEENA | |
| LESSINA | |
| LEVONEST | |
| <i>levonor-e estrad 0.1-0.02-0.01</i> | |
| <i>levonorg-eth estrad eth estrad (levono-e estrad 0.15-0.03-0.01, levonorg 0.15mg-ee 20-25-30mcg)</i> | |
| <i>levonorgestrel</i> | |
| <i>levonor-eth estra 0.09-0.02 mg</i> | |
| <i>levonor-eth estrad 0.15-0.03</i> | |
| <i>levonorgestrel-eth estradiol (0.1-0.02 mg, triphasic)</i> | |
| LEVORA-28 | |
| LO LOESTRIN FE | |
| LO-ZUMANDIMINE | |
| LOESTRIN | |
| LOESTRIN FE | |
| LOJAIMIESS | |
| LORYNA | |
| LOW-OGESTREL | |
| LUIZZA | |
| LUTERA | |
| LYLEQ | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| LYZA | |
| MARLISSA | |
| MELEYA | |
| MIBELAS 24 FE | |
| MICROGESTIN | |
| MICROGESTIN FE | |
| MILI | |
| MONO-LINYAH | |
| MY CHOICE | |
| MY WAY | |
| NECON | |
| NEW DAY | |
| NIKKI | |
| NORA-BE | |
| <i>norelgestromin-eth estradiol</i> | |
| <i>norethin-eth estra-ferrous fum</i> | |
| <i>norethindron-ethinyl estradiol (norethin-ee 1.5-0.03 mg(21) tb, norethind-eth estrad 1-0.02 mg)</i> | |
| <i>norethindrone 0.35 mg tablet</i> | |
| <i>norethindrone-e.estradiol-iron (1 mg/20-30-35 mcg, 1-0.02(24)-75 chw)</i> | |
| <i>norethindrone-e.estradiol-iron (1-0.02(21)-75 tab, 1.5-0.03mg(21)-75)</i> | |
| <i>norgestimate-ethinyl estradiol</i> | |
| NORTREL | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------|-----------------------|
| NUVARING | |
| NYLIA | |
| OCELLA | |
| OPCICON ONE-STEP | |
| OPTION 2 | |
| ORQUIDEA | |
| ORTHO-NOVUM | |
| PHILITH | |
| PIMTREA | |
| PLAN B ONE-STEP | |
| PORTIA | |
| RECLIPSEN | |
| RIVELSA | |
| ROSYRAH | |
| SETLAKIN | |
| SHAROBEL | |
| SHEWISE | |
| SIMLIYA | |
| SIMPESSE | |
| SPRINTEC | |
| SRONYX | |
| SYEDA | |
| TAKE ACTION | |
| TARINA 24 FE | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------------|-----------------------|
| TARINA FE | |
| TARINA FE 1-20 EQ | |
| TILIA FE | |
| TRI-ESTARYLLA | |
| TRI-LEGEST FE | |
| TRI-LINYAH | |
| TRI-LO-ESTARYLLA | |
| TRI-LO-MARZIA | |
| TRI-LO-MILI | |
| TRI-LO-SPRINTEC | |
| TRI-MILI | |
| TRI-SPRINTEC | |
| TRI-VYLIBRA | |
| TRI-VYLIBRA LO | |
| TRIVORA-28 | |
| TULANA | |
| TURQOZ | |
| TYDEMY | |
| VALTYA 1 MG-35 MCG TABLET | |
| VALTYA 1 MG-50 MCG TABLET | |
| VESTURA | |
| VIENVA | |
| VIORELE | |
| VOLNEA | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| VYFEMLA | |
| VYLIBRA | |
| WERA | |
| WYMZYA FE | |
| XARAH FE | |
| XELRIA FE | |
| XULANE | |
| ZAFEMY | |
| ZARAH | |
| ZOVIA 1-35 | |
| ZUMANDIMINE | |
| PITUITARY | |
| <i>desmopressin acetate (0.01% solution, ac 4 mcg/ml ampul, ac 4 mcg/ml vial, acetate 0.1 mg tb, acetate 0.2 mg tb, 40 mcg/10 ml vial)</i> | |
| GENOTROPIN (MINIQUICK 0.2 MG, MINIQUICK 0.4 MG, MINIQUICK 0.6 MG, MINIQUICK 0.8 MG, MINIQUICK 1 MG, MINIQUICK 1.2 MG, MINIQUICK 1.4 MG, MINIQUICK 1.6 MG, MINIQUICK 1.8 MG, MINIQUICK 2 MG, 5 MG CARTRIDGE, 12 MG CARTRIDGE) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> |
| OMNITROPE (5 MG/1.5 ML CRTG, 5.8 MG VIAL, 10 MG/1.5 ML CRTG) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center;">S</div> <div style="background-color: #804020; color: white; padding: 2px; text-align: center;">PA</div> |
| PROGESTINS | |
| GALLIFREY | |
| <i>medroxyprogesterone 150 mg/ml</i> | <div style="background-color: #6a3d9a; color: white; padding: 2px; text-align: center;">QL</div> max 90 days / fill |
| <i>medroxyprogesterone acetate (2.5 mg tab, 5 mg tab, 10 mg tab)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| <i>megestrol acetate (40 mg tablet, acet 40 mg/ml susp, 400 mg/10ml susp cup)</i> | |
| <i>megestrol 20 mg tablet</i> | |
| <i>norethindrone 5 mg tablet</i> | |
| <i>progesterone 100 mg capsule</i> | |
| <i>progesterone 200 mg capsule</i> | |
| <i>progesterone 500 mg/10 ml vial</i> | |
| IMMUNOMODULATORY AGENTS (90:00) | |
| COMPLEMENT INHIBITOR AGENTS (90:20) | |
| EMPAVELI | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 5.715 per day |
| FABHALTA | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #804020; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 2.0 per day |
| INSULINS | |
| INTERMEDIATE-ACTING INSULINS | |
| HUMULIN 70-30 | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| HUMULIN 70/30 KWIKPEN | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| HUMULIN N | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| HUMULIN N KWIKPEN | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| NOVOLIN 70-30 | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| NOVOLIN 70-30 FLEXPEN | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |
| NOVOLIN N | <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 3.334 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| NOVOLIN N FLEXPEN | QPD 3.334 per day |
| LONG-ACTING INSULINS | |
| <i>insulin glargine-yfgn (pen, vl)</i> | QPD 3.334 per day |
| LEVEMIR | QPD 3.334 per day |
| LEVEMIR FLEXPEN | QPD 3.334 per day |
| SEMGLEE (YFGN) | QPD 3.334 per day |
| SEMGLEE (YFGN) PEN | QPD 3.334 per day |
| SOLIQUA 100-33 | QPD 0.6 per day |
| TOUJEO MAX SOLOSTAR | QPD 3.334 per day |
| TOUJEO SOLOSTAR | QPD 3.334 per day |
| TRESIBA | QPD 3.334 per day |
| TRESIBA FLEXTOUCH U-100 | QPD 3.334 per day |
| TRESIBA FLEXTOUCH U-200 | QPD 3.334 per day |
| XULTOPHY 100-3.6 | QPD 0.5 per day |
| RAPID-ACTING INSULINS | |
| FIASP | QPD 3.334 per day |
| FIASP FLEXTOUCH | QPD 3.334 per day |
| FIASP PENFILL | QPD 3.334 per day |
| HUMALOG (100 UNIT/ML CARTRIDGE, 100 UNIT/ML VIAL) | QPD 3.334 per day |
| HUMALOG JUNIOR KWIKPEN | QPD 3.334 per day |
| HUMALOG KWIKPEN U-100 | QPD 3.334 per day |
| HUMALOG KWIKPEN U-200 | QPD 3.334 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|------------------------------|-----------------------|
| HUMALOG MIX 50-50 KWIKPEN | QPD 3.334 per day |
| HUMALOG MIX 75-25 | QPD 3.334 per day |
| HUMALOG MIX 75-25 KWIKPEN | QPD 3.334 per day |
| HUMALOG TEMPO PEN U-100 | QPD 3.334 per day |
| LYUMJEV | QPD 3.334 per day |
| LYUMJEV KWIKPEN U-100 | QPD 3.334 per day |
| LYUMJEV KWIKPEN U-200 | QPD 3.334 per day |
| LYUMJEV TEMPO PEN U-100 | QPD 3.334 per day |
| NOVOLOG | QPD 3.334 per day |
| NOVOLOG FLEXPEN | QPD 3.334 per day |
| NOVOLOG MIX 70-30 | QPD 3.334 per day |
| NOVOLOG MIX 70-30 FLEXPEN | QPD 3.334 per day |
| NOVOLOG PENFILL | QPD 3.334 per day |
| SHORT-ACTING INSULINS | |
| HUMULIN R | QPD 3.334 per day |
| HUMULIN R U-500 | QPD 3.334 per day |
| HUMULIN R U-500 KWIKPEN | QPD 3.334 per day |
| NOVOLIN R | QPD 3.334 per day |
| NOVOLIN R FLEXPEN | QPD 3.334 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| INTERLEUKIN INHIBITOR AGENTS | |
| INTERLEUKIN INHIBITOR AGENTS, MISC | |
| XOLAIR (75 MG/0.5 ML AUTOINJECT, 75 MG/0.5 ML SYRINGE, 150 MG/ML AUTOINJECTOR, 150 MG/ML SYRINGE, 300 MG/2 ML AUTOINJECT, 300 MG/2 ML SYRINGE) | S PA |
| INTERLEUKIN-MEDIATED AGENTS | |
| INTERLEUKIN-MEDIATED AGENTS, MISC | |
| COSENTYX (2 SYRINGES) | QL max 56 days / fill S PA QPD 0.072 per day |
| COSENTYX SENSOREADY (2 PENS) | QL max 56 days / fill S PA QPD 0.072 per day |
| COSENTYX SENSOREADY PEN | S PA QPD 0.036 per day |
| COSENTYX 150 MG/ML SYRINGE | S PA QPD 0.036 per day |
| COSENTYX 75 MG/0.5 ML SYRINGE | S PA QPD 0.018 per day |
| COSENTYX UNOREADY PEN | S PA QPD 0.072 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| SELARSDI 90 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| SELARSDI (45 MG/0.5 ML SYRINGE, 45 MG/0.5 ML VIAL) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 0.5 / 84 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| STEQEYMA 45 MG/0.5 ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 0.5 / 84 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| STEQEYMA 90 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| TYENNE 162 MG/0.9 ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">0.129 per day</div> </div> |
| TYENNE AUTOINJECTOR | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">0.129 per day</div> </div> |
| YESINTEK 90 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 1 / 56 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| YESINTEK (45 MG/0.5 ML SYRINGE, 45 MG/0.5 ML VIAL) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 0.5 / 84 days</div> <div style="background-color: #e31a1c; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b5722; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| ION-REMOVING AGENTS | |
| PHOSPHATE-REMOVING AGENTS | |
| <i>calcium acetate (667 mg capsule, 667 mg gelcap, 667 mg tablet)</i> | |
| <i>ferric citrate</i> | QPD 12.0 per day |
| <i>lanthanum carb 1,000 mg tb chw</i> | QPD 4.0 per day |
| <i>lanthanum carb 500 mg tab chew</i> | QPD 9.0 per day |
| <i>lanthanum carb 750 mg tab chew</i> | QPD 6.0 per day |
| <i>sevelamer 2.4 gm powder packet</i> | QPD 5.0 per day |
| <i>sevelamer carbonate (0.8 gm powder packet, carbonate 800 mg tab)</i> | QPD 17.0 per day |
| <i>sevelamer hcl 400 mg tablet</i> | QPD 32.0 per day |
| <i>sevelamer hcl 800 mg tablet</i> | QPD 16.0 per day |
| POTASSIUM-REMOVING AGENTS | |
| KIONEX | |
| LOKELMA | |
| <i>sodium polystyrene sulfonate (sodium polystyrene sulf powder, sps 15 gm/60 ml suspension)</i> | |
| SPS 15 GM/60 ML SUSPENSION | |
| JANUS KINASE INHIBITORS (90:24) | |
| JANUS KINASE INHIBITORS, MISCELLANEOUS | |
| RINVOQ (ER 15 MG TABLET, ER 30 MG TABLET) | S |
| | PA |
| | QPD 1.0 per day |
| RINVOQ ER 45 MG TABLET | QL max 84 / 365 days |
| | S |
| | PA |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| RINVOQ LQ | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 12.0 per day |
| XELJANZ 1 MG/ML SOLUTION | <div style="background-color: #9c27b0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QL</div> max 48 days / fill <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 8.0 per day |
| XELJANZ 10 MG TABLET | <div style="background-color: #9c27b0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QL</div> max 240 / 365 days <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> |
| XELJANZ 5 MG TABLET | <div style="background-color: #9c27b0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QL</div> max 60 days / fill <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 2.0 per day |
| XELJANZ XR 11 MG TABLET | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 1.0 per day |
| XELJANZ XR 22 MG TABLET | <div style="background-color: #9c27b0; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QL</div> max 120 / 365 days <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> |
| KALLIKREIN-KININ SYSTEM INHIBITORS FACTOR XI/A INHIBITORS | |
| ANDEMBRY AUTOINJECTOR | <div style="background-color: #e91e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">S</div> <div style="background-color: #8d6e63; color: white; padding: 2px; border-radius: 5px; display: inline-block;">PA</div> <div style="background-color: #2196f3; color: white; padding: 2px; border-radius: 5px; display: inline-block;">QPD</div> 0.04 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| KALLIKREIN INHIBITORS (24:48:08) | |
| DAWNZERA | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 5px; margin-bottom: 2px;">QL</div> <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8c564b; color: white; padding: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 5px;">QPD</div> </div> <div style="margin-top: 5px;">max 56 days / fill 0.029 per day</div> |
| TAKHZYRO (300 MG/2 ML SYRINGE, 300 MG/2 ML VIAL) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8c564b; color: white; padding: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 5px;">QPD</div> </div> <div style="margin-top: 5px;">0.143 per day</div> |
| TAKHZYRO 150 MG/ML SYRINGE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 5px; margin-bottom: 2px;">S</div> <div style="background-color: #8c564b; color: white; padding: 5px; margin-bottom: 2px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 5px;">QPD</div> </div> <div style="margin-top: 5px;">0.072 per day</div> |
| MACROLIDE ANTIBIOTICS | |
| ERYTHROMYCIN ANTIBIOTICS | |
| E.E.S. 400 | |
| ERY-TAB | |
| ERYTHROCIN STEARATE | |
| <i>erythromycin (250 mg tablet, dr 250 mg tablet, dr 333 mg tablet, 500 mg tablet, dr 500 mg tablet)</i> | |
| <i>erythromycin ethylsuccinate (200 mg/5 ml susp, 400 mg/5 ml susp, es 400 mg tab)</i> | |
| OTHER MACROLIDE ANTIBIOTICS | |
| <i>azithromycin 1 gm pwd packet</i> | |
| <i>azithromycin (100 mg/5 ml susp, 600 mg tablet)</i> | |
| <i>azithromycin (200 mg/5 ml susp, 250 mg tablet, 500 mg tablet)</i> | |
| <i>clarithromycin (250 mg tablet, 500 mg tablet)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|----------------------------|
| <i>clarithromycin er</i> | |
| DIFICID 40 MG/ML SUSPENSION | |
| <i>fidaxomicin</i> | |
| MINERALOCORTICOID (ALDOSTERONE) ANTAGNTS STEROIDAL MINERALOCORTICOID RECEPTOR ANT | |
| <i>eplerenone</i> | |
| <i>spironolactone (25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | |
| <i>spironolactone-hctz</i> | |
| MISCELLANEOUS THERAPEUTIC AGENTS 5-ALPHA-REDUCTASE INHIBITORS (92:04) | |
| <i>dutasteride 0.5 mg capsule</i> | |
| <i>finasteride 5 mg tablet</i> | |
| ANTIGOUT AGENTS | |
| <i>allopurinol (100 mg tablet, 300 mg tablet)</i> | |
| BONE RESORPTION INHIBITORS | |
| <i>alendronate sodium (10 mg tab, 35 mg tab, 70 mg tab)</i> | |
| <i>ibandronate sodium 150 mg tab</i> | |
| <i>risedronate sodium (35 mg tab, 150 mg tab)</i> | |
| <i>risedronate sodium 30 mg tab</i> | |
| IMMUNOMODULATORY AGENTS | |
| ACTIMMUNE | S |
| THALOMID 100 MG CAPSULE | S PA QPD 4.0 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|----------------------------|
| THALOMID 50 MG CAPSULE | S PA QPD 3.0 per day |
| OTHER MISCELLANEOUS THERAPEUTIC AGENTS | |
| <i>betaine anhydrous</i> | S |
| CYSTAGON | S |
| l-glutamine 5 gram powder pkt | S PA |
| <i>levocarnitine (1 g/10 ml soln, 330 mg tablet)</i> | |
| <i>levocarnitine sf</i> | |
| <i>tiopronin (100 mg tablet, dr 100 mg tablet, dr 300 mg tablet)</i> | S |
| VENXXIVA | S |
| PROTECTIVE AGENTS | |
| <i>dalfampridine er</i> | S |
| MTOR INHIBITORS | |
| MTOR INHIBITORS, MISCELLANEOUS | |
| <i>sirolimus (0.5 mg tablet, 1 mg tablet, 1 mg/ml solution, 2 mg tablet)</i> | S |
| MULTIPLE SCLEROSIS AGENTS | |
| AMINO ACID POLYMERS | |
| <i>glatiramer 20 mg/ml syringe</i> | S QPD 1.0 per day |
| <i>glatiramer 40 mg/ml syringe</i> | S QPD 0.429 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| GLATOPA 20 MG/ML SYRINGE | <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #2196f3; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QPD</div> 1.0 per day |
| GLATOPA 40 MG/ML SYRINGE | <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #2196f3; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QPD</div> 0.429 per day |
| ANTIMETABOLITES | |
| <i>cladribine (10 mg 4 tablet pk, 10 mg 8 tablet pk)</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 8 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |
| <i>cladribine 10 mg x 10 tab pk</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 20 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |
| <i>cladribine 10 mg x 5 tablet pk</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 10 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |
| <i>cladribine 10 mg x 6 tablet pk</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 12 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |
| <i>cladribine 10 mg x 7 tablet pk</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 14 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |
| <i>cladribine 10 mg x 9 tablet pk</i> | <div style="background-color: #9c27b0; color: white; padding: 2px; display: inline-block; border-radius: 4px;">QL</div> max 9 / 301 days <div style="background-color: #e91e63; color: white; padding: 2px; display: inline-block; border-radius: 4px;">S</div> <div style="background-color: #795548; color: white; padding: 2px; display: inline-block; border-radius: 4px;">PA</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------------------------|--|
| <i>teriflunomide</i> | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 1.0 per day |
| FUMARATES | |
| <i>dimethyl fumarate 30d start pk</i> | <div style="background-color: purple; color: white; padding: 2px; display: inline-block;">QL</div> max 60 / 180 days <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> |
| <i>dimethyl fumarate dr 120 mg cp</i> | <div style="background-color: purple; color: white; padding: 2px; display: inline-block;">QL</div> max 56 / 180 days <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> |
| <i>dimethyl fumarate dr 240 mg cp</i> | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 2.0 per day |
| VUMERITY | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: brown; color: white; padding: 2px; display: inline-block;">PA</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 4.0 per day |
| INTERFERONS | |
| AVONEX (4 PACK) | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: brown; color: white; padding: 2px; display: inline-block;">PA</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 0.036 per day |
| AVONEX PEN (4 PACK) | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: brown; color: white; padding: 2px; display: inline-block;">PA</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 0.036 per day |
| BETASERON 0.3 MG KIT | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: brown; color: white; padding: 2px; display: inline-block;">PA</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 0.5 per day |
| PLEGRIDY 125 MCG/0.5 ML SYRING | <div style="background-color: red; color: white; padding: 2px; display: inline-block;">S</div> <div style="background-color: brown; color: white; padding: 2px; display: inline-block;">PA</div> <div style="background-color: blue; color: white; padding: 2px; display: inline-block;">QPD</div> 0.036 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| PLEGRIDY SYRINGE STARTER PACK | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 5px;">QL</div> <div style="margin-bottom: 5px;">max 1 / 180 days</div> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> </div> |
| PLEGRIDY 125 MCG/0.5 ML PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> <div style="margin-top: 5px;">0.036 per day</div> </div> |
| PLEGRIDY PEN INJ STARTER PACK | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 5px;">QL</div> <div style="margin-bottom: 5px;">max 1 / 180 days</div> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> </div> |
| REBIF (22 MCG/0.5 ML SYRINGE, 44 MCG/0.5 ML SYRINGE) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> <div style="margin-top: 5px;">0.215 per day</div> </div> |
| REBIF TITRATION PACK | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 5px;">QL</div> <div style="margin-bottom: 5px;">max 4.2 / 180 days</div> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> </div> |
| REBIF REBIDOSE (22 MCG/0.5 ML, 44 MCG/0.5 ML) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> <div style="margin-top: 5px;">0.215 per day</div> </div> |
| REBIF REBIDOSE TITRATION PACK | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 5px;">QL</div> <div style="margin-bottom: 5px;">max 4.2 / 180 days</div> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> </div> |
| MONOCLONAL ANTIBODIES (90:04) | |
| KESIMPTA PEN | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #d62728; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #8c564b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #1f77b4; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> <div style="margin-top: 5px;">0.015 per day</div> </div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| SPHINGOSINE 1-PHOSPHATE (S1P) AGENTS | |
| <i> fingolimod </i> | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">S</div> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| MAYZENT 0.25MG START-1MG MAINT | <div style="display: flex; align-items: center;"> <div style="background-color: purple; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QL</div> <div>max 7 / 180 days</div> </div> <div style="display: flex; align-items: center; margin-top: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">S</div> <div style="background-color: brown; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">PA</div> </div> |
| MAYZENT 0.25MG START-2MG MAINT | <div style="display: flex; align-items: center;"> <div style="background-color: purple; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QL</div> <div>max 12 / 180 days</div> </div> <div style="display: flex; align-items: center; margin-top: 5px;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">S</div> <div style="background-color: brown; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">PA</div> </div> |
| MAYZENT (1 MG TABLET, 2 MG TABLET) | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">S</div> <div style="background-color: brown; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">PA</div> </div> <div style="display: flex; align-items: center; margin-top: 5px;"> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>1.0 per day</div> </div> |
| MAYZENT 0.25 MG TABLET | <div style="display: flex; align-items: center;"> <div style="background-color: red; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">S</div> <div style="background-color: brown; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">PA</div> </div> <div style="display: flex; align-items: center; margin-top: 5px;"> <div style="background-color: blue; color: white; padding: 2px 5px; border-radius: 3px; margin-right: 5px;">QPD</div> <div>4.0 per day</div> </div> |
| NONHORMONAL CONTRACEPTIVES | |
| <i> aimsco </i> | |
| <i> caya contoured </i> | |
| <i> durex avanti bare real feel </i> | |
| <i> durex extra sensitive </i> | |
| <i> durex tropical </i> | |
| <i> fantasy </i> | |
| <i> fc2 female condom </i> | |
| <i> femcap </i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>kimono</i> | |
| <i>kimono microthin (, large)</i> | |
| <i>kimono microthin aqua lube</i> | |
| <i>kimono textured</i> | |
| <i>kimono thin</i> | |
| <i>omniflex diaphragm</i> | |
| <i>trojan bareskin</i> | |
| <i>trojan enz</i> | |
| <i>trojan magnum</i> | |
| <i>trojan ultra ribbed</i> | |
| <i>trojan ultra thin</i> | |
| <i>trojan ultra thin-spermicidal</i> | |
| <i>true cover</i> | |
| <i>trustex</i> | |
| <i>trustex condom</i> | |
| <i>trustex latex condom</i> | |
| <i>trustex-ria</i> | |
| VCF CONTRACEPTIVE FILM | |
| <i>wide seal diaphragm</i> | |
| NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | |
| CYCLOOXYGENASE-2 (COX-2) INHIBITORS | |
| <i>celecoxib (50 mg capsule, 100 mg capsule, 200 mg capsule)</i> | |
| <i>celecoxib 400 mg capsule</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| REVERSIBLE COX-1/COX-2 INHIBITORS | |
| <i>diclofenac pot 50 mg tablet</i> | |
| <i>diclofenac 1.5% topical soln</i> | QPD 10.0 per day |
| <i>diclofenac sodium 1% gel</i> | QPD 33.334 per day |
| <i>diclofenac sodium (dr 25 mg tab, ec 25 mg tab)</i> | |
| <i>diclofenac sodium (dr 50 mg tab, dr 75 mg tab, ec 50 mg tab, ec 75 mg tab)</i> | |
| <i>diclofenac sodium-misoprostol</i> | |
| <i>diflunisal</i> | |
| <i>etodolac (200 mg capsule, 300 mg capsule, 400 mg tablet, 500 mg tablet)</i> | |
| <i>etodolac er</i> | |
| IBU | |
| <i>ibuprofen 100 mg/5 ml susp</i> | |
| <i>ibuprofen (400 mg tablet, 600 mg tablet, 800 mg tablet)</i> | |
| <i>indomethacin (25 mg capsule, 50 mg capsule)</i> | |
| <i>indomethacin er</i> | |
| <i>ketorolac 10 mg tablet</i> | QPD 4.0 per day |
| <i>meloxicam (7.5 mg tablet, 15 mg tablet)</i> | |
| <i>nabumetone (500 mg tablet, 750 mg tablet)</i> | |
| <i>naproxen (250 mg tablet, 375 mg tablet, 500 mg kit, 500 mg tablet)</i> | |
| <i>naproxen sodium (275 mg tab, 550 mg tab)</i> | |
| <i>oxaprozin (600 mg caplet, 600 mg tablet)</i> | |
| <i>piroxicam (10 mg capsule, 20 mg capsule)</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>sulindac (150 mg tablet, 200 mg tablet)</i> | |
| SALICYLATES | |
| ADULT ASPIRIN REGIMEN | |
| <i>aspirin (81 mg chewable tablet, 81 mg tablet, cvs 81 mg chewable tab, eq 81 mg chewable tab, eql 81 mg chewable tab, ft 81 mg chewable tab, gnp 81 mg chewable tab, gs 81 mg chewable tab, hm 81 mg chewable tab, kro 81 mg chewable tab, pub 81 mg chewable tab, qc 81 mg chewable tab, ra 81 mg chewable tab, sm 81 mg chewable tab)</i> | |
| <i>aspirin ec (cvs ec 81 mg tablet, ec 81 mg tablet, eq ec 81 mg tablet, eql ec 81 mg tablet, ft ec 81 mg tablet, gnp ec 81 mg tablet, gs ec 81 mg tablet, heb ec 81 mg tablet, hm ec 81 mg tablet, kro ec 81 mg tablet, qc ec 81 mg tablet, ra ec 81 mg tablet, sm ec 81 mg tablet)</i> | |
| ASPIRIN REGIMEN | |
| <i>aspirin-dipyridamole er</i> | |
| BAYER CHEWABLE ASPIRIN | |
| <i>butalbital-aspirin-caffeine cp</i> | QPD 6.0 per day |
| <i>children's aspirin</i> | |
| ECOTRIN EC 81 MG TABLET | |
| LOW DOSE ASPIRIN EC | |
| ST. JOSEPH ASPIRIN | |
| ST. JOSEPH ASPIRIN EC | |
| OXYTOCICS | |
| <i>methylergonovine 0.2 mg tablet</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|------------------------------|
| PARATHYROID AND ANTIPARATHYROID AGENTS | |
| ANTIPARATHYROID AGENTS | |
| <i>calcitonin-salmon 200 unit spr</i> | |
| <i>calcitonin-salmon 400 unit/2ml</i> | S |
| <i>cinacalcet hcl</i> | S PA |
| PARATHYROID AGENTS | |
| <i>teriparatide</i> | S PA QPD 0.08 per day |
| TYMLOS | S PA QPD 0.052 per day |
| PENICILLIN ANTIBIOTICS | |
| AMINOPENICILLIN ANTIBIOTICS | |
| <i>amoxicillin (125 mg/5 ml susp, 200 mg/5 ml susp, 250 mg capsule, 250 mg/5 ml susp, 400 mg/5 ml susp, 500 mg capsule, 500 mg tablet, 875 mg tablet)</i> | |
| <i>amoxicillin-clavulanate pot er</i> | |
| <i>amoxicillin-clavulanate potass (200-28.5 mg/5 ml sus, 500-125 mg tablet, 875-125 mg tablet)</i> | |
| <i>amoxicillin-clavulanate potass (250-125 mg tablet, 250-62.5 mg/5 ml sus, 400-57 mg/5 ml susp, 600-42.9 mg/5 ml sus)</i> | |
| <i>ampicillin trihydrate</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| NATURAL PENICILLIN ANTIBIOTICS | |
| <i>penicillin v potassium (250 mg tablet, 500 mg tablet)</i> | |
| PENICILLINASE-RESISTANT PENICILLINS | |
| <i>dicloxacillin sodium</i> | |
| PHOSPHODIESTERASE-4 INHIBITORS (90:24) | |
| PHOSPHODIESTERASE-4 INHIBITORS, MISC | |
| OTEZLA (10-20 MG STARTER 28, 10-20-30MG START 28) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 55 / 180 days</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| OTEZLA (20 MG TABLET, 30 MG TABLET) | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">2.0 per day</div> </div> |
| OTEZLA XR 75 MG TABLET | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">1.0 per day</div> </div> |
| OTEZLA XR INITIATION PK 28 DAY | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="margin: 2px 0;">max 41 / 180 days</div> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> |
| RENIN-ANGIOTENSIN-ALDOSTERONE SYS. INHIB | |
| ANGIOTENSIN II RECEPTOR ANTAGONIST/NEPROLYS | |
| ENTRESTO SPRINKLE | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #8b4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #4169e1; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> <div style="margin: 2px 0;">8.0 per day</div> </div> |
| <i>sacubitril-valsartan</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|--|
| ANGIOTENSIN II RECEPTOR ANTAGONISTS | |
| <i>candesartan cilexetil</i> | |
| <i>candesartan-hydrochlorothiazid</i> | |
| <i>irbesartan</i> | |
| <i>irbesartan-hydrochlorothiazide</i> | |
| <i>losartan potassium (25 mg tab, 50 mg tab, 100 mg tab)</i> | |
| <i>losartan-hydrochlorothiazide</i> | |
| <i>olmesartan medoxomil</i> | |
| <i>olmesartan-amlodipine-hctz</i> | |
| <i>olmesartan-hydrochlorothiazide</i> | |
| <i>telmisartan (20 mg tablet, 80 mg tablet)</i> | |
| <i>telmisartan 40 mg tablet</i> | |
| <i>valsartan (40 mg tablet, 80 mg tablet, 160 mg tablet, 320 mg tablet)</i> | |
| <i>valsartan-hydrochlorothiazide (320-12.5 mg tab, 320-25 mg tab)</i> | |
| <i>valsartan-hydrochlorothiazide (80-12.5 mg tab, 160-12.5 mg tab, 160-25 mg tab)</i> | |
| ANGIOTENSIN-CONVERTING ENZYME INHIBITORS | |
| <i>benazepril hcl (5 mg tablet, 10 mg tablet, 20 mg tablet, 40 mg tablet)</i> | |
| <i>benazepril-hydrochlorothiazide</i> | |
| <i>captopril (12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | |
| <i>enalapril 1 mg/ml oral soln</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #8B4513; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070C0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> 40.0 per day </div> |
| <i>enalapril maleate (2.5 mg tab, 5 mg tablet, 10 mg tab, 20 mg tab)</i> | |
| <i>enalapril-hydrochlorothiazide</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| <i>fosinopril sodium</i> | |
| <i>fosinopril-hydrochlorothiazide</i> | |
| <i>lisinopril (2.5 mg tablet, 5 mg tablet, 10 mg tablet, 20 mg tablet, 30 mg tablet, 40 mg tablet)</i> | |
| <i>lisinopril-hydrochlorothiazide</i> | |
| <i>moexipril hcl</i> | |
| <i>perindopril erbumine (2 mg tab, 4 mg tab)</i> | |
| <i>quinapril hcl</i> | |
| <i>quinapril-hctz 20-25 mg tab (greenstone)</i> | |
| <i>quinapril-hydrochlorothiazide</i> | |
| <i>ramipril</i> | |
| <i>trandolapril</i> | |

MINERALOCORTICOID (ALDOSTERONE) ANTAGNTS

| | |
|----------|---|
| KERENDIA | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 5px;">ST</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> 1.0 per day </div> |
|----------|---|

RESPIRATORY TRACT AGENTS
ANTIFIBROTIC AGENTS

| | |
|--|---|
| <i>nintedanib esylate</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> 2.0 per day </div> |
| <i>pirfenidone (267 mg capsule, 267 mg tablet)</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> 6.0 per day </div> |
| <i>pirfenidone 801 mg tablet</i> | <div style="display: flex; align-items: center; gap: 10px;"> <div style="background-color: #c00000; color: white; padding: 2px 5px; border-radius: 5px;">S</div> <div style="background-color: #4b4b2b; color: white; padding: 2px 5px; border-radius: 5px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 5px;">QPD</div> 3.0 per day </div> |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|----------------------------|
| ANTITUSSIVES | |
| <i>benzonatate</i> | |
| BROMFED DM | |
| <i>brompheniramine-pseudoephed-dm</i> | |
| <i>hydrocodone-homatropine soln</i> | |
| <i>hydrocodone-homatropine 5-1.5</i> | |
| HYDROMET | |
| <i>promethazine-codeine</i> | |
| <i>promethazine-dm</i> | |
| MUCOLYTIC AGENTS | |
| PULMOZYME | S |
| PHOSPHODIESTERASE TYPE 4 INHIBITORS | |
| <i>roflumilast 250 mcg tablet</i> | |
| <i>roflumilast 500 mcg tablet</i> | |
| VASODILATING AGENTS (RESPIRATORY TRACT) | |
| <i>ambrisentan</i> | S PA QPD 1.0 per day |
| <i>bosentan (62.5 mg tablet, 125 mg tablet)</i> | S PA QPD 2.0 per day |
| <i>bosentan 32 mg tablet for susp</i> | S PA QPD 4.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| <p>OPSUMIT</p> | <p>S</p> <p>PA</p> <p>QPD 1.0 per day</p> |
| SKELETAL MUSCLE RELAXANTS | |
| CENTRALLY ACTING SKELETAL MUSCLE RELAXANT | |
| <i>chlorzoxazone 500 mg tablet</i> | |
| <i>cyclobenzaprine hcl (5 mg tablet, 10 mg tablet)</i> | |
| <i>methocarbamol (500 mg tablet, 750 mg tablet)</i> | |
| <i>tizanidine hcl (2 mg tablet, 4 mg tablet)</i> | |
| GABA-DERIVATIVE SKELETAL MUSCLE RELAXANT | |
| <i>baclofen (10 mg tablet, 20 mg tablet)</i> | |
| INDIRECT-ACTING SKELETAL MUSCLE RELAXANT | |
| <i>orphenadrine citrate er</i> | |
| SKIN AND MUCOUS MEMBRANE AGENTS | |
| ANTIPROLIFERANTS | |
| CARAC | |
| <i>fluorouracil (cream, topical soln)</i> | |
| <i>imiquimod 5% cream packet</i> | |
| VALCHLOR | S |
| ANTIPRURITICS AND LOCAL ANESTHETICS | |
| DERMACINRX LIDOCAN | <p>PA</p> <p>QPD 3.0 per day</p> |
| <i>lidocaine 5% patch</i> | <p>PA</p> <p>QPD 3.0 per day</p> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-------------------------|
| <i>lidocaine 5% ointment</i> | PA QPD 3.334 per day |
| <i>lidocaine-prilocaine</i> | QPD 2.0 per day |
| LIDOCAN III | PA QPD 3.0 per day |
| LIDOCAN IV | PA QPD 3.0 per day |
| LIDOCAN V | PA QPD 3.0 per day |
| CELL STIMULANTS AND PROLIFERANTS | |
| <i>tretinoin (0.01% gel, 0.025% cream, 0.05% cream, 0.1% cream)</i> | PA |
| KERATOLYTIC AGENTS | |
| ABSORICA LD | |
| ACCUTANE | |
| <i>acitretin</i> | |
| <i>adapalene (0.1% cream, 0.3% gel, 0.3% gel pump)</i> | PA |
| AMNESTEEM | |
| CLARAVIS | |
| <i>isotretinoin (10 mg capsule, 20 mg capsule, 30 mg capsule, 40 mg capsule)</i> | |
| <i>tazarotene 0.05% cream</i> | |
| <i>tazarotene (0.05% gel, 0.1% cream, 0.1% gel)</i> | PA |
| ZENATANE | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|---|
| SKIN AND MUCOUS MEMBRANE AGENTS, MISC. | |
| <i>adapalene-bnzyl perox 0.1-2.5%</i> | PA |
| <i>adapalene-bnzyl perox 0.3-2.5%</i> | PA |
| DUPIXENT 200 MG/1.14 ML PEN | QL max 56 days / fill S PA QPD 0.082 per day |
| DUPIXENT 300 MG/2 ML PEN | QL max 56 days / fill S PA QPD 0.143 per day |
| DUPIXENT 200 MG/1.14 ML SYRING | QL max 56 days / fill S PA QPD 0.082 per day |
| DUPIXENT 300 MG/2 ML SYRINGE | QL max 56 days / fill S PA QPD 0.143 per day |
| <i>ivermectin 1% cream</i> | |
| SMOOTH MUSCLE RELAXANTS | |
| RESPIRATORY SMOOTH MUSCLE RELAXANTS | |
| ELIXOPHYLLIN | |
| <i>theophylline</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|-----------------------|
| <i>theophylline er (er 300 mg tablet, er 400 mg tablet, er 450 mg tablet, er 600 mg tablet)</i> | |
| SOMATOSTATIN AGONISTS AND ANTAGONISTS | |
| SOMATOSTATIN AGONISTS | |
| <i>octreotide acetate (acet 50 mcg/ml amp, acet 50 mcg/ml vial, acet 100 mcg/ml amp, acet 100 mcg/ml vl, acet 500 mcg/ml amp, acet 500 mcg/ml vl, 1,000 mcg/5 ml vial, 5,000 mcg/5 ml vial)</i> | S |
| SOMATOTROPIN AGONISTS AND ANTAGONISTS | |
| SOMATOTROPIN AGONISTS | |
| INCRELEX | S |
| SYMPATHOMIMETIC (ADRENERGIC) AGENTS | |
| ALPHA- AND BETA-ADRENERGIC AGONISTS | |
| AUVI-Q | |
| <i>epinephrine (0.15 mg auto-inject, 0.3 mg auto-inject)</i> | |
| ALPHA-ADRENERGIC AGONISTS (12:12) | |
| <i>lofexidine hcl</i> | |
| <i>midodrine hcl</i> | |
| THYROID AND ANTITHYROID AGENTS | |
| ANTITHYROID AGENTS | |
| <i>methimazole (5 mg tablet, 10 mg tablet)</i> | |
| <i>propylthiouracil 50 mg tablet</i> | |
| THYROID AGENTS | |
| EUTHYROX | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|---|
| LEVO-T | |
| <i>levothyroxine sodium (25 mcg tablet, 50 mcg tablet, 75 mcg tablet, 88 mcg tablet, 100 mcg tablet, 112 mcg tablet, 125 mcg tablet, 137 mcg tablet, 150 mcg tablet, 175 mcg tablet, 200 mcg tablet, 300 mcg tablet)</i> | |
| LEVOXYL | |
| LIOMNY (25 MCG TABLET, 50 MCG TABLET) | |
| LIOMNY 5 MCG TABLET | |
| <i>liothyronine sod 5 mcg tab</i> | |
| <i>liothyronine sodium (25 mcg tab, 50 mcg tab)</i> | |
| SYNTHROID | |
| UNITHROID | |
| TUMOR NECROSIS FACTOR INHIBITORS | |
| TUMOR NECROSIS FACTOR INHIBITORS, MISC | |
| <i>adalimumab-aaty(cf)</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #80400; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.072 per day |
| <i>adalimumab-aaty(cf) ai crohns</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #6a3d9a; color: white; padding: 2px 5px; border-radius: 3px;">QL</div> <div style="background-color: #c00; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #80400; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> </div> max 3 / 180 days |
| <i>adalimumab-aaty(cf) autoinject</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #80400; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.072 per day |
| <i>adalimumab-adaz(cf) 10mg/0.1ml</i> | <div style="display: flex; flex-direction: column; align-items: flex-end;"> <div style="background-color: #c00; color: white; padding: 2px 5px; border-radius: 3px;">S</div> <div style="background-color: #80400; color: white; padding: 2px 5px; border-radius: 3px;">PA</div> <div style="background-color: #0070c0; color: white; padding: 2px 5px; border-radius: 3px;">QPD</div> </div> 0.008 per day |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|--|
| <i>adalimumab-adaz(cf) 20mg/0.2ml</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.015 per day</div> |
| <i>adalimumab-adaz(cf) 40 mg syrg</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.029 per day</div> |
| <i>adalimumab-adaz(cf) pen 40 mg</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.029 per day</div> |
| <i>adalimumab-adaz(cf) pen 80 mg</i> | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.058 per day</div> |
| ENBREL 25 MG/0.5 ML SYRINGE | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.073 per day</div> |
| ENBREL (25 MG/0.5 ML VIAL, 50 MG/ML SYRINGE) | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.143 per day</div> |
| ENBREL MINI | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.143 per day</div> |
| ENBREL SURECLICK | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.143 per day</div> |
| HADLIMA | <div style="background-color: #c00000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">S</div> <div style="background-color: #804000; color: white; padding: 2px; text-align: center; margin-bottom: 2px;">PA</div> <div style="background-color: #0056b3; color: white; padding: 2px; text-align: center;">QPD 0.058 per day</div> |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|------------------------------|
| HADLIMA PUSHTOUCH | S PA QPD 0.058 per day |
| HADLIMA(CF) | S PA QPD 0.029 per day |
| HADLIMA(CF) PUSHTOUCH | S PA QPD 0.029 per day |
| SIMLANDI(CF) | S PA QPD 0.072 per day |
| SIMLANDI(CF) AUTOINJECTOR | S PA QPD 0.072 per day |
| SIMPONI (100 MG/ML PEN INJECTOR, 100 MG/ML SYRINGE) | S PA QPD 0.036 per day |
| VASODILATING AGENTS | |
| CGMP SYNTHESIS AGENT | |
| VERQUVO | PA QPD 1.0 per day |
| DIRECT VASODILATORS | |
| <i>hydralazine hcl (10 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablet)</i> | |
| <i>isosorbide dinit-hydralazine</i> | |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---|------------------------------|
| <i>minoxidil (2.5 mg tablet, 10 mg tablet)</i> | |
| NITRATES AND NITRITES | |
| <i>isosorbide dinitrate (5 mg tab, 10 mg tab, 20 mg tab, 30 mg tab)</i> | |
| <i>isosorbide mononitrate</i> | |
| <i>isosorbide mononitrate er</i> | |
| NITRO-BID | |
| <i>nitroglycerin 2% ointment</i> | |
| <i>nitroglycerin 400 mcg spray</i> | |
| <i>nitroglycerin (0.3 mg tablet, 0.4 mg tablet, 0.6 mg tablet)</i> | |
| <i>nitroglycerin patch</i> | |
| PHOSPHODIESTERASE TYPE 5 INHIBITORS | |
| <i>tadalafil (2.5 mg tablet, 5 mg tablet)</i> | QPD 1.0 per day |
| VASODILATING AGENTS (RESPIRATORY TRACT) | |
| PHOSPHODIESTERASE-5 INHIBITORS (RESPIR) | |
| ALYQ | S PA QPD 2.0 per day |
| <i>sildenafil 10 mg/ml oral susp</i> | S PA QPD 7.467 per day |
| <i>sildenafil 20 mg tablet</i> | S PA QPD 3.0 per day |
| <i>tadalafil 20 mg tablet (pah)</i> | S PA QPD 2.0 per day |

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|--|-----------------------|
| VITAMINS | |
| MULTIVITAMIN PREPARATIONS | |
| PRENATABS RX | |
| <i>prenatal 19 chewable tablet</i> | |
| <i>prenatal plus iron tablet</i> | |
| <i>prenatal-u</i> | |
| SE-NATAL 19 (19 CHEWABLE TABLET, 19 TABLET) | |
| TRINATE | |
| VITAMIN B COMPLEX | |
| <i>cyanocobalamin injection</i> | |
| DODEX | |
| FA-8 | |
| <i>folic acid (0.4 mg tablet, 0.8 mg tablet, 400 mcg tablet, 800 mcg capsule, 800 mcg tablet, cvs 800 mcg tablet, ft 400 mcg tablet, ft 800 mcg tablet, gnp 400 mcg tablet, ra 0.4 mg tablet, ra 800 mcg tablet, sm 400 mcg tablet, sv 800 mcg tablet, true 667 mcg dfe tb, well 400 mcg tablet)</i> | |
| <i>folic acid 1 mg tablet</i> | |
| PUREVITA FOLIC ACID 400 MCG TB | |
| VITAMIN D | |
| <i>calcitriol 0.25 mcg capsule</i> | |
| <i>calcitriol 0.5 mcg capsule</i> | |
| <i>ergocalciferol (vitamin d2)</i> | |
| <i>vitamin d2 1.25mg(50,000 unit)</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| PRODUCT DESCRIPTION | LIMITS & RESTRICTIONS |
|---------------------------------|-----------------------|
| VITAMIN K ACTIVITY | |
| <i>phytonadione 5 mg tablet</i> | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

Index of Covered Drugs

| | |
|--------------------------------|---------|
| A | |
| abacavir | 65 |
| abacavir-lamivudine | 65 |
| ABIGALE | 99 |
| ABIGALE LO | 99 |
| abiraterone acetate | 45 |
| ABIRTEGA | 45 |
| ABRYSVO | 69 |
| ABSORICA LD | 140 |
| acarbose | 32 |
| ACCUTANE | 140 |
| acebutolol hcl | 85 |
| acetaminophen-codeine | 2 |
| acetazolamide | 37 |
| acetazolamide er | 37 |
| acetic acid | 9 |
| acetylcysteine | 34 |
| acitretin | 140 |
| ACTHIB | 69 |
| ACTIMMUNE | 125 |
| acyclovir | 11,75 |
| ADACEL TDAP | 69 |
| adalimumab-aaty(cf) | 143 |
| adalimumab-aaty(cf) ai crohns | 143 |
| adalimumab-aaty(cf) autoinject | 143 |
| adalimumab-adaz(cf) | 143,144 |
| adalimumab-adaz(cf) pen | 144 |
| adapalene | 140 |
| adapalene-benzoyl peroxide | 141 |
| ADBRY | 15 |
| ADBRY AUTOINJECTOR | 15 |
| adefovir dipivoxil | 75 |
| ADULT ASPIRIN REGIMEN | 133 |
| ADVAIR HFA | 80 |
| AFIRMELLE | 108 |
| AFLURIA 2025-2026 | 69 |
| AFLURIA 2025-2026 (3YR UP) | 69 |
| AFLURIA QUAD 2023-2024 | 69 |
| AFLURIA QUAD 2023-24 (3YR UP) | 69 |
| AFLURIA TRIV 2024-25 (3YR UP) | 69 |
| AFLURIA TRIVALENT 2024-25 | 69 |
| AFSTYLA | 38 |
| AFTERA | 108 |
| AIMOVIG AUTOINJECTOR | 43 |
| aimsco | 130 |
| AIRSUPRA | 80 |
| AJOVY AUTOINJECTOR | 43 |
| AJOVY AUTOINJECTOR (3 PACK) | 43 |
| AJOVY SYRINGE | 43 |
| AK-POLY-BAC | 9 |
| ALA-CORT | 13 |
| albendazole | 8 |
| albuterol sulfate | 80,81 |
| albuterol sulfate hfa | 81 |
| alclometasone dipropionate | 13 |
| ALECENSA | 45 |
| alendronate sodium | 125 |
| alfuzosin hcl er | 2 |
| ALINIA | 60 |
| allopurinol | 125 |
| alosetron hcl | 102 |
| ALPHANATE | 38 |
| ALPHANINE SD | 38 |
| alprazolam | 76 |
| alprazolam er | 76,77 |
| alprazolam xr | 77 |
| ALTavera | 108 |
| ALUNBRIG | 45,46 |
| ALYACEN | 108 |
| ALYFTREK | 89 |
| ALYQ | 146 |
| AMABELZ | 99 |
| amantadine | 58 |
| ambrisentan | 138 |
| AMETHIA | 108 |
| AMETHYST | 109 |
| amiloride hcl | 95 |
| amiloride-hydrochlorothiazide | 95 |
| aminocaproic acid | 38 |
| amiodarone hcl | 18 |
| amitriptyline hcl | 31 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|--|-----|--|-----|
| amlodipine besylate | 83 | atazanavir sulfate | 67 |
| amlodipine besylate-benazepril | 83 | atenolol | 85 |
| amlodipine-olmesartan | 83 | atenolol-chlorthalidone | 85 |
| amlodipine-valsartan | 84 | atomoxetine hcl | 6 |
| amlodipine-valsartan-hctz | 84 | atorvastatin calcium | 42 |
| ammonium lactate | 98 | atovaquone | 60 |
| AMNESTEEM | 140 | atovaquone-proguanil hcl | 59 |
| amoxicillin | 134 | atropine sulfate | 101 |
| amoxicillin-clavulanate pot er | 134 | ATTRUBY | 84 |
| amoxicillin-clavulanate potass | 134 | AUBRA | 109 |
| ampicillin trihydrate | 134 | AUBRA EQ | 109 |
| anagrelide hcl | 69 | AUROVELA | 109 |
| anastrozole | 46 | AUROVELA 24 FE | 109 |
| ANDEMBRY AUTOINJECTOR | 123 | AUROVELA FE | 109 |
| ANORO ELLIPTA | 22 | AUVI-Q | 142 |
| ANUCORT-HC | 13 | AVIANE | 109 |
| ANUSOL-HC | 13 | AVIDOXY | 21 |
| apomorphine hcl | 96 | AVONEX (4 PACK) | 128 |
| aprepitant | 35 | AVONEX PEN (4 PACK) | 128 |
| APRETUDE | 63 | AYUNA | 109 |
| APRI | 109 | AZASAN | 43 |
| ARANELLE | 109 | azathioprine | 43 |
| ARANESP | 82 | azelaic acid | 10 |
| AREXVY | 69 | azelastine hcl | 101 |
| AREXVY ADJUVANT COMPONENT | 69 | azithromycin | 124 |
| AREXVY ANTIGEN COMPONENT | 69 | AZSTARYS | 6 |
| arformoterol tartrate | 81 | AZURETTE | 109 |
| aripiprazole | 61 | | |
| aripiprazole odt | 61 | B | |
| armodafinil | 8 | bacitracin | 9 |
| ARNUIITY ELLIPTA | 107 | bacitracin-polymyxin | 9 |
| asa-butalb-caffeine-codeine | 2 | baclofen | 139 |
| ASCOMP WITH CODEINE | 2 | balsalazide disodium | 102 |
| asenapine maleate | 61 | BALZIVA | 109 |
| ASHLYNA | 109 | BAQSIMI | 40 |
| ASMANEX | 107 | BARACLUDE | 76 |
| ASMANEX HFA | 107 | BAYER CHEWABLE ASPIRIN | 133 |
| aspirin | 133 | BELBUCA | 5 |
| aspirin ec | 133 | BELSOMRA | 78 |
| ASPIRIN REGIMEN | 133 | benazepril hcl | 136 |
| aspirin-dipyridamole er | 133 | benazepril-hydrochlorothiazide | 136 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-------------------------------------|-------|-------------------------------------|-----|
| benznidazole..... | 60 | buprenorphine-naloxone..... | 5 |
| benzonatate..... | 138 | bupropion hcl..... | 28 |
| benztropine mesylate..... | 58 | bupropion hcl sr..... | 29 |
| bepotastine besilate..... | 101 | bupropion xl..... | 29 |
| BESIVANCE..... | 9 | bupirone hcl..... | 77 |
| BESREMI..... | 46 | butalb-acetaminoph-caff-codein..... | 2 |
| betaine anhydrous..... | 126 | butalbital-acetaminophen..... | 2 |
| betamethasone diprop augmented..... | 13 | butalbital-acetaminophen-caffe..... | 76 |
| betamethasone dipropionate..... | 13 | butalbital-aspirin-caffeine..... | 133 |
| betamethasone valerate..... | 13 | butorphanol tartrate..... | 5 |
| BETASERON..... | 128 | | |
| betaxolol hcl..... | 85 | C | |
| bethanechol chloride..... | 78 | cabergoline..... | 96 |
| bexarotene..... | 46 | CABOMETYX..... | 46 |
| BEXSERO..... | 70 | caffeine citrate..... | 6 |
| bicalutamide..... | 46 | calcipotriene..... | 98 |
| BIKTARVY..... | 64 | calcitonin-salmon..... | 134 |
| bimatoprost..... | 38 | calcitriol..... | 147 |
| bisoprolol fumarate..... | 85 | calcium acetate..... | 122 |
| bisoprolol-hydrochlorothiazide..... | 85 | CALQUENCE..... | 47 |
| BLISOVI 24 FE..... | 109 | CAMILA..... | 109 |
| BLISOVI FE..... | 109 | CAMRESE..... | 109 |
| BOOSTRIX TDAP..... | 69 | CAMRESE LO..... | 109 |
| bosentan..... | 138 | candesartan cilexetil..... | 136 |
| BOSULIF..... | 46 | candesartan-hydrochlorothiazid..... | 136 |
| BREO ELLIPTA..... | 81 | capecitabine..... | 47 |
| BREYNA..... | 81 | CAPRELSA..... | 47 |
| BREZTRI AEROSPHERE..... | 83 | captopril..... | 136 |
| BRIELLYN..... | 109 | CAPVAXIVE..... | 70 |
| brimonidine tartrate..... | 13,37 | CARAC..... | 139 |
| brivaracetam..... | 25 | carbamazepine..... | 25 |
| BROMFED DM..... | 138 | carbamazepine er..... | 25 |
| bromocriptine mesylate..... | 96 | carbidopa..... | 87 |
| brompheniramine-pseudoephed-dm..... | 138 | carbidopa-levodopa..... | 59 |
| BRUKINSA..... | 46 | carbidopa-levodopa er..... | 59 |
| budesonide..... | 107 | carbidopa-levodopa-entacapone..... | 59 |
| budesonide dr..... | 107 | carbinoxamine maleate..... | 40 |
| budesonide ec..... | 107 | carglumic acid..... | 97 |
| budesonide-formoterol fumarate..... | 81 | CARTIA XT..... | 19 |
| bumetanide..... | 94 | carvedilol..... | 85 |
| buprenorphine hcl..... | 5 | caya contoured..... | 130 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|---------------------------------------|------|--|----|
| CAZANT | 109 | CLINDACIN ETZ | 21 |
| cefadroxil | 88 | CLINDACIN P | 21 |
| cefdinir | 88 | clindamycin (pediatric) | 21 |
| cefixime | 89 | clindamycin hcl | 21 |
| cefpodoxime proxetil | 89 | clindamycin phos-benzoyl perox | 10 |
| cefprozil | 88 | clindamycin phosphate | 21 |
| cefuroxime | 88 | CLINPRO 5000 | 90 |
| celecoxib | 131 | clobazam | 26 |
| cephalexin | 88 | clobetasol emollient | 13 |
| cetirizine hcl | 40 | clobetasol propionate | 13 |
| cevimeline hcl | 78 | clomipramine hcl | 31 |
| CHANTIX | 79 | clonazepam | 26 |
| CHARLOTTE 24 FE | 109 | clonidine | 86 |
| CHATEAL EQ | 109 | clonidine hcl | 86 |
| CHEMET | 106 | clonidine hcl er | 86 |
| CHENODAL | 103 | clopidogrel | 68 |
| children's aspirin | 133 | clorazepate dipotassium | 77 |
| chlordiazepoxide hcl | 77 | clotrimazole | 36 |
| chlorhexidine gluconate | 10 | clotrimazole-betamethasone | 36 |
| chloroquine phosphate | 59 | clozapine | 61 |
| chlorpromazine hcl | 63 | clozapine odt | 61 |
| chlorthalidone | 95 | COAGADEX | 38 |
| chlorzoxazone | 139 | codeine sulfate | 2 |
| cholestyramine | 41 | colchicine | 86 |
| cholestyramine light | 41 | colesevelam hcl | 41 |
| CIBINQO | 17 | colestipol hcl | 41 |
| CICLODAN | 37 | COMBIVENT RESPIMAT | 22 |
| ciclopirox | 37 | COMETRIQ | 47 |
| cilostazol | 68 | COMIRNATY 2023-2024 | 70 |
| CIMDUO | 65 | COMIRNATY 2024-2025 | 70 |
| cimetidine | 74 | COMIRNATY 2025-2026 (12Y UP) | 70 |
| cinacalcet hcl | 134 | COMIRNATY 2025-2026(5-11Y) | 70 |
| ciprofloxacin | 20 | COMPRO | 35 |
| ciprofloxacin hcl | 9,20 | conjugated estrogens | 99 |
| ciprofloxacin-dexamethasone | 9 | CONSTULOSE | 97 |
| citalopram hbr | 30 | contour | 91 |
| cladribine | 127 | contour next control solution | 91 |
| CLARAVIS | 140 | contour next test strip | 94 |
| clarithromycin | 124 | contour plus test strip | 94 |
| clarithromycin er | 125 | contour test strip | 94 |
| CLIMARA PRO | 99 | CORIFACT | 38 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|------------------------------|-------|--------------------------------|-----------|
| CORLANOR | 84 | DELSTRIGO | 64 |
| CORTIFOAM | 14 | demeclocycline hcl | 21 |
| COSENTYX (2 SYRINGES) | 120 | DENTA 5000 PLUS | 90 |
| COSENTYX SENSOREADY (2 PENS) | 120 | DENTA 5000 PLUS SENSITIVE | 90 |
| COSENTYX SENSOREADY PEN | 120 | DENTAGEL | 90 |
| COSENTYX SYRINGE | 120 | DEPO-TESTOSTERONE | 108 |
| COSENTYX UNOREADY PEN | 120 | DERMACINRX LIDOCAN | 139 |
| COTELLIC | 47 | DESCOVY | 65 |
| CREON | 103 | desipramine hcl | 31 |
| cromolyn sodium | 13 | desloratadine | 40 |
| CRYSSELLE | 109 | desmopressin acetate | 116 |
| CTEXTI | 103 | desogestr-eth estrad eth estra | 110 |
| CURAE | 109 | desonide | 14 |
| cyanocobalamin injection | 147 | desoximetasone | 14 |
| cyclobenzaprine hcl | 139 | desvenlafaxine succinate er | 29 |
| cyclopentolate hcl | 101 | dexamethasone | 107 |
| cyclophosphamide | 47 | dexamethasone sodium phosphate | 107 |
| cyclosporine | 83 | dexcom g6 receiver | 91 |
| cyclosporine modified | 83 | dexcom g6 sensor | 91 |
| cyproheptadine hcl | 101 | dexcom g6 transmitter | 91 |
| CYRED | 110 | dexcom g7 15 day sensor | 91 |
| CYRED EQ | 110 | dexcom g7 receiver | 91 |
| CYSTAGON | 126 | dexcom g7 sensor | 92 |
| CYTRA-2 | 96 | dexlansoprazole dr | 74 |
| D | | dexmethylphenidate hcl | 6 |
| dabigatran etexilate | 23 | dexmethylphenidate hcl er | 6 |
| dalfampridine er | 126 | dextroamphetamine sulfate | 5 |
| danazol | 108 | dextroamphetamine sulfate er | 5 |
| dapagliflozin | 33 | dextroamphetamine-amphet er | 5 |
| dapsone | 44 | dextroamphetamine-amphetamine | 5,6 |
| DAPTACEL DTAP | 69 | diazepam | 77 |
| darunavir | 67 | diazoxide | 40 |
| dasatinib | 47,48 | diclofenac potassium | 132 |
| DASSETA | 110 | diclofenac sodium | 12,17,132 |
| DAWNZERA | 124 | diclofenac sodium-misoprostol | 132 |
| DAYSEE | 110 | dicloxacillin sodium | 135 |
| DEBLITANE | 110 | dicyclomine hcl | 22 |
| deferasirox | 106 | DIFICID | 125 |
| deferiprone | 106 | diflunisal | 132 |
| deferiprone (3 times a day) | 106 | DIGITEK | 84 |
| | | digoxin | 84,85 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|------------------------------------|------|---|-----|
| dihydroergotamine mesylate | 2 | DUPIXENT SYRINGE | 141 |
| DILANTIN | 28 | durex avanti bare real feel | 130 |
| DILT-XR | 19 | durex extra sensitive | 130 |
| diltiazem 12hr er | 19 | durex tropical | 130 |
| diltiazem 24hr er | 19 | dutasteride | 125 |
| diltiazem 24hr er (cd) | 19 | | |
| diltiazem 24hr er (la) | 19 | E | |
| diltiazem 24hr er (xr) | 19 | E.E.S. 400 | 124 |
| diltiazem hcl | 19 | EBGLYSS PEN | 15 |
| dimethyl fumarate | 128 | EBGLYSS SYRINGE | 15 |
| DIPHEN | 101 | econazole nitrate | 36 |
| diphenoxylate-atropine | 102 | ECONTRA EZ | 110 |
| dipyridamole | 68 | ECONTRA ONE-STEP | 110 |
| DISKETS | 2 | ECOTRIN | 133 |
| disopyramide phosphate | 18 | efavirenz | 64 |
| divalproex sodium | 26 | efavirenz-emtricitabine-tenofovir disoproxil fumarate | 65 |
| divalproex sodium er | 27 | efavirenz-lamivudine-tenofovir disoproxil fumarate | 64 |
| DIVIGEL | 99 | eletriptan hbr | 44 |
| DODEX | 147 | ELINEST | 110 |
| dofetilide | 18 | ELIQUIS | 23 |
| DOLISHALE | 110 | ELIQUIS SPRINKLE | 23 |
| donepezil hcl | 78 | ELIXOPHYLLIN | 141 |
| donepezil hcl odt | 78 | ELLA | 110 |
| DOPTELET | 82 | ELOCTATE | 38 |
| DOPTELET SPRINKLE | 82 | eltrombopag olamine | 82 |
| dorzolamide hcl | 38 | EMCYT | 48 |
| dorzolamide-timolol | 37 | EMEND | 35 |
| DOTTI | 100 | EMGALITY PEN | 43 |
| DOVATO | 64 | EMGALITY SYRINGE | 43 |
| doxazosin mesylate | 85 | EMPAVELI | 117 |
| doxepin hcl | 31 | emtricitabine | 65 |
| doxycycline hyclate | 9,21 | emtricitabine-rilpivirine-tenofovir disoproxil fumarate | 66 |
| doxycycline monohydrate | 21 | emtricitabine-tenofovir disoproxil fumarate | 66 |
| doxylamine succ-pyridoxine hcl | 35 | EMZAHH | 110 |
| dronabinol | 103 | enalapril maleate | 136 |
| drospirenone-eth estradiol-levomef | 110 | enalapril-hydrochlorothiazide | 136 |
| drospirenone-ethinyl estradiol | 110 | ENBREL | 144 |
| DUAVEE | 100 | ENBREL MINI | 144 |
| DULERA | 81 | ENBREL SURECLICK | 144 |
| duloxetine hcl | 29 | ENDOCET | 2,3 |
| DUPIXENT PEN | 141 | ENGERIX-B ADULT | 70 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|--|-------|--|-------|
| ENGERIX-B PEDIATRIC-ADOLESCENT | 70 | ethynodiol-ethinyl estradiol | 110 |
| enoxaparin sodium | 23,24 | etodolac | 132 |
| ENPRESSE | 110 | etodolac er | 132 |
| ENSKYCE | 110 | etoposide | 48 |
| ENSTILAR | 98 | etravirine | 64 |
| entacapone | 59 | EUCRISA | 17 |
| entecavir | 76 | EUTHYROX | 142 |
| ENTRESTO SPRINKLE | 135 | everolimus | 48,49 |
| ENTYVIO PEN | 94 | EVOTAZ | 67 |
| ENULOSE | 97 | exemestane | 49 |
| EPCLUSA | 105 | EYSUVIS | 11 |
| EPIDIOLEX | 25 | ezetimibe | 41 |
| epinastine hcl | 101 | ezetimibe-simvastatin | 41 |
| epinephrine | 142 | | |
| EPITOL | 25 | F | |
| eplerenone | 125 | FA-8 | 147 |
| EPOGEN | 82 | FABHALTA | 117 |
| ergocalciferol (vitamin d2) | 147 | FALMINA | 110 |
| ERIVEDGE | 48 | famciclovir | 76 |
| ERLEADA | 48 | famotidine | 74 |
| erlotinib hcl | 48 | fantasy | 130 |
| ERRIN | 110 | FARXIGA | 33 |
| ERY-TAB | 124 | FASENRA PEN | 12 |
| ERYTHROCIN STEARATE | 124 | fc2 female condom | 130 |
| erythromycin | 9,124 | FEIBA | 39 |
| erythromycin ethylsuccinate | 124 | FEIRZA | 110 |
| escitalopram oxalate | 30 | felbamate | 25 |
| eslicarbazepine acetate | 28 | felodipine er | 84 |
| esomeprazole magnesium | 74 | femcap | 130 |
| ESPEROCT | 39 | fenofibrate | 42 |
| ESTARYLLA | 110 | fentanyl | 3 |
| estazolam | 77 | fentanyl citrate | 3 |
| estradiol | 100 | FER-IN-SOL | 17 |
| estradiol (once weekly) | 100 | ferric citrate | 122 |
| estradiol (twice weekly) | 100 | ferrous sulfate | 17 |
| estradiol valerate | 100 | FIASP | 118 |
| estradiol-norethindrone acetat | 100 | FIASP FLEXTOUCH | 118 |
| ESTRING | 100 | FIASP PENFILL | 118 |
| eszopiclone | 77 | FIBRYGA | 39 |
| ethambutol hcl | 44 | fidaxomicin | 125 |
| ethosuximide | 28 | finasteride | 125 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|------------------------------------|-------|-------------------------------------|-----|
| fingolimod..... | 130 | fluticasone-salmeterol..... | 81 |
| FINZALA..... | 110 | fluvoxamine maleate..... | 30 |
| FLAC OTIC OIL..... | 11 | FLUZONE 2025-2026..... | 71 |
| flecainide acetate..... | 18 | FLUZONE HIGH-DOSE 2025-2026..... | 71 |
| FLUAD 2025-2026..... | 70 | FLUZONE HIGH-DOSE QUAD 2023-24..... | 71 |
| FLUAD QUAD 2023-2024..... | 70 | FLUZONE HIGH-DOSE TRIV 2024-25..... | 71 |
| FLUAD TRIVALENT 2024-2025..... | 70 | FLUZONE QUAD 2023-2024..... | 71 |
| FLUARIX 2025-2026..... | 70 | FLUZONE QUAD SOUTHERN HEM 2024..... | 71 |
| FLUARIX QUAD 2023-2024..... | 70 | FLUZONE TRIVALENT 2024-2025..... | 71 |
| FLUARIX TRIVALENT 2024-2025..... | 70 | folic acid..... | 147 |
| FLUBLOK 2025-2026..... | 70 | fondaparinux sodium..... | 24 |
| FLUBLOK QUAD 2023-2024..... | 70 | fosamprenavir calcium..... | 67 |
| FLUBLOK TRIVALENT 2024-2025..... | 70 | fosfomycin tromethamine..... | 8 |
| FLUCELVAX 2025-2026..... | 70 | fosinopril sodium..... | 137 |
| FLUCELVAX QUAD 2023-2024..... | 70 | fosinopril-hydrochlorothiazide..... | 137 |
| FLUCELVAX TRIVALENT 2024-2025..... | 70 | FRAICHE 5000..... | 90 |
| fluconazole..... | 36 | freestyle control solution..... | 92 |
| flucytosine..... | 36 | freestyle insulinx..... | 94 |
| fludrocortisone acetate..... | 107 | freestyle insulinx test strips..... | 94 |
| FLULAVAL 2025-2026..... | 70 | freestyle lite test strip..... | 94 |
| FLULAVAL QUAD 2023-2024..... | 71 | freestyle precision neo..... | 94 |
| FLULAVAL TRIVALENT 2024-2025..... | 71 | freestyle test strips..... | 94 |
| FLUMIST 2025-2026..... | 71 | FULPHILA..... | 82 |
| FLUMIST HOME 2025-2026..... | 71 | furosemide..... | 95 |
| FLUMIST QUAD 2023-2024..... | 71 | FYAVOLV..... | 100 |
| FLUMIST TRIVALENT 2024-2025..... | 71 | FYLNETRA..... | 82 |
| flunisolide..... | 11 | | |
| fluocinolone acetonide..... | 14 | G | |
| fluocinolone acetonide oil..... | 11 | gabapentin..... | 27 |
| fluocinonide..... | 14 | gabapentin er..... | 27 |
| fluocinonide-e..... | 14 | galantamine er..... | 78 |
| fluoride..... | 90 | galantamine hbr..... | 78 |
| FLUORIDEX..... | 90 | GALBRIELA..... | 110 |
| FLUORIDEX SENSITIVITY RELIEF..... | 90 | GALLIFREY..... | 116 |
| FLUORIMAX 5000..... | 90 | GARDASIL 9..... | 71 |
| FLUORIMAX 5000 SENSITIVE..... | 90 | gatifloxacin..... | 9 |
| fluorometholone..... | 11 | GAVILYTE-G..... | 102 |
| fluorouracil..... | 139 | GAVILYTE-N..... | 102 |
| fluoxetine hcl..... | 30 | gefitinib..... | 49 |
| fluphenazine hcl..... | 63 | GEL-KAM..... | 90 |
| fluticasone propionate..... | 11,14 | gemfibrozil..... | 42 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|----------------------------------|-------|----------------------------------|--------|
| GENERLAC..... | 97 | haloperidol lactate..... | 62 |
| GENGRAF..... | 83 | HARVONI..... | 106 |
| GENOTROPIN..... | 116 | HAVRIX..... | 71 |
| gentamicin sulfate..... | 9,10 | HEATHER..... | 111 |
| GENVOYA..... | 66 | HEMANGEOL..... | 85 |
| GILOTRIF..... | 49 | HEMMOREX-HC..... | 14 |
| glatiramer acetate..... | 126 | heparin sodium..... | 24 |
| GLATOPA..... | 127 | HEPLISAV-B..... | 71 |
| GLEOSTINE..... | 49 | HER STYLE..... | 111 |
| glimepiride..... | 34 | HIBERIX..... | 71 |
| glipizide..... | 34 | HUMALOG..... | 118 |
| glipizide er..... | 34 | HUMALOG JUNIOR KWIKPEN..... | 118 |
| glipizide xl..... | 34 | HUMALOG KWIKPEN U-100..... | 118 |
| glipizide-metformin..... | 34 | HUMALOG KWIKPEN U-200..... | 118 |
| GLUCAGON EMERGENCY KIT..... | 40 | HUMALOG MIX 50-50 KWIKPEN..... | 119 |
| glyburide..... | 34 | HUMALOG MIX 75-25..... | 119 |
| glyburide-metformin hcl..... | 34 | HUMALOG MIX 75-25 KWIKPEN..... | 119 |
| glycerol phenylbutyrate..... | 97 | HUMALOG TEMPO PEN U-100..... | 119 |
| glycopyrrolate..... | 22 | HUMATE-P..... | 39 |
| GLYXAMBI..... | 33 | HUMATIN..... | 59 |
| granisetron hcl..... | 35 | HUMULIN 70-30..... | 117 |
| griseofulvin..... | 36 | HUMULIN 70/30 KWIKPEN..... | 117 |
| griseofulvin ultramicrosize..... | 36 | HUMULIN N..... | 117 |
| guanfacine hcl..... | 86 | HUMULIN N KWIKPEN..... | 117 |
| guanfacine hcl er..... | 86,87 | HUMULIN R..... | 119 |
| GVOKE..... | 40 | HUMULIN R U-500..... | 119 |
| GVOKE HYOPEN 1-PACK..... | 41 | HUMULIN R U-500 KWIKPEN..... | 119 |
| GVOKE HYOPEN 2-PACK..... | 41 | HYCANTIN..... | 49 |
| GVOKE PFS 1-PACK SYRINGE..... | 41 | hydralazine hcl..... | 145 |
| GVOKE PFS 2-PACK SYRINGE..... | 41 | hydrochlorothiazide..... | 95 |
| H | | hydrocodone-acetaminophen..... | 3 |
| HADLIMA..... | 144 | hydrocodone-homatropine mbr..... | 138 |
| HADLIMA PUSHTOUCH..... | 145 | hydrocodone-ibuprofen..... | 3 |
| HADLIMA(CF)..... | 145 | hydrocortisone..... | 14,107 |
| HADLIMA(CF) PUSHTOUCH..... | 145 | hydrocortisone acetate..... | 14 |
| HAILEY..... | 111 | hydrocortisone valerate..... | 14 |
| HAILEY 24 FE..... | 111 | hydrocortisone-acetic acid..... | 9 |
| HAILEY FE..... | 111 | HYDROMET..... | 138 |
| halobetasol propionate..... | 14 | hydromorphone hcl..... | 3 |
| haloperidol..... | 62 | hydroxychloroquine sulfate..... | 59 |
| | | hydroxyurea..... | 49 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|---|--------|-------------------------------------|-------|
| hydroxyzine hcl..... | 76 | irbesartan-hydrochlorothiazide..... | 136 |
| hydroxyzine pamoate..... | 76 | IRONUP..... | 17 |
| I | | ISENTRESS..... | 64 |
| ibandronate sodium..... | 125 | ISENTRESS HD..... | 64 |
| IBRANCE..... | 49 | ISIBLOOM..... | 111 |
| IBU..... | 132 | isoniazid..... | 44 |
| ibuprofen..... | 132 | isosorbide dinit-hydralazine..... | 145 |
| ICAR..... | 17 | isosorbide dinitrate..... | 146 |
| icatibant..... | 89 | isosorbide mononitrate..... | 146 |
| ICLEVIA..... | 111 | isosorbide mononitrate er..... | 146 |
| IDELVION..... | 39 | isotretinoin..... | 140 |
| ilet infusion kit-flex..... | 92 | ITOVEBI..... | 50 |
| ilet infusion kit-inset..... | 92 | itraconazole..... | 36 |
| ilet infusion-contact detach..... | 92 | ivabradine hcl..... | 85 |
| ilet insulin pump..... | 92 | ivermectin..... | 8,141 |
| ilet starter kit-inset..... | 92 | IXINITY..... | 39 |
| imatinib mesylate..... | 49 | J | |
| IMBRUVICA..... | 49,50 | JAIMIESS..... | 111 |
| imipramine hcl..... | 31 | JAKAFI..... | 50 |
| imiquimod..... | 139 | JANTOVEN..... | 22 |
| IMOVAX RABIES VACCINE..... | 71 | JANUMET..... | 32 |
| IMPAVIDO..... | 60 | JANUMET XR..... | 32 |
| INBRIJA..... | 59 | JANUVIA..... | 32 |
| INCASSIA..... | 111 | JARDIANCE..... | 33 |
| INCRELEX..... | 142 | JASMIEL..... | 111 |
| INCRUSE ELLIPTA..... | 22 | JENCYCLA..... | 111 |
| indapamide..... | 95 | JINTELI..... | 100 |
| indomethacin..... | 132 | JOLESSA..... | 111 |
| indomethacin er..... | 132 | JORNAY PM..... | 6 |
| INFANRIX DTAP..... | 69 | JUBLIA..... | 36 |
| infant-toddler iron..... | 17 | JULEBER..... | 111 |
| inhaler assistance devices and accessories..... | 92 | JULUCA..... | 64 |
| INLYTA..... | 50 | JUNEL..... | 111 |
| insulin glargine-yfgn..... | 118 | JUNEL FE..... | 111 |
| INTELENCE..... | 65 | JUNEL FE 24..... | 111 |
| INTROVALE..... | 111 | JUST RIGHT 5000..... | 90 |
| IPOL..... | 71 | JYNARQUE..... | 95 |
| ipratropium bromide..... | 22,101 | JYNNEOS..... | 71 |
| ipratropium-albuterol..... | 22 | JYNNEOS (NATIONAL STOCKPILE)..... | 71 |
| irbesartan..... | 136 | | |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|----------------------------|--------|--------------------------------|-------|
| K | | lactulose | 97 |
| K-PHOS NO.2 | 96 | LAGEVRIO (EUA) | 76 |
| KAITLIB FE | 111 | lamivudine | 66 |
| KALETRA | 67 | lamivudine hbv | 66 |
| KALLIGA | 111 | lamivudine-zidovudine | 66 |
| KALYDECO | 90 | lamotrigine | 25 |
| KARIVA | 111 | lamotrigine (blue) | 25 |
| KELNOR 1-35 | 111 | lamotrigine (green) | 25 |
| KELNOR 1-50 | 111 | lamotrigine (orange) | 25 |
| KERENDIA | 137 | lamotrigine er | 25 |
| KESIMPTA PEN | 129 | lancets | 92 |
| ketoconazole | 36,37 | lancing device/lancets | 92 |
| ketorolac tromethamine | 12,132 | lansoprazole | 74 |
| kimono | 131 | lanthanum carbonate | 122 |
| kimono microthin | 131 | lapatinib | 51 |
| kimono microthin aqua lube | 131 | LARIN | 111 |
| kimono textured | 131 | LARIN 24 FE | 112 |
| kimono thin | 131 | LARIN FE | 112 |
| KINRIX | 72 | latanoprost | 38 |
| KIONEX | 122 | LAYOLIS FE | 112 |
| KISQALI | 50,51 | LEENA | 112 |
| KISQALI FEMARA CO-PACK | 51 | leflunomide | 94 |
| KLAYESTA | 37 | lenalidomide | 51 |
| KLOR-CON | 97 | LENVIMA | 51,52 |
| KLOR-CON 10 | 97 | LESSINA | 112 |
| KLOR-CON 8 | 97 | letrozole | 52 |
| KLOR-CON M10 | 97 | leucovorin calcium | 34 |
| KLOR-CON M15 | 97 | LEUKERAN | 52 |
| KLOR-CON M20 | 97 | leuprolide acetate | 105 |
| KLOXXADO | 87 | levalbuterol concentrate | 81 |
| KOATE | 39 | levalbuterol hcl | 81 |
| KOGENATE FS | 39 | LEVEMIR | 118 |
| KOURZEO | 14 | LEVEMIR FLEXPEN | 118 |
| KOVALTRY | 39 | levetiracetam | 25 |
| KURVELO | 111 | levetiracetam er | 25 |
| L | | LEVO-T | 143 |
| l-glutamine | 126 | levocarnitine | 126 |
| labetalol hcl | 85 | levocarnitine sf | 126 |
| lacosamide | 28 | levocetirizine dihydrochloride | 40 |
| | | levofloxacin | 20 |
| | | LEVONEST | 112 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-------------------------------------|---------|-------------------------------------|-------|
| levonorg-eth estrad eth estrad..... | 112 | lovastatin..... | 42 |
| levonorgestrel..... | 112 | LOW DOSE ASPIRIN EC..... | 133 |
| levonorgestrel-eth estradiol..... | 112 | LOW-OGESTREL..... | 112 |
| LEVORA-28..... | 112 | loxapine..... | 62 |
| levothyroxine sodium..... | 143 | LUZZA..... | 112 |
| LEVOXYL..... | 143 | LUMIGAN..... | 38 |
| lidocaine..... | 139,140 | LUPRON DEPOT..... | 105 |
| lidocaine hcl..... | 101 | LUPRON DEPOT-PED..... | 105 |
| lidocaine hcl viscous..... | 101 | lurasidone hcl..... | 61 |
| lidocaine-prilocaine..... | 140 | LUTERA..... | 112 |
| LIDOCAN III..... | 140 | LYLEQ..... | 112 |
| LIDOCAN IV..... | 140 | LYLLANA..... | 100 |
| LIDOCAN V..... | 140 | LYNPARZA..... | 52 |
| linezolid..... | 21 | LYSODREN..... | 52 |
| LIOMNY..... | 143 | LYUMJEV..... | 119 |
| liothyronine sodium..... | 143 | LYUMJEV KWIKPEN U-100..... | 119 |
| lisdexamphetamine dimesylate..... | 6 | LYUMJEV KWIKPEN U-200..... | 119 |
| lisinopril..... | 137 | LYUMJEV TEMPO PEN U-100..... | 119 |
| lisinopril-hydrochlorothiazide..... | 137 | LYZA..... | 113 |
| lithium carbonate..... | 87 | | |
| lithium carbonate er..... | 87 | M | |
| lithium citrate..... | 87 | M-M-R II VACCINE..... | 72 |
| LO LOESTRIN FE..... | 112 | malathion..... | 11 |
| LO-ZUMANDIMINE..... | 112 | maraviroc..... | 63 |
| LOESTRIN..... | 112 | MARLISSA..... | 113 |
| LOESTRIN FE..... | 112 | MATULANE..... | 52 |
| lofexidine hcl..... | 142 | MAVYRET..... | 106 |
| LOJAIMI ESS..... | 112 | MAYZENT..... | 130 |
| LOKELMA..... | 122 | meclizine hcl..... | 35 |
| lomustine..... | 52 | medisense..... | 92 |
| LONSURF..... | 52 | medisense glucose ketone..... | 92 |
| loperamide..... | 102 | medisense glucose ketone contr..... | 92 |
| lopinavir-ritonavir..... | 68 | medroxyprogesterone acetate..... | 116 |
| lorazepam..... | 77 | mefloquine hcl..... | 59 |
| LORAZEPAM INTENSOL..... | 77 | megestrol acetate..... | 117 |
| LORYNA..... | 112 | MEKINIST..... | 52,53 |
| losartan potassium..... | 136 | MELEYA..... | 113 |
| losartan-hydrochlorothiazide..... | 136 | meloxicam..... | 132 |
| LOTEMAX..... | 12 | memantine hcl..... | 87 |
| LOTEMAX SM..... | 12 | MENQUADFI..... | 72 |
| loteprednol etabonate..... | 12 | MENVEO A-C-Y-W-135-DIP..... | 72 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|--|-------|-------------------------------------|-------|
| mercaptopurine..... | 53 | MICROGESTIN..... | 113 |
| mesalamine..... | 102 | MICROGESTIN FE..... | 113 |
| mesalamine dr..... | 102 | midodrine hcl..... | 142 |
| mesalamine er..... | 102 | mifepristone..... | 32 |
| mesna..... | 35 | miglustat..... | 99 |
| metformin hcl..... | 32 | MILI..... | 113 |
| metformin hcl er..... | 32 | MIMVEY..... | 100 |
| methadone hcl..... | 3 | minocycline hcl..... | 21 |
| METHADONE INTENSOL..... | 3 | minoxidil..... | 146 |
| METHADOSE..... | 3 | mirabegron er..... | 80 |
| methazolamide..... | 38 | mirtazapine..... | 31 |
| methenamine hippurate..... | 8 | misoprostol..... | 74 |
| methimazole..... | 142 | MNEXSPIKE 2025-2026 (12Y UP)..... | 72 |
| methocarbamol..... | 139 | modafinil..... | 8 |
| methotrexate..... | 53 | MODERNA COVID 23-24(6M-11Y)EUA..... | 72 |
| methotrexate sodium..... | 53 | MODERNA COVID 24-25(6M-11Y)EUA..... | 72 |
| methscopolamine bromide..... | 22 | moexipril hcl..... | 137 |
| methsuximide..... | 28 | mometasone furoate..... | 12,14 |
| methyl dopa..... | 87 | MONDOXYNE NL..... | 21 |
| methylergonovine maleate..... | 133 | MONO-LINYAH..... | 113 |
| methylphenidate er..... | 6,7 | montelukast sodium..... | 13 |
| methylphenidate er (la)..... | 7 | morphine sulfate..... | 3,4 |
| methylphenidate er 27 mg tab (mallinckrodt and kremers/lannett)..... | 7 | morphine sulfate er..... | 4 |
| methylphenidate er 36 mg tab (mallinckrodt and kremers/lannett)..... | 7 | MOUNJARO..... | 32 |
| methylphenidate er 54 mg tab (mallinckrodt and kremers/lannett)..... | 7 | MOVANTIK..... | 89 |
| methylphenidate hcl..... | 7 | moxifloxacin..... | 9 |
| methylphenidate hcl cd..... | 7 | moxifloxacin hcl..... | 20 |
| methylphenidate hcl er (cd)..... | 7 | MRESVIA..... | 72 |
| methylprednisolone..... | 107 | MULPLETA..... | 82 |
| methyltestosterone..... | 108 | MULTAQ..... | 18 |
| metoclopramide hcl..... | 104 | mupirocin..... | 10 |
| metolazone..... | 95 | MY CHOICE..... | 113 |
| metoprolol succinate..... | 85 | MY WAY..... | 113 |
| metoprolol tartrate..... | 85 | mycophenolate mofetil..... | 43 |
| metoprolol-hydrochlorothiazide..... | 86 | mycophenolic acid..... | 43 |
| metronidazole..... | 10,60 | MYFEMBREE..... | 104 |
| mexiletine hcl..... | 18 | MYHIBBIN..... | 43 |
| MIBELAS 24 FE..... | 113 | MYLERAN..... | 53 |
| | | MYRBETRIO..... | 80 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | |
|--------------------------------------|---------|
| N | |
| nabumetone..... | 132 |
| nadolol..... | 86 |
| naloxone hcl..... | 87 |
| naltrexone hcl..... | 87 |
| naproxen..... | 132 |
| naproxen sodium..... | 132 |
| naratriptan hcl..... | 44 |
| NATACYN..... | 10 |
| nateglinide..... | 33 |
| nebivolol hcl..... | 86 |
| NEBUSAL..... | 97 |
| NECON..... | 113 |
| needles (including pen needles)..... | 92 |
| NEMLUVIO..... | 15 |
| NEO-POLYCIN..... | 9 |
| NEO-POLYCIN HC..... | 9 |
| neomycin sulfate..... | 20 |
| neomycin-bacitracin-poly-hc..... | 9 |
| neomycin-bacitracin-polymyxin..... | 9 |
| neomycin-polymyxin-dexameth..... | 9 |
| neomycin-polymyxin-hc..... | 10 |
| neomycin-polymyxin-hydrocort..... | 10 |
| NEUAC..... | 10 |
| nevirapine..... | 65 |
| nevirapine er..... | 65 |
| NEW DAY..... | 113 |
| NEXLETOL..... | 41 |
| NEXLIZET..... | 41 |
| niacin er..... | 41 |
| NICODERM CQ..... | 79 |
| NICORETTE..... | 79 |
| nicotine gum..... | 79 |
| nicotine lozenge..... | 79 |
| nicotine patch..... | 79,80 |
| NICOTROL NS..... | 80 |
| nifedipine..... | 84 |
| nifedipine er..... | 84 |
| NIKKI..... | 113 |
| nilotinib hcl..... | 53 |
| nilutamide..... | 53 |
| nimodipine..... | 84 |
| NINLARO..... | 53 |
| nintedanib esylate..... | 137 |
| nitazoxanide..... | 60 |
| nitisinone..... | 98 |
| NITRO-BID..... | 146 |
| nitrofurantoin..... | 8 |
| nitrofurantoin mono-macro..... | 8 |
| nitroglycerin..... | 98,146 |
| nitroglycerin patch..... | 146 |
| NITYR..... | 98 |
| NIVESTYM..... | 83 |
| nizatidine..... | 74 |
| NORA-BE..... | 113 |
| norelgestromin-eth estradiol..... | 113 |
| norethin-eth estra-ferrous fum..... | 113 |
| norethindron-ethinyl estradiol..... | 100,113 |
| norethindrone..... | 113 |
| norethindrone acetate..... | 117 |
| norethindrone-e.estradiol-iron..... | 113 |
| norgestimate-ethinyl estradiol..... | 113 |
| NORTREL..... | 113 |
| nortriptyline hcl..... | 31 |
| NOVAFERRUM YUMMY PEDIATRIC..... | 17 |
| NOVAVAX COVID 2023-2024 (EUA)..... | 72 |
| NOVAVAX COVID 2024-2025 (EUA)..... | 72 |
| NOVOEIGHT..... | 39 |
| NOVOLIN 70-30..... | 117 |
| NOVOLIN 70-30 FLEXPEN..... | 117 |
| NOVOLIN N..... | 117 |
| NOVOLIN N FLEXPEN..... | 118 |
| NOVOLIN R..... | 119 |
| NOVOLIN R FLEXPEN..... | 119 |
| NOVOLOG..... | 119 |
| NOVOLOG FLEXPEN..... | 119 |
| NOVOLOG MIX 70-30..... | 119 |
| NOVOLOG MIX 70-30 FLEXPEN..... | 119 |
| NOVOLOG PENFILL..... | 119 |
| novopen echo..... | 92 |
| NOVOSEVEN RT..... | 39 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-------------------------------------|-------|------------------------------|---------|
| NOXAFIL..... | 36 | ondansetron hcl..... | 35 |
| NUBEQA..... | 53 | ondansetron odt..... | 35 |
| NUCALA..... | 12 | OPCICON ONE-STEP..... | 114 |
| NUCYNTA ER..... | 4 | OPSUMIT..... | 139 |
| NUDEXTA..... | 87 | OPTION 2..... | 114 |
| NURTEC ODT..... | 44 | optium ez..... | 94 |
| NUVARING..... | 114 | OPVEE..... | 88 |
| NUVAXOVID 2025-2026..... | 72 | ORALONE..... | 14 |
| NUWIQ..... | 39 | ORFADIN..... | 98 |
| NYAMYC..... | 37 | ORIAHNN..... | 104 |
| NYLIA..... | 114 | ORLISSA..... | 104,105 |
| nystatin..... | 37 | orphenadrine citrate er..... | 139 |
| NYSTOP..... | 37 | ORQUIDEA..... | 114 |
| | | ORTHO-NOVUM..... | 114 |
| O | | oseltamivir phosphate..... | 75 |
| OCELLA..... | 114 | OTEZLA..... | 135 |
| octreotide acetate..... | 142 | OTEZLA XR..... | 135 |
| ODEFSEY..... | 66 | OTREXUP..... | 54 |
| ODOMZO..... | 53 | oxaprozin..... | 132 |
| ofloxacin..... | 10,20 | oxazepam..... | 77 |
| OGSIVEO..... | 53 | oxcarbazepine..... | 28 |
| olanzapine..... | 61 | oxcarbazepine er..... | 28 |
| olanzapine odt..... | 61 | oxybutynin chloride..... | 104 |
| olmesartan medoxomil..... | 136 | oxybutynin chloride er..... | 104 |
| olmesartan-amlodipine-hctz..... | 136 | oxycodone hcl..... | 4 |
| olmesartan-hydrochlorothiazide..... | 136 | oxycodone-acetaminophen..... | 4 |
| olopatadine hcl..... | 101 | oxymorphone hcl..... | 4 |
| omeprazole..... | 74 | OZEMPIC..... | 32,33 |
| omeprazole-sodium bicarbonate..... | 74 | | |
| omniflex diaphragm..... | 131 | P | |
| omnipod 5 (g6/libre 2 plus)..... | 92 | PACERONE..... | 18 |
| omnipod 5 dexg7g6 intro(gen 5)..... | 93 | paliperidone er..... | 61,62 |
| omnipod 5 dexg7g6 pods (gen 5)..... | 93 | pantoprazole sodium..... | 75 |
| omnipod 5 g6-g7 intro kt(gen5)..... | 93 | paroxetine hcl..... | 30 |
| omnipod 5 g6-g7 pods (gen 5)..... | 93 | PAXLOVID..... | 75 |
| omnipod 5 intro(g6/libre2plus)..... | 93 | pazopanib hcl..... | 54 |
| omnipod dash intro kit (gen 4)..... | 93 | PEDIA IRON..... | 18 |
| omnipod dash pods (gen 4)..... | 93 | PEDIARIX..... | 72 |
| OMNITROPE..... | 116 | PEDIATRIC FE-VITE..... | 18 |
| OMVOH..... | 103 | pediatric iron..... | 18 |
| OMVOH PEN..... | 103 | PEDVAXHIB..... | 72 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-------------------------------------|-------|------------------------------------|---------|
| peg 3350-electrolyte..... | 102 | PLEGRIDY..... | 128,129 |
| peg-3350 and electrolytes..... | 102 | PLEGRIDY PEN..... | 129 |
| PEGASYS..... | 75 | PNEUMOVAX 23..... | 72 |
| PENBRAYA..... | 72 | POLYCIN..... | 10 |
| penciclovir..... | 11 | polymyxin b sul-trimethoprim..... | 10 |
| penicillamine..... | 106 | pomalidomide..... | 54 |
| penicillin v potassium..... | 135 | PORTIA..... | 114 |
| PENMENVY MEN A-B-C-W-Y..... | 72 | posaconazole..... | 36 |
| PENMENVY MENACWY COMPONENT..... | 72 | potassium chloride..... | 98 |
| PENMENVY MENB COMPONENT..... | 72 | potassium citrate er..... | 96 |
| PENTACEL..... | 72 | pramipexole dihydrochloride..... | 96 |
| pentamidine isethionate..... | 60 | prasugrel hcl..... | 68 |
| pentoxifylline..... | 83 | pravastatin sodium..... | 42 |
| perampanel..... | 25 | praziquantel..... | 8 |
| perindopril erbumine..... | 137 | prazosin hcl..... | 85 |
| PERIOGARD..... | 10 | precision xtra..... | 94 |
| PERIOMED..... | 90 | prednisolone..... | 107 |
| permethrin..... | 11 | prednisolone acetate..... | 12 |
| perphenazine..... | 63 | prednisolone sodium phosphate..... | 107 |
| PFIZER COVID 2023-24(5-11Y)EUA..... | 72 | prednisone..... | 107,108 |
| PFIZER COVID 2024-25(5-11Y)EUA..... | 72 | pregabalin..... | 27 |
| PFIZER COVID 2024-25(6M-4Y)EUA..... | 72 | PREHEVBRIO..... | 72 |
| phenobarbital..... | 76 | PREMARIN..... | 100 |
| phenoxybenzamine hcl..... | 2 | PREMPHASE..... | 100 |
| PHENYTEK..... | 28 | PREMPRO..... | 100 |
| phenytoin..... | 28 | PRENATABS RX..... | 147 |
| phenytoin sodium extended..... | 28 | prenatal 19..... | 147 |
| PHILITH..... | 114 | prenatal plus..... | 147 |
| PHOSPHA 250 NEUTRAL..... | 96 | prenatal-u..... | 147 |
| PHOSPHO-TRIN 250 NEUTRAL..... | 96 | pretomanid..... | 45 |
| PHOSPHO-TRIN K500..... | 96 | PREVALITE..... | 41 |
| PHOSPHOROUS..... | 96 | PREVIDENT 5000 ENAMEL PROTECT..... | 91 |
| phytonadione..... | 148 | PREVIDENT 5000 SENSITIVE..... | 91 |
| pilocarpine hcl..... | 38,78 | PREVNAR 20..... | 73 |
| PIMTREA..... | 114 | PREZCOBIX..... | 68 |
| pindolol..... | 86 | PREZISTA..... | 68 |
| pioglitazone hcl..... | 34 | PRIFTIN..... | 45 |
| pioglitazone-metformin..... | 34 | primaquine..... | 59 |
| pirfenidone..... | 137 | primidone..... | 26 |
| piroxicam..... | 132 | PRIORIX..... | 73 |
| PLAN B ONE-STEP..... | 114 | probenecid..... | 98 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|--|-------|-------------------------------|-----|
| probenecid-colchicine | 98 | quinine sulfate | 60 |
| PROCENTRA | 6 | QUIT 2 | 80 |
| prochlorperazine | 35 | QUIT 4 | 80 |
| prochlorperazine maleate | 35 | QULIPTA | 44 |
| PROCRIT | 83 | QVAR REDIHALER | 108 |
| PROCTO-MED HC | 15 | | |
| PROCTOSOL-HC | 15 | R | |
| PROCTOZONE-HC | 15 | RABAVERT | 73 |
| PROFILNINE | 39 | rabeprazole sodium | 75 |
| progesterone | 117 | raloxifene hcl | 99 |
| promethazine hcl | 102 | ramipril | 137 |
| promethazine-codeine | 138 | ranolazine er | 84 |
| promethazine-dm | 138 | rasagiline mesylate | 59 |
| PROMETHEGAN | 102 | RASUVO | 54 |
| propafenone hcl | 18 | REBIF | 129 |
| propafenone hcl er | 18 | REBIF REBIDOSE | 129 |
| propranolol hcl | 86 | REBINYN | 39 |
| propranolol hcl er | 86 | RECLIPSEN | 114 |
| propylthiouracil | 142 | RECOMBINATE | 40 |
| PROQUAD | 73 | RECOMBIVAX HB | 73 |
| protriptyline hcl | 32 | RELGAABI | 27 |
| PULMOSAL | 97 | repaglinide | 33 |
| PULMOZYME | 138 | REPATHA PUSHTRONEX | 42 |
| PUREVITA FOLIC ACID | 147 | REPATHA SURECLICK | 42 |
| PURIXAN | 54 | REPATHA SYRINGE | 42 |
| pyrazinamide | 45 | RESTASIS | 101 |
| pyridostigmine bromide | 78 | RETACRIT | 83 |
| pyridostigmine bromide er | 78 | REVCIVI | 99 |
| pyrimethamine | 60 | REXTOVY | 88 |
| PYRUKYND | 81,82 | REXULTI | 62 |
| | | RHAPSIDO | 15 |
| Q | | RIASTAP | 40 |
| QUADRACEL DTAP-IPV | 73 | ribavirin | 76 |
| quetiapine fumarate | 62 | rifabutin | 45 |
| quetiapine fumarate er | 62 | rifampin | 45 |
| QUILLICHEW ER | 7 | rilpivirine | 65 |
| QUILLIVANT XR | 7 | riluzole | 87 |
| quinapril hcl | 137 | RINVOQ | 122 |
| quinapril-hctz 20-25 mg tab (greenstone) | 137 | RINVOQ LQ | 123 |
| quinapril-hydrochlorothiazide | 137 | risedronate sodium | 125 |
| quinidine gluconate | 18 | risperidone | 62 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|----------------------------------|-----|-------------------------------------|-----|
| risperidone odt..... | 62 | SHEWISE..... | 114 |
| ritonavir..... | 68 | SHINGRIX..... | 73 |
| rivaroxaban..... | 23 | sildenafil citrate..... | 146 |
| rivastigmine..... | 78 | silodosin..... | 2 |
| RIVELSA..... | 114 | silver sulfadiazine..... | 11 |
| RIXUBIS..... | 40 | SIMBRINZA..... | 38 |
| rizatriptan..... | 44 | SIMLANDI(CF)..... | 145 |
| roflumilast..... | 138 | SIMLANDI(CF) AUTOINJECTOR..... | 145 |
| ROMVIMZA..... | 54 | SIMLIYA..... | 114 |
| ropinirole hcl..... | 96 | SIMPESSE..... | 114 |
| ROSDAN..... | 11 | SIMPONI..... | 145 |
| rosuvastatin calcium..... | 42 | simvastatin..... | 42 |
| ROSYRAH..... | 114 | sirolimus..... | 126 |
| ROTARIX..... | 73 | SIRTURO..... | 45 |
| ROTATEO..... | 73 | SKYRIZI..... | 16 |
| ROWEEPRA..... | 26 | SKYRIZI ON-BODY..... | 16 |
| ROZLYTREK..... | 54 | SKYRIZI PEN..... | 16 |
| RUBRACA..... | 54 | sod sulf-potass sulf-mag sulf..... | 102 |
| rufinamide..... | 28 | sodium chloride..... | 97 |
| RYBELSUS..... | 33 | sodium citrate-citric acid..... | 96 |
| RYDAPT..... | 55 | sodium fluoride..... | 91 |
| S | | SODIUM FLUORIDE 5000 DRY MOUTH..... | 91 |
| sacubitril-valsartan..... | 135 | SODIUM FLUORIDE 5000 PLUS..... | 91 |
| sapropterin dihydrochloride..... | 98 | sodium fluoride enamel protect..... | 91 |
| SCSEMBLIX..... | 55 | sodium fluoride sensitive..... | 91 |
| scopolamine..... | 22 | sodium fluoride-potassium nitr..... | 91 |
| SE-NATAL 19..... | 147 | sodium oxybate..... | 8 |
| SELARSDI..... | 121 | sodium phenylbutyrate..... | 97 |
| selegiline hcl..... | 59 | sodium polystyrene sulfonate..... | 122 |
| selenium sulfide..... | 11 | solifenacin succinate..... | 104 |
| SEMGLEE (YFGN)..... | 118 | SOLIQUA 100-33..... | 118 |
| SEMGLEE (YFGN) PEN..... | 118 | SOLOSEC..... | 60 |
| SEREVENT DISKUS..... | 81 | SOLTAMOX..... | 99 |
| sertraline hcl..... | 31 | sorafenib..... | 55 |
| SETLAKIN..... | 114 | sotalol..... | 86 |
| sevelamer carbonate..... | 122 | SOTALOL AF..... | 86 |
| sevelamer hcl..... | 122 | SOTYKTU..... | 17 |
| SF..... | 91 | SOVALDI..... | 106 |
| SF 5000 PLUS..... | 91 | SPIKEVAX 2023-2024..... | 73 |
| SHAROBEL..... | 114 | SPIKEVAX 2024-2025..... | 73 |
| | | SPIKEVAX 2025-2026 (12Y UP)..... | 73 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|---------------------------------------|-----|-------------------------------|---------|
| SPIKEVAX 2025-2026 (6M-11Y) | 73 | | |
| SPIRIVA RESPIMAT | 22 | T | |
| spironolactone | 125 | TABLOID | 55 |
| spironolactone-hctz | 125 | tacrolimus | 16,83 |
| SPRINTEC | 114 | tadalafil | 146 |
| SPS | 122 | tadalafil 20 mg tablet (pah) | 146 |
| SRONYX | 114 | TAFINLAR | 55,56 |
| SSD | 11 | TAKE ACTION | 114 |
| ST. JOSEPH ASPIRIN | 133 | TAKHZYRO | 124 |
| ST. JOSEPH ASPIRIN EC | 133 | TALICIA | 73 |
| stavudine | 66 | TALZENNA | 56 |
| STEQEYMA | 121 | tamoxifen citrate | 99 |
| STIOLTO RESPIMAT | 22 | tamsulosin hcl | 2 |
| STIVARGA | 55 | TARINA 24 FE | 114 |
| STOP SMOKING AID | 80 | TARINA FE | 115 |
| STRIVERDI RESPIMAT | 81 | TARINA FE 1-20 EQ | 115 |
| SUBVENITE | 26 | tasimelteon | 77 |
| SUBVENITE (BLUE) | 26 | tazarotene | 140 |
| SUBVENITE (GREEN) | 26 | TAZTIA XT | 19 |
| SUBVENITE (ORANGE) | 26 | TAZVERIK | 56 |
| sucalfate | 74 | tdvax | 69 |
| sulfacetamide sodium | 11 | telmisartan | 136 |
| sulfadiazine | 20 | temazepam | 77 |
| sulfamethoxazole-trimethoprim | 20 | temozolomide | 56 |
| sulfasalazine | 20 | TENIVAC | 69 |
| sulfasalazine dr | 20 | tenofovir disoproxil fumarate | 66 |
| SULFATRIM | 20 | terazosin hcl | 85 |
| sulindac | 133 | terbinafine hcl | 35 |
| sumatriptan | 44 | terbutaline sulfate | 81 |
| sumatriptan succinate | 44 | terconazole | 37 |
| sunitinib malate | 55 | teriflunomide | 128 |
| SUNOSI | 8 | teriparatide | 134 |
| SYEDA | 114 | testosterone | 108 |
| SYMDEKO | 89 | testosterone cypionate | 108 |
| SYMPROIC | 89 | tetrabenazine | 88 |
| SYMTUZA | 68 | tetracycline hcl | 11 |
| SYNJARDY | 33 | TEZSPIRE | 12 |
| SYNJARDY XR | 33 | THALOMID | 125,126 |
| SYNTHROID | 143 | theophylline | 141 |
| syringes (including insulin syringes) | 93 | theophylline er | 142 |
| | | thiothixene | 63 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-------------------------------|--------|--------------------------------|-----|
| TIADYL ER | 19 | TRI-LEGEST FE | 115 |
| tiagabine hcl | 27 | TRI-LINYAH | 115 |
| ticagrelor | 68 | TRI-LO-ESTARYLLA | 115 |
| TILIA FE | 115 | TRI-LO-MARZIA | 115 |
| timolol maleate | 37 | TRI-LO-MILI | 115 |
| tinidazole | 60 | TRI-LO-SPRINTEC | 115 |
| tiopronin | 126 | TRI-MILI | 115 |
| TIVICAY | 64 | TRI-SPRINTEC | 115 |
| TIVICAY PD | 64 | TRI-VYLIBRA | 115 |
| tizanidine hcl | 139 | TRI-VYLIBRA LO | 115 |
| tobramycin | 10,20 | triamcinolone acetonide | 15 |
| tobramycin-dexamethasone | 10 | triamterene | 95 |
| tolcapone | 59 | triamterene-hydrochlorothiazid | 95 |
| tolterodine tartrate | 104 | TRIDERM | 15 |
| tolterodine tartrate er | 104 | trientine hcl | 106 |
| tolvaptan | 95,96 | trifluoperazine hcl | 63 |
| topiramate | 26 | trifluridine | 10 |
| topiramate er sprinkle | 26 | trihexyphenidyl hcl | 58 |
| toremifene citrate | 99 | TRIJARDY XR | 34 |
| TORPENZ | 56 | TRIKAFTA | 90 |
| toremide | 95 | trimethobenzamide hcl | 35 |
| TOUJEO MAX SOLOSTAR | 118 | trimethoprim | 8 |
| TOUJEO SOLOSTAR | 118 | trimipramine maleate | 32 |
| tramadol hcl | 4 | TRINATE | 147 |
| tramadol hcl er | 4 | TRIUMEO | 66 |
| tramadol hcl-acetaminophen | 4 | TRIUMEO PD | 66 |
| trandolapril | 137 | TRIVORA-28 | 115 |
| tranexamic acid | 40 | trojan bareskin | 131 |
| tranylcypromine sulfate | 29 | trojan enz | 131 |
| trazodone hcl | 31 | trojan magnum | 131 |
| TRELEGY ELLIPTA | 22 | trojan ultra ribbed | 131 |
| TREMFYA | 16 | trojan ultra thin | 131 |
| TREMFYA ONE-PRESS | 16 | trojan ultra thin-spermicidal | 131 |
| TREMFYA PEN | 16 | tropium chloride | 104 |
| TREMFYA PEN INDUCTION (2 PEN) | 17 | tropium chloride er | 104 |
| TRESIBA | 118 | true cover | 131 |
| TRESIBA FLEXTOUCH U-100 | 118 | TRULANCE | 89 |
| TRESIBA FLEXTOUCH U-200 | 118 | TRULICITY | 33 |
| tretinoin | 56,140 | TRUMENBA | 73 |
| TRETTEN | 40 | trustex | 131 |
| TRI-ESTARYLLA | 115 | trustex condom | 131 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|--|-------|--------------------------------|-----|
| trustex latex condom | 131 | VENXXIVA | 126 |
| trustex-ria | 131 | verapamil er | 19 |
| TULANA | 115 | verapamil hcl | 20 |
| TURQOZ | 115 | verapamil sr | 20 |
| twiist refill kt(csst-ndl-syr) | 93 | VERQUVO | 145 |
| twiist rfl(infus-csst-ndl-syr) | 93 | VERZENIO | 57 |
| twiist starter kit | 93 | VESTURA | 115 |
| TWINRIX | 73 | VIBERZI | 102 |
| TYDEMY | 115 | VIENVA | 115 |
| TYENNE | 121 | vigabatrin | 27 |
| TYENNE AUTOINJECTOR | 121 | VIGADRONE | 27 |
| TYMLOS | 134 | VIGPODER | 27 |
| | | vilazodone hcl | 31 |
| U | | VIORELE | 115 |
| UBRELVY | 44 | VIREAD | 67 |
| UNITHROID | 143 | vitamin d2 | 147 |
| ursodiol | 103 | VITRAKVI | 57 |
| | | VOLNEA | 115 |
| V | | voriconazole | 36 |
| valacyclovir | 76 | VOSEVI | 106 |
| VALCHLOR | 139 | VRAYLAR | 62 |
| valganciclovir hcl | 76 | VUMERITY | 128 |
| valproic acid | 27 | VYFEMLA | 116 |
| valsartan | 136 | VYLIBRA | 116 |
| valsartan-hydrochlorothiazide | 136 | VYNDAMAX | 84 |
| VALTYA | 115 | VYNDAQEL | 84 |
| vancomycin hcl | 21 | | |
| VAQTA | 73 | W | |
| varenicline tartrate | 80 | warfarin sodium | 23 |
| VARIVAX VACCINE | 73 | WEE CARE | 18 |
| VARUBI | 35 | WERA | 116 |
| VASCEPA | 42 | WES-PHOS 250 NEUTRAL | 96 |
| VAXELIS | 69 | wide seal diaphragm | 131 |
| VAXNEUVANCE | 73 | WILATE | 40 |
| VCF | 131 | WIXELA INHUB | 81 |
| VEMLIDY | 76 | WYMZYA FE | 116 |
| VENCLEXTA | 56 | | |
| VENCLEXTA STARTING PACK | 57 | X | |
| venlafaxine hcl | 29 | XALKORI | 57 |
| venlafaxine hcl er | 29,30 | XARAH FE | 116 |
| VENTOLIN HFA | 81 | XARELTO | 23 |

****ATTENTION FHK PROVIDERS AND ENROLLEES****

ANY medication not seen on the current formulary is eligible for a prior authorization (PA) review for medical necessity. Providers, please complete the required PA form and submit supporting documentation to Prime Therapeutics via fax at 866-291-3728.

| | | | |
|-----------------------|-----|------------------|-----|
| XELJANZ..... | 123 | ZOVIA 1-35..... | 116 |
| XELJANZ XR..... | 123 | ZUMANDIMINE..... | 116 |
| XELRIA FE..... | 116 | ZURNAI..... | 88 |
| XIFAXAN..... | 22 | ZURZUVAE..... | 29 |
| XIGDUO XR..... | 34 | ZYDELIG..... | 58 |
| XOLAIR..... | 120 | ZYKADIA..... | 58 |
| XTAMPZA ER..... | 4,5 | | |
| XTANDI..... | 57 | | |
| XULANE..... | 116 | | |
| XULTOPHY 100-3.6..... | 118 | | |

Y

| | |
|---------------|-----|
| YARGESA..... | 99 |
| YESINTEK..... | 121 |
| YEZTUGO..... | 63 |
| YONSA..... | 58 |
| YUVAFEM..... | 100 |

Z

| | |
|-----------------------------|-----|
| ZAFEMY..... | 116 |
| zafirlukast..... | 13 |
| zaleplon..... | 78 |
| ZARAH..... | 116 |
| ZARXIO..... | 83 |
| ZEGALOGUE AUTOINJECTOR..... | 41 |
| ZEGALOGUE SYRINGE..... | 41 |
| ZEJULA..... | 58 |
| ZELBORAF..... | 58 |
| ZENATANE..... | 140 |
| ZENPEP..... | 103 |
| ZENZEDI..... | 6 |
| zidovudine..... | 67 |
| ZILXI..... | 11 |
| ziprasidone hcl..... | 62 |
| ZOKINVY..... | 99 |
| ZOLINZA..... | 58 |
| zolmitriptan..... | 44 |
| zolpidem tartrate..... | 78 |
| zolpidem tartrate er..... | 78 |
| ZOMIG..... | 44 |
| zonisamide..... | 28 |